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Abstract 
During the last decade there has been a growing interest in studying extracellular 
vesicles, in particular exosomes and their miRNA contents. Exosomes are released 
by almost all cell types. They are packed with specific information, stable against 
degradation processes, are small and flexible enough to cross the blood-brain barrier 
(BBB), and are readily found in biological fluids including blood. MicroRNAs 
(miRNAs) are involved in nearly every cellular process and play a regulatory role in 
central nervous system (CNS) associated diseases. Accordingly, exosomal miRNAs 
could be ideal biomarkers to measure CNS disease activity and treatment response. 
In this thesis, the aim was to establish a robust protocol to investigate whether the 
differential expression of serum exosomal miRNA can be used as a biomarker for the 
accurate diagnosis of the CNS diseases multiple sclerosis (MS) and glioblastoma 
multiforme (GBM), as well as for the monitoring of disease progression and 
treatment response. 
Exosomes were purified from serum and their RNA contents profiled using high-
throughput sequencing. In my first study, I profiled exosome–associated miRNAs in 
serum samples from MS patients and identified distinct biomarkers for the diagnosis 
of MS and identification of the disease subtype. In my second study, I investigated 
the effect of treatment in MS patients. I hypothesised that the deregulation of serum 
exosomal miRNAs is associated with the efficacy of therapy and is predictive of MS 
activity phases. Finally, I studied serum exosomal miRNA profiles to discover 
diagnostic biomarkers for GBM, and to demonstrate the applicability of my protocol 
to other neurological diseases. 
Taken together, my results demonstrate the exceptional utility of serum exosomal 
miRNA profiles as a blood-based biomarker to diagnose the CNS associated 
diseases, using a robust and easily reproducible protocol. 
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Chapter 1: 
Introduction and literature review 
Introduction 
Biomarkers are molecules that reveal biological state and may indicate the presence of a 
disease or dysfunction. There is growing interest in finding biomarkers to aid the 
diagnosis and prognosis of central nervous system (CNS) diseases.1 One of the most 
substantial barriers to finding biomarkers for CNS conditions is the presence of the 
blood-brain barrier (BBB). The brain is firmly protected by a highly selective 
semipermeable membrane that separates circulating blood from the extracellular fluid in 
the CNS. This barrier has made the brain’s chemistry difficult to monitor. However, the 
discovery of the roles of free circulating microRNA (miRNA) in biology over the last 
decade offers hope that these molecules may provide effective biomarkers for CNS 
conditions.2 
miRNAs are small (18–25 nucleotides), non-coding RNA molecules that regulate gene 
expression post-transcriptionally.3 A single miRNA can target multiple genes, and an 
individual mRNA may be regulated by distinct miRNAs.4 miRNAs have been shown to 
be involved in the regulation of many molecular signalling pathways affecting various 
cellular processes.5,6 It has been reported that miRNAs are abundant in the brain, and 
deregulation of their function has been implicated in human diseases.7  
Exosomes contain a selective package of small regulatory RNA and are enriched in 
miRNAs.7-9 Exosomes are membrane–bound vesicles, small enough to cross the BBB8,9 
and released by almost all cell types. In many neurologic and inflammatory diseases 
there is a significant increase in circulating exosome concentration.7-9  
This project aims to develop a robust protocol to purify serum exosomal miRNAs using 
unbiased next-generation sequencing to identify and validate their potential as 
biomarkers of disease activity and therapeutic efficacy in multiple sclerosis and 
glioblastoma, and to predict the functional role of dysregulated miRNAs using 
integrative bioinformatics. 
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Extracellular vesicles  
Extracellular vesicles (EVs) are small vesicles (30 nm to 1 µm) enclosed by a 
phospholipid bilayer. They are released by almost all cell types and are readily found in 
biological fluids including blood.10,11 When EVs were first identified in the 20th century, 
their roles were not fully appreciated and they were dismissed by many as biochemical 
artifacts.12 However, EVs are now widely accepted as an essential component in 
fundamental cellular responses including intercellular communication and immune 
reactions. Along with other attributes, their relatively stable structure safeguards their 
contents against degradation processes.13,14 Therefore, there is a growing interest in the 
use of the RNA contents of EVs as biomarkers. 
Discovery of EVs 
Chargaff and West initially reported cell-derived vesicles in 1946 as a pro-coagulant 
particle in platelet-free plasma. They centrifuged plasma at different speeds then 
measured the clotting time. It was recorded that prolonged high-speed centrifugation 
extended the clotting time of the supernatant, which indicated the presence of 
subcellular clotting particles.11 In 1967, Peter Wolf identified the subcellular particles 
by electron microscopy as small lipid-rich vesicles (20–50 nm), originating from 
platelets, which he named ‘platelet dust’.15 One decade later, it was reported that fetal 
calf serum also contained numerous microvesicles (30–60 nm).11 Then, in the mid-
1980s, Johnstone observed that immature sheep reticulocytes release small membrane–
enclosed vesicles, termed ‘exosomes’, to the conditioned culture medium during their 
maturation into erythrocytes.14 Released exosomes had compatible characteristics with 
the plasma membrane of reticulocytes. It had been earlier observed that mature 
erythrocytes reduce their enzyme activity compared to reticulocytes. Therefore, it was 
believed that these vesicles function only to remove unnecessary proteins.12,14 Two 
years later, in 1989, the same group reported that although the plasma membrane of 
reticulocytes contains both lysosomal activity and transferrin receptor proteins, released 
vesicles carried transferrin receptor as an abundant membrane protein but expressed no 
lysosomal activity. This observation suggested a highly selective pathway for protein 
sorting in exosomes.16 
  ERROR! REFERENCE SOURCE NOT FOUND.  
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Extracellular vesicles have since been purified from most body fluids. They play a role 
in cell-to-cell communication in both normal physiological processes and the pathology 
underlying several diseases.12,17 
Subtypes of EVs  
Early studies revealed different types of vesicle, but did not use an unified terminology. 
Now, according to their size, origin, and mode of secretion (biogenesis), EVs are 
grouped into three main classes: apoptotic bodies (ABs), microvesicles (MVs), and 
exosomes. These are produced by different cell types in different conditions (Figure 1-
1).18-20 
Apoptotic bodies are 800–5000 nm in diameter and unlike MVs and exosomes, which 
are released from normal viable cells, ABs are generated from the fragmentation of the 
cell membrane of apoptotic cells	(Figure 1-1A).21,22	This study does not examine ABs. 
Microvesicles are 100–1000 nm in size, heterogeneous in shape, and are directly shed 
from the cell membrane (Figure 1-1B). The biogenesis of MVs is the result of 
interaction between lipids and proteins. Vesicle formation is induced by phospholipid 
redistribution complemented by calcium-dependent enzymes like flippase and floppase. 
Contractions of cytoskeletal structures complete the budding process.19,23 
Exosomes are the smallest vesicles, with a size of 30–150 nm and a characteristic well-
delimited round morphology when observed under transmission electron microscopy.11 
They are released to the extracellular environment after formation of intraluminal 
vesicles (ILVs) in multivesicular bodies (MVBs) in the cell interior, transport of MVBs 
to the plasma membrane and fusion of MVBs with the plasma membrane (Figure 1-
1C).24 
Although the formation and release mechanisms of MVs and exosomes are different the 
size of large exosomes and small MVs are comparable.25 Despite efforts to define the 
distinction between various subsets of EVs, no consensus has developed. Currently the 
International Society of Extracellular Vesicles recommends using the generic term 
‘EVs’ for all vesicles isolated from body fluids by currently available methods.26 
  ERROR! REFERENCE SOURCE NOT FOUND.  
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Figure 1-1 Extracellular vesicles 
A) Apoptotic bodies are released from cells undergoing death. B) Microvesicles form by outward 
blebbing of the plasma membrane with incorporation of cytosolic proteins. C) Exosomes form 
intracellularly, fuse to the plasma membrane and release to the extracellular space. 
Exosome biogenesis  
Exosomes originate from endocytic pathways so as a result contain endosome-
associated proteins such as annexins and flotillin. Some of these proteins (e.g., Alix and 
Tsg101) are required in exosome biogenesis. Early endosomes form by inward budding 
of the plasma membrane, which carries specific cytoplasmic cargo. Early endosomes 
mature into late endosomes by accumulating ILVs in their lumen and develop into 
MVBs.18,19,22 MVB destinations depend on their designation molecules; they are either 
degraded by fusion with lysosomes or migrated toward and fused with the plasma 
membrane, subsequently to release into the extracellular space their ILVs, which are 
referred to as exosomes (Figure 1-1).11,19,27 
In most cells, MVBs carry acidic compartments that contain lysosomal hydrolases, for 
degradation of their content. However, some MVBs carry other molecules such as 
tetraspanin CD63, and lysosomal-associated membrane proteins LAMP1 and LAMP2 
which are required to fuse with the plasma membrane and release the vesicle contents 
into the extracellular milieu.19 Overall, it has been observed that cells host different 
subpopulations of MVBs. For instance, most of the cholesterol-containing MVBs tend 
  ERROR! REFERENCE SOURCE NOT FOUND.  
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to fuse with the plasma membrane in an exocytic manner, approving exosomes are 
enriched in cholesterol.19,20  
Multiple mechanisms can mediate ILV/MVB biogenesis. These include endosomal-
sorting complex required for transport (ESCRT) components, lipids, and tetraspanins 
(Figure 1-1). It is not known whether different processes are specific to different types 
of MVB or not.19 ESCRT machinery plays an important role in the formation of ILVs 
and MVBs. ESCRT is composed of approximately thirty proteins that assemble into 
four complexes (0, -I, -II and –III) and the profoundly conserved associated proteins 
AAA ATPase Vps4 (vacuolar protein sorting-associated protein 4) complex and Alix.20 
ESCRT-0, ESCRT-I, and ESCRT-II recognise early endosomes with an abundance of 
phosphatidylinositol 3 phosphates in their membrane, ubiquitinylated cargo, and the 
curved membrane topology and drive membrane bud formation.22 To complete the 
budding, ESCRT-III binds to the compound of ESCRT-I and II via interaction of other 
protein components: Alix, Tsg101, and CHMP422. Then the associated proteins AAA-
ATPase Vps4 complex dissociate and recycle the ESCRT machinery.19,24 
ESCRT-independent is an alternative pathway for MVB biogenesis.28 ESCRT-
independent mechanisms require lipid metabolism enzymes or tetraspanins. Neutral 
sphingomyelinase (nSMase) hydrolyses sphingomyelin to ceramide, and ceramide can 
trigger budding of vesicles into MVBs. Also, phospholipase D2, which hydrolyses 
phosphatidylcholine into phosphatidic acid, induces a negative membrane curvature.23,29 
Additionally, there is some evidence to suggest that cells concomitantly depleted of the 
four sub-units of the ESCRT complex are still generating CD63-positive MVBs. 
Therefore tetraspanins with a high concentration in exosome membranes have been 
proposed to play role in exosome formation.20 Tetraspanins consist of four 
transmembrane domains, which are connected via variable sequence defined specific 
protein-protein interactions. Two main tetraspanins that may play roles in exosome 
formation are CD9 and CD63.22 
Several pathways are implicated in exosome formation so there is no specific surface 
marker related to exosomes. However, available data suggest that Tsg101, Alix, CD63, 
and CD9 are useful identifiers of exosomes.18,22  
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Molecular composition of exosomes 
The molecular composition of exosomes is not entirely similar to their parental cell.12,30 
The most recent exosome content database (Exocarta, http://www.exocarta.org) lists 
4563 proteins, 194 lipids, 1639 mRNA and 764 miRNAs that have been identified in 
exosomes.12 The enrichment of specific proteins, lipids, and nucleic acids and the 
absence of the rest, indicate a controlling mechanism which sorts molecules in 
exosomes (Figure 1-2).30 
  
Figure 1-2 Molecular composition of exosomes  
Exosomes are protective membrane vesicles with a selective package of proteins, lipids, and nucleic 
acids. 
Proteins  
The protein content of exosomes depends on the secreting cell, for instance exosomes 
released from antigen-presenting cells are abundant with an antigen presenting 
molecule, and tumour-derived exosomes contain tumour antigens.12 Yet exosomes are 
also enriched for certain molecules, such as cytoplasmic enzymes (e.g., lactate 
dehydrogenase and peroxidases), targeting and fusion proteins (e.g., tetraspanin, 
lactadherin, and intergrins), chaperones (e.g., heat shock proteins Hsp60, Hsp70, Hsp90, 
and the small HSPs), vesicle trafficking proteins (e.g., Rab proteins, ARF GTPase, and 
annexins), multivesicular body biogenesis proteins (e.g., Alix, TSG101 and clathrin), 
cytoskeletal proteins (e.g., actin and tubulin), and signal transduction proteins (e.g., 
protein kinases and heterotrimeric G proteins).14,30-32 Interestingly, proteins from 
intracellular organelles such as a nucleus, endoplasmic reticulum, golgi complex, and 
mitochondria are less abundant in exosomes.29,33 
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Lipids 
Johnstone et al. 1989, were the first to investigate the lipid content of exosomes 
released from reticulocytes, yet so far the number of studies in this area is not 
sufficient16. Several studies have reported the enrichment of ceramide and its 
derivatives, sphingolipid, phosphatidylserine, and cholesterol, and depletion 
phosphatidylcholine in exosome membranes19,34-36 independent of the parental cell. 
Interestingly, bismonoacyl glycerophosphate also called lysobisphsphatic acid, a 
membrane lipid of ILVs, is not detected in exosome membranes.19 It is reported that 
sphingomyelin, a member of the sphingolipid family, plays a major role in the structure 
of exosomes.18 
Enrichment of cholesterol and sphingomyelin in exosome membranes provides tighter 
lipid packaging and results in structural rigidity of EVs with detergent-resistant 
potential.33 However, it should be noted that this enrichment is not reported in all 
studies; for instance, exosomes released from dendritic cells are not enriched for 
cholesterol. Dendritic cells have high expression of cholesterol already, and further load 
in their released exosomes is not expected.34 Overall it is revealed that lipid composition 
in exosomes differs from their parental cells, which indicates a specific mechanism 
sorting specific lipid species into the vesicles. 
Nucleic Acids 
Exosomes carry nucleic acids, including DNA and RNA species, and preserve them 
from degradation.37  
DNA 
Guescini et al. in 2010 stated that purified exosomes from astrocytes and glioblastoma 
cells contain mitochondrial DNA and not genomic DNA.38 The authors confirmed the 
reported mitochondrial DNA was enclosed inside the exosomes by treating purified 
exosomes, before DNA extraction, with DNase.38 Further study on exosomes released 
by glioblastoma multiforme (GBM) cells (in both culture and tumours) revealed the 
presence of single-strand genomic and transposable elements.39 Studies on exosomes 
released by pancreatic cancer cell lines and isolated from patient’s serum revealed large 
fragments of double-strand genomic DNA.40 While encapsulated DNA in exosomes has 
been indicated in few studies,38,39,40 in comparison with exosomal RNA, they are not 
entirely characterised40,41.  
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RNA 
Valadi et al. in 2007 for the first time reported the presence of RNA in exosomes 
released from mast cell lines (mouse and human) and primary bone marrow-derived 
mouse mast cells.42 Purified exosomes were stable in RNase and trypsin treatment, and 
could be internalised into other recipient cells and remain functional.42,43 This study was 
the first proof-of-concept for gene-based delivery in mammalian cells.29  
Further studies revealed that in comparison with the secreting cell, exosomes, besides 
carrying some parental RNA, possess a distinct RNA profile; enriched for small RNAs 
including significant amounts of miRNA44,45 and depleted for ribosomal RNA44,46. 
These observations provide additional proof for the selective packaging of specific 
RNA species in exosomes.44,45 Thanks to advanced technologies such as next-
generation sequencing, RNA species in mammalian cell-derived exosomes are well 
characterized.23 In general, exosomes are able to carry all RNA species of the cell; 
messenger RNA (mRNA), long non-coding RNA, small non-coding RNA (sncRNA), 
transfer RNA (tRNA), ribosomal RNA (rRNA), small nuclear RNA, small nucleolar 
RNA, small cytoplasmic RNA, Y RNA (a type of structural RNA in ribonucleoprotein 
particles) and vault RNA, with a relative difference in their abundance.29,44,45,47 
Different studies show several distributions of RNA classes within exosomes. The 
diversity can be attributed to differences in the source of the exosomes, or reflect 
variations in sample preparation, exosome and RNA purification methods, RNA study 
techniques or even sequencing platform.23,45 
Function of exosomes 
For a long time, it was assumed that genetic information could be conveyed through two 
mechanisms: either vertical gene exchange from parents to the next generation or 
horizontal through bacteriophages and viruses.48 During the last two decades scientists 
in both basic and applied research have become interested in the topic of intercellular 
communication, which can be broadly classified based on the distance between the 
communicating cells. While short-distance intercellular communication systems include 
gap junctions, ligand-receptor interactions and extracellular molecules such as 
neurotransmitters and hormones,49,50 long-distance intercellular communication systems 
are achieved via particular membrane-based structures such as tunneling nanotubes, 
apoptotic bodies, nucleic acid binding proteins/lipids, and small vesicles.49-51 
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EVs open up a new avenue for vertical transfer of genetic information. Extracellular 
vesicles (including exosomes) provide a protective structure for their contents, and form 
a communication network between different cell types and across species.48,52,53 Several 
studies have reported that exosomes are essential to maintaining the normal physiology 
of the body.12 Due to the wide range of molecules in exosomes’ cargo they could 
regulate several important biological functions such as cell growth, differentiation, 
immune protection and response.51,53 Exosomes have also been implicated in the spread 
of diseas54 and many other roles in pathological states.20,48,53 
The role of exosomes in diseases 
Study of the role of exosomes in cancer has demonstrated the impact of tumour-derived 
exosomes on tumour initiation, growth, progression, metastasis and the 
stimulation/suppression of immune responses.12,20,42 Exosomes are also released from 
the immune system, and have immune modulatory function, with both 
immunosuppressive and immunoactivation effect on different steps of the immune 
response in their recipient cells.51 For instance, dendritic cell, an antigen-presenting cell 
in the immune system, releases exosomes under different maturation states. Mature 
dendritic cell produce exosomes with immunoactivation ability to eliminate viruses and 
bacteria or eradicate tumours, while immature dendritic cell derived exosomes harbor 
anti-inflammatory characteristics and reduce adaptive immune activation, resulting in 
the promotion of tolerogenic immune responses in transplantation and autoimmune 
disesases.55 
Several reports have demonstrated that different cell types of the nervous system 
release exosomes with neuronal communication roles in the normal physiology of the 
nervous system as well as neurodegenerative disease.51 For instance, the presence of 
mature neuron-derived exosomes has been reported in the vicinity of synaptic 
connections with a normal physiological function.56 Conversely, neuron shed exosomes 
may play a detrimental role by spreading pathogenic agents or degenerative proteins 
like beta-amyloid in Alzheimer’s disease.56,57 Beside healthy brain cells, exosomes 
released from glioma can also transfer oncogenic proteins among cancer cells.57 
Therefore, exosomes released within the CNS can modulate signaling pathways, and 
spread neurotoxic proteins. 
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Roles of exosomes in therapeutics and diagnostics 
Exosomes carry a particular package of cargo which reflects their cellular origin and 
plays roles in both physiologic and pathologic conditions. Moreover, these membrane-
bound vesicles are small and flexible and can cross biological barriers such as the BBB 
and target specific organs/tissues. These characteristics plus recent technological 
advancement make exosomes a distinct diagnostics and therapeutic candidate,12,51 so 
several studies have attempted to exploit exosomes’ potential. 
Exosomes for therapeutic approaches are mainly considered as a new delivery system 
that can be loaded with several molecules (e.g., nanoparticles, oligos, and drugs), and 
modulate the function of target cells with low toxicity, high stability, and intrinsic 
homing capacity.12 Exosomes capability regarding transport of endogenous mRNA and 
miRNA to other cells resulting in recipient-cell protein product modulation had been 
previously described in both mouse and human cell culture studies.41,42 Based on this 
knowledge, in 2010, Alvarez-Erviti et al. examined the possibility of delivering loaded 
exosomes with exogenous cargos small interfering RNA (siRNA) to a particular tissue 
or cell types in vivo. In this study, modified exosomes with specific targeting proteins 
were used to deliver siRNA to a mouse brain via a systemic injection. The results were 
comparable to gene knockdown with a potential therapeutic approach to Alzheimer’s 
disease.8 Since then, several studies have considered exosomes reliable vehicles to 
shuttle exogenous cargos for therapeutic purposes. However, there are some technical, 
functional and safety features to be solved and addressed.51 
Another therapeutic approach is based on the presence of surface antigens on tumour-
derived exosomes, which stimulate the immune system to respond against the tumours. 
These exosomes could be utilised to induce antitumor immunity in patients.12,20,41 Even 
though experimental evidence indicates the use of exosomes for cancer vaccine is a 
safe and successful strategy, these are some limitation because exosomes must be 
prepared from treated patients resulting in variation in the yield of exosomes and the 
amount of received treatment.51  
It has also been reported that the number of exosomes is elevated in samples from 
patients suffering cancer,29,51 inflammatory20 and neurodegenerative54,58 conditions 
compared to healthy individuals. Therefore, one therapeutic strategy would be 
modulating the number of secreted exosomes through inhibiting their formation, 
release, or uptake by target cells.12,20  
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Since exosomes circulate in almost all biofluids, they have been considered as an easily 
accessible diagnostic biomarker to indicate pathological conditions. Several studies 
have investigated the level of circulating exosomes as well as their cargo (e.g., miRNA, 
long non-coding RNA and proteins) as potential biomarkers.12 
Exosome purification 
Exosomes have received great attention in recent years due to their vital roles in cell-to-
cell communication.59 Therefore, the isolation and quantification of exosomes has 
become indispensable in both basic research and clinical applications.59 Extracellular 
vesicles including exosomes can be isolated from cell culture-conditional media or body 
fluids including plasma, serum, saliva, urine, milk and cerebrospinal fluid (CSF).26,47 
Given that exosomes can cross the BBB, it is thus likely that at least some of the 
circulating exosomes in a patient’s blood sample are derived from affected CNS cells or 
the associated inflammatory milieu.8,9 Therefore, the presence of exosomes and their 
cargo, such as miRNAs in body fluid has incited considerable interest in their use as 
biomarkers for many diseases including MS and brain cancer.41,60  
The comparison between plasma and serum as a source of exosomes demonstrated 
diversity in the final results, which is related to either the clotting process of serum 
(exosomes trapped within the clot) or the existence of heparin in plasma (exosomes-
heparin complexes).61 Although plasma had initially been considered the best source for 
exosome purification compared to serum61, further studies have demonstrated higher 
yields for extracted miRNAs from serum exosomes in comparison with plasma29,62.  
Several techniques have been employed for the isolation of various EV subpopulations 
utilising their particular features, such as density, shape, size, and surface proteins.59,63 
The techniques mainly used for exosome isolation include ultracentrifugation, 
precipitation, immunoaffinity capture-based technique and size exclusion 
chromatography. 
Ultracentrifugation 
Johnstone et al. in 1987, developed the first protocol to purify reticulocyte exosomes 
from tissue–conditioned medium, which was based on differential centrifugation.19 
Centrifugation applies a force to separate particles in a suspension according to their 
physical properties and the density and viscosity of the solvent. Ultracentrifugation 
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(UC) is a centrifugation process with exceptionally high centrifugal forces to fractionate 
small bioparticles.59 Ultracentrifugation-based exosome isolation is the most commonly 
used and reported technique and considered as the gold standard protocol.59,63 To isolate 
exosomes by differential ultracentrifugation, a series of centrifugation cycles of 
different forces and durations is applied. First, bigger particles and debris are eliminated 
by low-speed centrifugation for a short time-period. Then, the smallest vesicles are 
sedimented by higher-speed ultracentrifugation with extended time.19,59,63  
Due to the heterogeneity of exosomes, the final result of ultracentrifugation is not the 
enrichment of pure exosomes, and it is contaminated with other small EVs and protein 
aggregation.19 Overall, this method suffers from low recovery (5–25%) and purity for 
exosome purification. To date, this protocol has been optimised in many ways such as 
adding an extra density gradient centrifugation step, combining ultrafiltration 
membranes or size exclusion chromatography to exclude soluble proteins.59,63 One way 
to optimise ultracentrifugation-based exosome purification is ultrafiltration, using 
hydrophilic polyvinylidene difluoride membranes of different pore sizes, with the first 
and second low-speed centrifugation steps.63 Ultrafiltration is an independent size-based 
exosome isolation technique, which separate particles based on their size and weight.59 
Substituting ultrafiltration instead of centrifugation reduce the risk of bigger particles 
fragmenting into smaller vesicles.15 Alternatively, in density gradient 
ultracentrifugation, exosomes are isolated based on their size, mass and density in a pre-
constructed density gradient medium of sucrose or iodixanol (OptiprepTM) in a 
centrifuge tube. This method allows exosomes to float during centrifugation through the 
density gradient medium and move as an individual zone (density region 1.10 and 1.21 
g/ml), which can later be recovered by fraction collection.59,63,64 While adding a density 
gradient centrifugation step improves the total yield of purified exosomes, it is often 
contaminated with viruses or large microvesicles with comparable sedimentation 
velocities.47 
In conclusion, sequential ultracentrifugation alone is not sufficient to separate EV’s 
based on their size and further combinations of alternative methods, gradient 
centrifugation or ultrafiltration, may help to overcome the limitations.  
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Exosome precipitation   
This method relies on changing exosomes’ solubility or dispersibility using a 
commercial agglutinating agent, such as polyethylene glycol to sediment exosomes.59 
Samples are mixed and incubated with polyethylene glycol-containing reagents 
followed by either low-speed centrifugation or filtration to isolate the precipitate 
containing exosomes.63 Currently, several biotechnology companies have developed 
compatible exosome precipitation kits for a variety of samples including culture 
medium, serum, plasma, and urine.59,63 Although this method is easy to use without any 
specific technology requirement, it co-precipitates other EV populations, proteins, and 
polymeric materials in the isolated samples. These can interfere with subsequent 
experiments.65 
Immunoaffinity capture-based technique 
The presence of proteins in the membrane of exosomes can be employed to isolate 
exosomes by immunoaffinity interactions between these proteins and their antibodies.59 
Therefore, immunoaffinity capture-based techniques utilise the monoclonal antibody 
coated on magnetic beads directed against exosome-specific antigens to purify certain 
exosome sub-populations.47 This method can be used as an individual experiment to 
colocalise exosomes or as a complementary technique to further purify and select a 
particular sub-population of exosomes.63 Although this method prepares high-quality 
exosomes, it is limited to isolating only a subpopulation of marker-positive exosomes, 
while excluding the negative exosome population (for the examined membrane protein) 
and the yield might be contaminated with other positive extracellular vesicles.66,67  
Size-exclusive chromatography 
Another size-based separation technique to isolate exosomes is single-step size 
exclusive chromatography (SEC) or ‘gel filtration’.68 A SEC column is a syringe with 
10 ml sepharose resin CL-2B, which is equilibrated with Phosphate buffered saline-
citrate 0.32% (w/v).68 This column has a porous stationary phase which is utilised to 
sort macromolecules and particles based on their size. Small components in a sample 
are able to pass through the pores resulting in late elution, while components with large 
hydrodynamic radii such as exosomes, are excluded from entering the pores and are 
eluted in earlier fractions. Therefore SEC can be used to isolate exosomes from sera or 
plasma by fractionating vesicles based on their size. In general, the early fractions 
contain vesicles around 70 nm in size and delayed ones are mostly other 
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contaminations. Accordingly, the use of SEC results in excluding proteins and high-
density lipoproteins.69 The combination of SEC with other techniques such as 
ultracentrifugation is also applicable to reduce the initial volume of samples and 
improve the final yields of exosomes.59  
In conclusion, various conventional strategies are available to purify exosomes and 
there is currently no consensus on a gold standard method. Despite the overall 
similarities, the isolation protocols for each method must be validated based on the 
prime aim of the research, the sample type and the downstream applications.26,63  
Exosome heterogeneity 
It has been shown that the molecular composition of exosomes is not only cell-type 
dependent but can also depend on the activation status of the parental cell. The 
heterogeneity in exosomes is reflected in their lipid, protein and also nucleic acid 
compositions. Despite these findings, the current limitations in exosomes isolation 
techniques mean that the majority of studies employ the bulk isolation of exosomes.70 
For example, using ultracentrifugation for isolating exosomes separates vesicles 
according to their size and density.59 Even more specific methods such as the 
immunocapturing technique relies on purifying a subpopulation of exosomes based on a 
specific protein displayed on their surface, (e.g., CD63-positive), is equally problematic 
as it introduces bias into the subpopulation of interest and neglects the fact that there are 
diverse subpopulations exosomes.63 There are new techniques, which allow the 
detection and isolation of exosomal subtypes and rely on known and common exosomal 
or disease specific markers and can be used for applications such as therapeutic drug 
delivery vehicles and for cancer vaccination. However for the de novo identification of 
any unknown exosomal subtypes, such as for biomarker studies, exosome purification 
remains challenging.71 
Exosome characterisation 
Regardless of the employed method, the isolated vesicles should be characterised to 
demonstrate the presence of vesicles and assess their purity.60 
Size and morphology  
In general, the isolated vesicles should be visualised to characterise individual EVs and 
indicate their heterogeneity.26 The size of EVs are too small to fit within the resolution 
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threshold of optical microscopy22,19,72 and classical flow cytometry15,34,73. Classical flow 
cytometry does not distinguish vesicles >200 nm from noise, so that electron 
microscopy and light scattering techniques are adopted to observe and confirm the size 
and morphology of exosomes.19,59  
Transmission electron microscopy 
Transmission electron microscopy (TEM) studies demonstrated a cup-shaped 
appearance as the natural morphology of exosomes with a diameter of 50–100 nm over 
the past 10 years.19 However, cryo-EM show exosomes have a round-shape 
morphology, and a cup-shaped feature is actually an artifact that forms during 
preparation of the exosomal samples for TEM. In TEM studies, heavy metals such as 
uranyl acetate and osmium tetroxide are utilised to increase the contrast of EV samples, 
which results in dehydration of samples and induces shriveling of cellular 
structure.15,19,74 Despite this drawback, TEM is the standard method in EV studies to 
determine size and structure of single vesicles and to represent particles heterogeneity 
with wide field images encompassing multiple vesicles.15,19,26  
Nanoparticle tracking analysis 
Nanoparticle tracking analysis (NTA) is a light scattering technique, which provides the 
size distribution and concentration of nanoparticles based on their Brownian motion and 
size.19,72,75 NTA tracks the random movement of particles illuminated by a laser beam 
and uses light scattering to calculate their diameter.19,75 The movement rate of particles 
is related to their size (smaller particles move faster), the viscosity and the temperature 
of the solvent.59,75 NTA is a fast and simple method to analyse scores of particles and 
since 2011 was accepted as one of the standard methods for EV characterisation.74 
Nevertheless, it does not provide a precise result for vesicles since it counts all particles 
with similar size including membrane vesicles and co-isolated artifacts such as protein 
aggregates.19,26 Therefore, a combination of both TEM and NTA results are required to 
characterise EVs size, morphology, and concentration.26 
Membrane protein composition 
Alongside specific proteins from the parental cell,14 several studies reported a defined 
set of cellular proteins in EVs, regardless of their parent cell type23,73. Surface 
membrane proteins enriched in mammalian cell-derived exosomes include adhesion 
molecules such as integrin and tetraspanins (CD9, CD63, CD81) which regulate cargo-
loading process, antigen-presenting proteins, major histocompatibility complex (MHC) 
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class I and II, and membrane transport/fusion proteins (annexins and flotillins).30,31 
These observations affirm the specificity of exosomes’ endosomal formation.14 Since 
another type of EV might represent the same proteins,29 these proteins are considered as 
exosome-enriched proteins rather than exosome-specific markers.26 Therefore, it is 
suggested to determine at least three enriched endosomal origin proteins with a semi-
quantitative method in exosome preparation.26 Western blotting is antibody-based 
detection technique to identify a particular protein, while proteomic analysis with mass 
spectrometry covers a broader approach.76 Mass spectrometry has improved in the last 
20 years and several thousand EV proteins rom various sources have been deposited in 
the free web-based EVpedia (http://evpedia.info) database.77 
Non-coding RNA 
The genome of multicellular eukaryotes, unlike prokaryotes, is transcribed into a 
diversity of RNAs, the vast majority of which (>90%) do not encode proteins, but are 
non-coding RNAs (ncRNAs).78,79 Genome sequencing projects have revealed that the 
number of protein-coding RNAs is relatively constant across vertebrates and does not 
indicate the complexity of the organism, whereas the developmental programming is 
associated with the proportion of non-protein coding RNAs (e.g., the human genome 
contains 98% non-protein coding RNAs).80 This observation suggested that ncRNAs 
perform a significant function in genetic programming during differentiation and 
development, through regulation of gene expression.81 The first ncRNA with gene 
expression regulatory function, miRNA, was identified about 25 years ago (in 1993), 
with the discovery of lin-4 in the nematode worm in Caenorhabditis Elegans.82,83 This 
finding followed by the discovery of RNA interference in 1998, highlighted the 
importance of ncRNAs.82 Since then, a broad spectrum of ncRNAs with multiple 
functions has been discovered84,85 and, based on the size and synthesis mechanism, 
categorised into two main groups, the small and long ncRNAs78. 
Small ncRNAs (>200nt) are generated by the post-transcriptional processing of longer 
transcripts by endogenous RNases.86 sncRNAs have been classified into various 
categories by their length, biogenesis, function and structural or sequence feature.78 
Three subclasses: siRNAs, piwi-interacting RNAs, and miRNAs are mainly involved in 
gene silencing in the cell through RNAi interference mechanisms.86 These sncRNAs 
(~20–30 nt) carry nucleotide sequence complementarity, which mediates regulatory 
  ERROR! REFERENCE SOURCE NOT FOUND.  
 29 
control after incorporation into a complex of proteins (RNA-protein complexes).86 
SiRNAs (21–24 nt) are double-strand RNA with a gene silencing function, which 
induces transcript degradation in a sequence-specific manner.87,88 Endogenous siRNAs 
selectively target double-strand RNA viruses and transposons to protect the eukaryotic 
cells.78 Both siRNAs and miRNAs function as post-transcriptional gene regulators and 
use the same enzymatic mechanism to be activated. Thus, synthetic siRNAs became a 
therapeutic tool for several diseases and disorders, yet certain drawbacks such as low 
stability under in vivo conditions remain to be addressed.78,82,87 Piwi-interacting RNAs 
(28–32 nt) were discovered in 2006, and play a pivotal role in the physiological 
modulation of spermiogenesis.82 Piwi-interacting RNAs protect the genome integrity of 
germ cells by silencing transposons and other random integrates, and are involved in 
gametogenesis by guiding DNA methylation to suppress the expression of repetitive 
elements. PiRNAs function, unlike siRNAs and miRNAs, are associated with the piwi 
subclass of the Argonaute superfamily, not Argonaute protein, and produce 
independently of Dicer.78,89 
Long ncRNA (<200 nt) were later introduced as large portions of the mammalian 
noncoding transcriptome, with little or no protein coding capacity, which also regulate 
gene expression and relevant to evolution.84,85 
MicroRNAs 
MicroRNAs (miRNA) — from 17–24 nt ⎯ are the most extensively studied sncRNAs, 
and are involved in almost every biological process—both physiological and 
pathological.90,18,84 MicroRNAs regulate gene expression in one-third of human genes 
by pairing to their complementary sequence, located in the 3′ untranslated region (UTR) 
or open reading frame of target mRNAs, and mediate post-transcriptional gene 
silencing.83,84,91 RNA polymerase II or III transcribe miRNA genes into monocistronic 
(single) or polycistronic (cluster) precursor miRNA named primary miRNA (pri-
miRNA) with a phosphorylated 5′ end and a short overhang on the 3′ end, and a double 
strand stem-loop shape. In the nucleus pri-miRNA binds to the dsRNA-binding 
protein—DGCR5 (DiGeorge Syndrome chromosome region)—of the Drosha complex 
and is digested by the complex’s enzyme -RNase III enzyme Drosha- to form short (60–
70 nt) hairpin precursor miRNAs (pre-miRNA). Pre-miRNAs are exported to the 
cytoplasm by exportin5-Ran-GTP complex and further digested by Dicer, another 
  ERROR! REFERENCE SOURCE NOT FOUND.  
 30 
member of RNase III protein, into mature ~22 nt double-stranded miRNA (guided 
strand/passenger strand of the same hairpin structure). One strand of mature miRNAs is 
incorporated into RNA-induced silencing complex as a guide strand to silence target 
mRNA (Figure 1-3).78,92,93 
 
Figure 1-3 miRNA biogenesis 
MiRNA genes are transcribed as Pri-miRNAs. In the nucleus, the complex Drosha processes Pri-miRNAs 
into Pre-miRNAs, which are transported to the cytoplasm by the Exportin5 complex. IN the cytoplasm 
Dicer processes the pre-miRNA to form mature double-stranded miRNA. One strand of mature miRNA is 
incorporated into the RNA-induced silencing complex. 
miRNAs recognize their specific target mRNAs by 2–7nt in the 5′ end called the ‘seed 
sequence’. The degree of the miRNAs and target mRNAs complementarity determines 
the result: either translational repression or mRNA degradation. The relatively short 
complementarity sequence between miRNAs and mRNAs imply a single miRNA can 
target many genes and mRNAs harbor multiple miRNA-binding sites in their 
3′UTR.79,84,90 
Genome location of miRNAs can be intergenic, intronic, or exonic. DNA sequences 
between gene-coding DNA are independent transcription units called intergenic regions 
that may or may not encode regulatory functions. Many miRNAs are encoded in the 
intergenic region with miRNA-specific promoters. Intronic miRNAs are processed from 
the introns of the host genes either: protein-coding genes or long non-coding RNAs. 
And exonic miRNAs are mostly process from noncoding genes. The host gene promoter 
transcribes intronic and exonic miRNAs.90,93  
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Several studies reported the contribution of ncRNAs to not only regulating almost all 
steps of gene expression but also the cellular processes involved in development and 
disease.78,79 Due to the purpose of our study, this section is concentrated on miRNAs. 
Functions of miRNAs 
The role of miRNAs in disease and diagnosis 
Non-invasive tools to diagnose and monitor the progress of diseases has long been a 
goal of research.94 Animal examinations, particularly mouse disease models, reveal that 
miRNA levels change to trigger disease and also as a direct consequence of disease 
onset or progression and as such could be used for prognosis and potential therapy. 
Therefore, miRNAs are at the center of attention for studies of numerous different 
diseases.84 Based on version 21 of miRBase (http://www.mirbase.org), the main 
reference miRNA database, over 35,800 mature miRNAs in 223 different species have 
been identified.95 Each miRNA can regulate more than several hundred potential target 
mRNAs.93,96 Also, several single nucleotide polymorphisms,97 length and sequence 
heterogeneities provoke enormous polymorphisms in miRNAs, which might result in 
phenotypic diversities and are responsible for or contribute to the pathogenesis of 
disorders95,98.  
Unbiased high-throughput techniques (e.g., microarray and sequencing) enables the 
screening of all known miRNAs while eliminating the possibility of missing some 
affected miRNAs.85 This achievement leads to better understanding of the association 
between miRNAs and numerous human pathologies. Therefore, altered miRNAs, as a 
result of diseases could either be detected for diagnosis or be used as therapeutic 
targets.84  
MicroRNAs are a promising tissue-based biomarker for cancer research.99 Several 
studies report the abnormal expression of miRNAs in cancer initiation and progression 
– they may act to inhibit tumour suppressor gene expression or activate oncogene 
expression. The study of aberrant miRNA expression profiles in the body fluids of 
patients with cancer represents an innovative way to identify new biomarkers for 
disease detection and progression.15 Importantly, miRNAs signatures with highly tissue-
specific origin could lead to efficient identification of metastatic cancers of unknown 
primary origin.100,101 
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In prostate cancer, several studies report the value of serum and plasma circulating 
miRNAs in the detection and prognosis of prostate cancer.100 Deregulated miRNAs 
have been implicated in several processes in this cancer including cell proliferation, 
differentiation and progression. Despite variation in patients’ age, ethnicity, and the 
different balance between local and advanced prostate cancer, the expression of miR-
141, miR-375 and miR-21 were reported significantly higher in patients than in matched 
healthy individuals, repeatedly.100,102 
In 2011, Kanemaru et al. for the first time demonstrated a diagnostic role of circulating 
miRNA expression in melanoma by reporting an increase in the serum level of miR-221 
in patients with metastatic disease. In later studies, a serum-based signature of four 
miRNAs (miR-15b, miR-30d, miR-150 and miR- 425) were found to predict recurrence 
of cancer; co-detection of miR-185 and miR-1246 was found to distinguish patients 
with metastatic melanoma from healthy individuals.103 
MicroRNAs also perform a critical function to modulate both the innate and acquired 
immune systems and develop autoimmune reactions.104 It has been reported that Dicer 
enzyme with regulatory responsibility in RNA biogenesis is required for T-cell function 
and removing Dicer enzyme results in autoimmune disorders.104 Moreover, several 
specific miRNAs are present within the immune system and have a dramatic impact on 
autoimmune responses through their regulation of inflammatory T cells.105 For instance, 
miR-155 promotes inflammatory responses, while miR-146a, in contrast, limits T-cell 
activation and mediates immune suppression.105,106 Therefore, these miRNAs can be 
considered as therapeutic or diagnostic tools. It has been suggested modulating these 
miRNA’s expression level with specific and targeted approaches might be a therapeutic 
means to treat autoimmune disease.106  
Development of the CNS and generating interconnection between distinct cells within 
the CNS require coordinated events (e.g., transcriptional networks and cell signaling) 
and multilayered regulatory networks (e.g., electrochemical signals).93 In this regard, 
abundant numbers of miRNAs have been revealed in the brain, compared to other 
organs, contributing to neuronal development regulation.107 These miRNAs are highly 
tissue-specific, and even distinct cell types in the CNS shed miRNAs with specific 
patterns and function.108 The first reports translating profiles of deregulated miRNA 
studies to the brain identified some brain enriched miRNAs such as miR-9, miR-29a, 
miR-125, miR-128, miR-134, and miR-137. A number of these deregulated miRNA 
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(miR-9, miR20a, and miR-132) have been reported to correlate with Alzheimer 
disease.109  
The resident innate immune cell of the CNS, microglia, performs as the primary 
defender in immune surveillance, which in response to brain injury or other stressors 
activates inflammation. Dysfunction in microglia results in nonresponsive pro-
inflammatory activity leading to neurodegeneration.108,110 Microglia are enriched for 
specific miRNAs (e.g., miR-124 and miR-155) with heterogeneous expression in 
different brain regions. For instance, miR-155 promotes microglia pro-inflammatory 
function while miR124 inactivates microglia and reduces CNS inflammation. These 
findings indicate miRNAs regulatory roles in the behavior of microglia, and their effect 
on inflammation and related neurological diseases.110 Therefore, modulating miRNAs to 
skew the behavior of microglia based on each disease’s specific requirement is a novel 
therapeutic strategy.84 
Although several studies have confirmed that miRNAs have a biomarker potential, free 
circulating miRNAs are fluctuating in their stability.111 Conversely, miRNAs related to 
extracellular vesicles are a better candidate to study as they carry a selective package of 
miRNAs, and reflect their cell or tissue origin.111 Thus, in this study, we have focused 
on exosomal miRNA as a valuable biomarker to monitor the neurological diseases and 
assess their treatment, which can be measured in the serum in a minimally invasive 
manner. 
Multiple sclerosis 
Background 
Multiple sclerosis (MS) is an idiopathic inflammatory, demyelinating, and progressive 
neurodegenerative disease of the CNS.112 It is a chronic disease with a widely variable 
clinical course that results in functional and cognitive deterioration over time, and a 
reduced lifespan. MS is the most common neurological disease of young adults, and 
disproportionally affects women. This chronic disease results in ongoing functional 
deterioration and increasing disability.113 MS affects 2.5 million people worldwide114 
and over 23,000 people were living with MS in Australia in 2013115. 
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The reported incidence of MS has increased in the last five decades, especially in 
women. This is partially attributable to new diagnostic technologies and increased 
awareness. Alternatively, environmental factors (e.g., smoking) and reproductive factors 
(e.g., pregnancy) may contribute to the female to male ratio increase.116,117 
MS was first characterised as a distinct disease in 1868 by Jean-Martin Charcot, who 
correlated the clinical features of MS with pathological changes noted post-mortem.118 
Despite being described almost 150 years ago the cause of MS still remains unknown. 
The disease primarily affects the myelin sheath around central axons, slowing axonal 
conduction and leading to a variety of deficits based primarily on the location of the 
demyelinating lesion(s). It has become increasingly evident that not only the myelin 
sheath is affected in MS; there is significant and cumulative axonal damage and even 
neuronal cell loss in chronic MS, and these latter effects correlate most closely with 
long-term motor and cognitive disability. The immune system is clearly dysregulated in 
multiple sclerosis; however, it is unknown whether MS represents a primary 
autoimmune disease targeting the CNS, or whether there is a primary abnormality 
within the CNS that recruits a secondary adaptive immune response (the ‘inside-out’ 
hypothesis).112,119 
With modern treatments, MS rarely develops into a life threating disease: 95% of 
patients have a normal life expectancy. However, disease symptoms significantly affect 
the patient's quality of life: 43% of MS patients suffer from progressive motor 
deterioration that leads to physical and mental disability. This not only imposes 
increased dependency on affected individuals but also a heavy financial burden on their 
families and society.115 
MS development and propagation 
MS is a chronic inflammatory autoimmune demyelinating disease of the CNS, which 
involves the brain, spinal cord, and optical nerves and causes motor, sensory, and 
cognitive deficits. Initially, remyelination⎯a spontaneous repair in the adult 
CNS⎯recovers the demyelination. However, the pathology of the disease changes over 
time and neurological dysfunction becomes dominant.120,121 
MS pathogenesis is unknown and the current theory is that it begins with an 
inappropriate cascade of activated T cells into the CNS by crossing the broken BBB. 
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Activated T cells produce inflammatory cytokines and trigger an immune response 
against myelin, oligodendrocytes (myelin-forming cells), and surrounding tissue, 
resulting in the formation of demyelination plaques and axonal degeneration. The 
demyelinated axons lead to weak conduction velocity of action potentials and in 
extreme cases, may completely inhibit the signaling pathways.122 Demyelination and 
axonal degeneration patterns are shown in Figure 1-4. 
 
Figure 1-4 Demyelination pattern 
A) The axon of a healthy nerve cell covered with myelin sheaths that contribute to conducting signals 
from the nervous system to the rest of the body. B) Disruptions in myelin sheaths result in slowing down 
or halting signal conduction. C) In the case of axonal degeneration, demyelination is irreversible, and 
signal conduction is lost.  
MS plaques (MS lesions) can occupy different spots in the white matter, including the 
spinal cord.120 Magnetic resonance imaging123 is used to diagnose these lesions in MS 
suspected patients. There is a growing recognition that grey matter demyelination is also 
involved in disease propagation. While the lesions in the grey matter are mostly 
undetectable with traditional magnetic resonance imaging (MRI), the results of 
immunohistochemical studies in the past decade have shown intense involvement of the 
grey matter of the CNS in the pathology of MS.124 Thus, MS is a complex disease with 
a wide range of symptoms affecting several parts of the body with varying severity.125 
Etiology of MS 
MS is thought to have a multifactorial etiology. To date, no causative agent has been 
identified in MS; susceptible genes, an abnormal immune system, and specific 
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environmental exposure have all been proposed as factors involved in the causation, 
exacerbation, and prognosis of MS (Figure 1-5).126 
 
 
Figure 1-5 Etiology of MS  
Multiple sclerosis is a complex neurological condition with an unknown etiology. A variety of factors are 
involved in developing MS; abnormal immune system, environmental components and susceptible genes, 
and interactions between. 
Twenty five per cent of MS patients have a family history of the disease in a first-
degree relative. However, no single causative gene has been identified. This suggests 
that MS is not a classic Mendelian heritable disease. Instead, it is more likely to be 
polygenic, and/or a combination genetic predisposition and environmental stressors. 
Interestingly, epidemiological data also has shown that imprinting or parent-of-origin 
effect in MS plays a substantial role.127 
The first evidence of the association between human leukocyte antigen (HLA)128 
haplotype and MS susceptibility was shown in 1972129. Later this association was 
referred to as HLA-DRB1*1501, a haplotype with significant genetic effect in MS 
(heterozygosity odds ratio (OD) of 2.7 and homozygosity OD 6.7). Despite the strong 
phenotypic effect of HLA-DRB1*1501 on the disease, this association is not 
straightforward. In fact, a combination of different haplotypes has a positive or negative 
impact on MS. For instance, HLA-DRB1*08 in combination with HLA-DRB1*15 
doubles the risk of MS. Conversely, HLA-DRB1*14, as a protective haplotype, 
completely nullifies the increased risk of HLA-DRB1*15.130 It has been showed that 
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between 20–60% of the genetic susceptibility in MS is related to the HLA locus. In 
addition to the HLA regions, two other risk loci (IL-7RA, interleukin 7 receptor alpha, 
and IL-2RA) have been identified in promoting lymphocyte growth and differentiation. 
More than a hundred (102) single nucleotide polymorphisms have also been shown to 
affect MS disease risk, mostly through affecting the immune function.131 
Many studies demonstrate that age and gender play a definitive role in MS 
susceptibility. MS occurs most commonly in young people, between ages 20 and 40 
(onset before 10 and after 55 is rare), and in women.122,132 Over the past century, the 
female predominance of MS has increased significantly. The mechanisms underlying 
the observed gender specificity are still largely unknown. Factors such as the role of 
hormones, differences in the male and female immune system and the CNS, genetic and 
epigenetic factors may be relevant.126 
MS susceptibility is also strongly influenced by the environment. For example, 
geographical locations are closely associated with MS risks. Distance from the equator 
and the climate correlate with the prevalence of MS, with the lowest rate of incidence in 
Africa, South America, and Asia, and the highest incidence in Scotland and parts of 
Scandinavia and Canada.127 This fluctuation may be partially explained by common 
genetic factors of the ethnic groups who live in these risk areas. However, migration has 
been shown to change the likelihood of developing MS especially for migrants who 
have relocated at a young age.131 Similarly, exposure to sunlight has been shown to 
decrease MS susceptibility. It is thought to have a protective effect mediated by 
ultraviolet radiation, as the primary source of vitamin D for most people. Vitamin D is 
important for both normal physiology and several autoimmune diseases.133 
Systemic infection during childhood or early adulthood is thought to be another 
etiological factor for MS. This is because increased level of IgG and the presence of 
alkaline oligoclonal bands in the cerebrospinal fluid (CSF) are detectable in almost all 
of the MS patients (95%). Direct viral damage to brain cells or the productions of 
antibodies, which attach the myelin, are hypothesized to act as a trigger for 
demyelination in MS patients. Human Herpes Virus-6 (also known Epstein Barr Virus; 
EBV) is the best known candidate for MS causation.134 Current or past cigarette 
smoking also increases MS risk. While there is no known mechanism for this, smoking 
has a direct effect on the immune system.133 
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Overall, the exact causes of MS are unknown, although solving the complex genetics 
underlying the disease as well as the environmental risk factors such as EBV infection, 
smoking and vitamin D status may help to achieve a better understanding of MS 
etiology.126 
Immunopathogenesis of MS 
MS is a common debilitating disease characterised by inflammation in CNS. It is 
associated with focal plaques of primary demyelination and distributed 
neurodegeneration in the brain and spinal cord.126 There are many conflicting theories to 
explain MS. The most widely accepted theory is that multiple sclerosis begins with an 
inflammatory cascade in the CNS. Autoreactive T- and B- cells from the peripheral 
immune system infiltrate the CNS by crossing the BBB and trigger an immune response 
against myelin, myelin-forming cells (oligodendrocytes), and the surrounding tissue (the 
outside-in hypothesis) (Figure 1-6A). Alternatively, there is a hypothesis that a primary 
infection or neuronal disruption within the brain can act as an initial trigger, and 
inflammation occurs as a secondary response followed by tissue damage and disease 
(the inside-out hypothesis) (Figure 1-6B).  
 
Figure 1- 6 MS: the demyelination disease with an immune system disorder and an unknown 
trigger 
A) Outside-in hypothesis: MS is an autoimmune disease targeting the CNS. B) Inside-out hypothesis: 
There is an abnormality in the CNS that initiates the disease and an activated immune system response to 
it. 
However, there is no known autoimmune reaction or infectious agent specific to MS 
that can provide evidence for either hypothesis of MS initiation. Therefore, it is still 
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largely unknown whether MS represents a primary autoimmune disease targeting the 
CNS, or if there is a primary abnormality within the CNS that recruits a secondary 
adaptive immune response.135 
Types of MS 
Despite the prevailing dogma in neurology that the CNS was relatively stable in 
structure, evidence from the 1990s demonstrated that CNS is capable of plasticity and 
repair. Indeed, remyelination of CNS axons is now a well-documented phenomenon.121 
This phenomenon is best seen in the white matter of the brain and spinal cord in MS 
patients. Remyelination occurs in two major phases: oligodendrocyte progenitor cells 
colonise in the lesions and then differentiate into myelination oligodendrocytes. The 
process of remyelination cannot keep pace with deterioration, so inadequate 
remyelination is generally observed in the MS brain and spinal cord. In this regard, the 
balance between number of oligodendrocytes and macrophages in lesions play a vital 
role.121  
Patients with MS present wide range of clinical manifestations. The type and severity of 
symptoms depend on the location of scar tissue and the extent of demyelination. 
Different patients demonstrate a variety of symptoms and even the same patient shows 
highly variable duration and expression of symptoms over time.136 Based on the course 
of the disease MS patients are categorised  into four major groups. Clinically isolated 
syndrome is the first neurological presentation of the disease with inflammatory 
demyelination characteristics that can be optic neuritis, incomplete myelitis, or 
brainstem syndrome (Figure 1-7A).137 
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Figure 1-7 Different types of MS 
A) Clinically isolated syndrome is the first episode of neurological disorder and demyelination with a 
chance of developing into MS. B) Relapsing remitting multiple sclerosis (RRMS) the most common 
phenotype of MS with various numbers of disease symptom flare ups (relapses) and spontaneous 
recoveries (remitting). C) Secondary progressive multiple sclerosis (SPMS) in which symptoms of the 
disease progress constantly. D) Primary progressive multiple sclerosis (PPMS) without relapsing 
remitting stage and disease diagnose in a progressive stage.  
People presenting these symptoms may or may not meet MS diagnosis criteria and 
develop the disease.137 The disease in 85% of patients starts with a relapsing- remitting 
course.138 The symptoms of disease flare-up (relapse) and then in a period of days or 
weeks the symptoms recover to very low levels- symptoms may improve or disappear 
(Figure 1-7B). After 10 to 15 years the disease in the majority of RRMS patients 
gradually become progressive with or without acute exacerbations during the 
progressive course, named SPMS (Figure 1-7C).139 This transformation occurs with no 
clear clinical, imaging, immunologic or pathologic criteria. Another spectrum of 
progressive MS is primary progressive MS (PPMS) seen in 10-15% patients. These 
patients miss the relapsing- remitting stage as a clinical manifestation, so symptoms 
tend to worsen consistently from the disease onset (Figure 1-7D).140 The absence of 
exacerbations prior to clinical progression separates secondary progressive MS (SPMS) 
from PPMS141, while both are considered as progressive MS with similar clinical and 
imaging features142,143.  
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Disease management 
A variety of pharmacological therapies are available for MS: symptomatic treatment 
and disease modifying therapies (DMT).144 While symptomatic therapeutics focus on 
relieving specific symptoms such as fatigue, DMTs suppress the peripheral adaptive 
immune response to reduce the inflammation and alter the course of the disease by 
minimizing the frequency of relapses, the number of MRI lesions and slowing down the 
progression step.145 The first DMT medication, interferon beta-1b, was introduced in 
1993 and since then many other treatments have become available, which can be 
categorised as platform (self-injectable) medications (e.g., Plegridy, Rebif, and 
Copaxone), infusions (e.g., Natalizumab and Alemtuzumab), and oral medications (e.g., 
Fingolimod and Tecfidera).146 DMTs have been reported to have greater efficacy in 
RRMS patients, mainly in early initiation compared to delayed commencement, rather 
than in MS patients in progressive stage.147  
DMTs can also be divided into two groups based on their mechanism of action: low-
efficacy, and high-efficacy. While high-efficacy treatments are more efficient in 
reducing relapses and inverting brain atrophy, the common strategy to manage MS 
begins with low-efficacy DMTs with fewer side effects. The therapy intensifies to high-
efficacy DMTs in patients demonstrating declining response. Although there is evidence 
that early treatment with high-efficacy DMTs offers better control over disease activity 
compared to low-efficacy DMTs; further consideration based on each patient’s 
condition, is required to balance the safety and efficacy of either treatment.144,145  
MS activity monitoring and diagnosis 
Despite being described almost 150 years ago, the cause of MS still remains unknown 
and no one definitive test exist for MS. Diagnosis and disease activity monitoring is 
based on clinical examination, MRI, CSF studies and neurophysiology.146  
Clinical marker 
The clinical examination is the classical way to evaluate MS disease activity, 
progression, and frequency of relapses.143 However, due to the heterogeneity of 
symptoms of MS, MRI of the CNS is necessary to support, supplement or even replace 
some clinical criteria. MRI examination can detect a new lesion in MS patients with or 
without clinical symptoms.122 Therefore, MRI is a standard technology for the diagnosis 
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and monitoring of MS, by assessing focal lesions in the white matter and visualising the 
gray matter involvement and brain atrophy.148,149 
The diagnosis of MS rests on proving dissemination of inflammatory CNS lesions in 
both space and time, and the exclusion of other disease processes. The incorporation of 
MRI into the McDonald Criteria for MS has facilitated the earlier diagnosis of the 
disease.150  
Expanded disability status scale 
The expanded disability status scale (EDSS) is the oldest clinical assessment tool in 
MS. It measures seven functional abilities of patients without concentration on 
cognitive changes. Although, EDSS represents a low sensitivity in clinical examination, 
is still listed as a quantifying disability in MS patients.146 
There are significant numbers of new patients whose MRI findings are unclear or 
ambiguous due to white matter lesions of unknown etiology. Current monitoring of 
RRMS patients requires regular MRI scanning (every six months) which is associated 
with high cost and limited accessibility. Thus, an urgent need exists to identify blood-
based biomarkers to confirm MS diagnosis and monitor disease activity. Using 
peripheral blood for diagnostic tests is a non-invasive and cost-effective method. 
However, identifying a reliable panel of biomarkers in MS has been extremely 
challenging with regard to obtaining high sensitivity and specificity and also 
reproducibility upon validation.151 Many potential biomarkers have been proposed, 
including myelin-specific antibodies in serum,152 neurofilament light chains,153 and 
inflammatory markers in CSF,151 however to date, no reliable biomarker has been 
introduced into routine clinical practice. 
Biological markers 
Biological markers (biomarkers) are measurable characteristics that indicate biological 
processes, pathogenic processes or pharmacologic responses to a therapeutic. Scientists 
have been utilising biomarkers to diagnose various diseases for more than 50 years. 
This process has expanded in the 21st century and more candidate biomarkers have 
been generated using high-throughput technologies such as –omics. Nowadays the 
importance of valid biomarkers in molecular diagnosis is undeniable.154 Different 
molecules and cellular component can be used as biomarkers. In this study we are 
interested in examining some processes of intercellular communication to discover 
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reliable blood-based biomarkers for neurological diseases such as multiple sclerosis and 
glioblastoma. 
Biomarker study in MS has a long history. Many molecules have been investigated, but 
no strong correlation has been detected. For instance, many studies have examined the 
level of proteins in the CSF or serum of MS patients, such as neurofilament, glial 
fibrillar acidic protein, Nogo and CD163. None of the studied proteins has sufficient 
specificity and sensitivity to be used as a marker, except for the IgG index and 
oligoclonal bands, which provide supportive evidence in MS diagnosis.53 The focus of 
early epidemiology studies was on understanding the genetics of MS. The most reliable 
genetic link for MS susceptibility is the HLA-DRB1*15 haplotype.130 However, 
progress in genome studies using whole genome admixture studies and next-generation 
sequencing methodologies have provided new molecular targets for mechanistic 
investigations, and biomarker discovery.155 Bomprezzi et al. studied gene expression 
profiles in PBMC and observed a significant increase in the IL-7 receptor transcript in 
MS patients in comparison to healthy individuals.156 Subsequent studies confirmed that 
the IL-7 gene is linked to increased MS susceptibility and also showed expression 
changes between RRMS patients in remission versus active relapse, and between SPMS 
and PPMS patients versus healthy individuals.155,156 Later, Hecker et al. identified two 
gene transcripts, GPR3 and IL17RC, with increased expression in the blood of RRMS 
patients that had potential as biomarkers. Also, there have been many studies focused on 
determining the efficacy of drug treatment by monitoring changes in gene expression.157 
Overall, the result of these studies is mixed with very few overlapping gene transcripts 
between reports which might be attributable to a variety of factors such as the difference 
in MS patients subpopulations, sample sources, and experimental design.155 
The role miRNAs in MS 
MS is one of the most common neurological disorders in young adults. MS is a 
heterogeneous disease with unclear etiology and no definitive diagnostic test, which 
makes it a perfect candidate for biomarker study.122,142  
In 2009, Junker et al.96 and Du et al.158 assessed the expression of miRNAs for the first 
time in cells derived from MS patients’ lesions and blood samples respectively96,158. The 
first group96 was interested in analysing miRNA profiles in active and chronic inactive 
MS lesions to find a link between miRNAs and specific dysregulated genes in MS and 
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also to identify novel miRNA targets. While Du et al. evaluated the expression of 
miRNAs in MS patients after treatment to determine a diagnosis biomarker and estimate 
drug responses.158 Interestingly, both groups reported a particular dysregulated miRNA 
(miR-326)96,158 with a regulatory function toward MS-associated proinflammatory 
lymphocytes Th17 differentiation.159 Subsequently, several studies have profiled 
miRNAs from the brain, different cell populations10 and peripheral blood mononuclear 
cells160,161 from MS patients to identify potential biomarkers. The correlation between 
cellular dysregulated miRNAs and diseases, including MS, raised the question whether 
circulating miRNAs in body fluids are also correlated with diseases physiopathology.162  
There is evidence of the existence of miRNAs and mRNAs outside cells. Valadi et al., 
in 2007, detected them in cell culture.42 This report was followed by parallel studies 
addressing the detection of cell-free miRNAs in the human biological fluid.94,99,163,164 In 
2008, Chim et al. demonstrated the presence of placental miRNAs in maternal plasma, 
which is readily detectable and is promising as a marker in the clinical setting.164  
The elevation of miRNAs in serum94 and plasma from cancer patients also confirmed 
that the expression levels of specific circulating miRNAs⎯tumour-derived 
miRNAs⎯could be related to the disease.99 This finding was confirmed by a 
subsequent discovery of miRNAs derived from circulating blood cells under normal 
conditions, that could change in the disease state. Cell-free miRNAs in body fluids are 
reported being stable under harsh conditions (e.g., low/high PH, long-term storage and 
multiple freeze-thaw cycles) and resistant to RNase A digestion.163,165 Thus circulating 
miRNA profiles in body fluids including serum, plasma and CSF, shed from different 
cells, reflect the biological status of the body and have been described as a novel 
biomarker.165  
The first study that showed the involvement of the plasma circulating miRNAs as a 
potential prognostic and diagnostic biomarker for MS was reported in 2012 by Seigel et 
al. who compared a small group of MS patients to healthy individuals (four people in 
each group).166 This initial report was followed by another plasma circulating miRNA 
study on a bigger number of RRMS161 and SPMS patients167. Due to differences in the 
procedure for miRNA profiling (e.g., RNA extraction, miRNA quantification, and 
statistical analysis), the reported miRNAs represent minimal compatibility.159,168 To 
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solve this issue, the standard method for sample handling shows a significant capacity 
in reducing technical variability between protocols.109,168,169 
The fundamental approach to analysing miRNA profiles is based on a microarray 
analysis,123 quantitative reverse transcriptase PCR,166,167,170,171 and lately next-
generation sequencing (NGS)123 techniques. Keller et al. in 2014, for the first time, used 
NGS to assess dysregulated miRNAs in the whole blood of MS patients. They also 
confirmed identical regulation pattern for the eight miRNAs in the microarray analysis 
and NGS.123 Although they demonstrated converging results for microarray and NGS 
methods, NGS is the better technique to detect almost all miRNAs in each sample with 
higher sensitivity as compared to microarray screens.123,159,172 Nevertheless, microarrays 
and quantitative reverse transcriptase PCR have been employed in multiple studies to 
conduct miRNA profiling experiments as NGS is an expensive method and produces a 
large output which requires data processing pipelines to process and analyse the 
data.96,123,159,167,173,174  
The stability of endogenous miRNAs in body fluids is a consequence of being loaded 
into high-density lipoprotein,175 bounded by proteins,176-178 or packed into extracellular 
vesicles18,179. However, although purified extracellular miRNAs from the culture 
medium of different cell lines and human body fluids have been demonstrated to be 
protected and delivered by high-density lipoproteins and proteins (e.g., Ago2 and 
nucleophosmin 1), so far no releasing mechanisms have been described to be associated 
with them.175,176 Moreover, some studies highlighted that the majority of circulating 
miRNAs in body fluids are associated with Ago2 proteins rather than being packed in 
extracellular vesicles.178 In fact, these miRNA-Ago2 complexes could drive from dead 
cells or degradated exosomes as they have been reported to be carried by exosomes.162  
Role of exosomes in MS 
Recently, exosomes and their cargo became a candidate for a potential biomarker, and 
many studies have attempted to determine their involvement in MS. Verderio et al. in 
2011 for the first time reported the release of exosomes from microglia, the immune 
cells in the CNS, which is detectable with a high concentration upon brain inflammation 
in human and rodent. Thus, the presence and concentration of these exosomes in the 
CSF represent a biomarker of ‘inflamed CNS’, which may reflect a signature of the 
disease.57 The following study on this topic has revealed that the number of exosomes in 
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the serum of RRMS patients, especially during relapsing, is higher in comparison to 
both progressive patients and healthy individuals. RRMS and SPMS/PPMS characterise 
distinctive clinical states. Relapsing-remitting patients are in an inflammatory state of 
disease, with a peak during relapses and decrease on remitting periods, while 
SPMS/PPMS patients present less inflammatory activity and turn to the progressive 
degenerative phase.180 The association between the number of immune cell-derived 
exosomes and inflammatory conditions in autoimmune disease has been well 
established.14 And the result of these two studies demonstrated the association between 
increased amount of exosomes and development of neuroinflammation.57,180 Although it 
demonstrated exosomes’ role in MS pathogenesis and their reflection of disease status, 
thus far these findings have not yielded a diagnostic or prognostic biomarker in 
MS.53,180  
Several studies have demonstrated that exosomes released from different neuron cells 
could regulate the process of myelination in the CNS.53 Myelin formation is a multistep 
process, which occurs during the development of the CNS and is controlled by a variety 
of factors. Oligodendrocyte precursor cells differentiate into mature oligodendrocytes 
with a capacity of producing myelin membrane component. Synthesised myelin lipids 
and proteins require signals received from the microenvironment or axon to induce 
myelin membrane trafficking and start to enwrap axons.56 It is reported that 
oligodendrocyte-derived exosomes inhibit the growth of mature oligodendrocytes and 
myelin formation. Therefore, this study suggested that neurons coordinate myelin 
membrane biogenesis by controlling the secretion of oligodendrocytes -derived 
exosomes.56,57,180 Conversely, exosomes released from mature oligodendrocytes in 
response to activation via specific receptors enhance myelin formation both at the 
development level and at the regeneration of damaged sheets.53 Exosomes are also 
released from astrocytes possessing synapsinI, and dendritic cells. Astrocyte-derived 
exosomes promote nerve cell growth, survival, and differentiation, while exosomes 
secreted by dendritic cells stimulate oligodendrocyte precursor cells growth and 
promote the process of repair during demyelination.53 Overall, exosomes released from 
different cells within the CNS play vital roles in myelination by influencing the growth 
and function of oligodendrocytes and neurons.53 
Moreover, exosomes secreted from endothelial cells, lymphocytes, and platelets in 
response to pro-inflammatory stimulation induce disintegration of the BBB and 
  ERROR! REFERENCE SOURCE NOT FOUND.  
 47 
facilitate immune and myeloid cells transmigration.53 So exosomes can reflect the status 
of cell activation and pathological changes.181 Despite the low concentration of secreted 
exosomes, their information-rich contents including miRNA, and the remarkable 
stability of those contents within exosomes make exosomes a potential biomarker to 
indicate disease states.18 
Glioma 
Gliomas are tumours of the CNS that arise from glial cells.182 The most common site of 
gliomas in the CNS is the brain, with rare metastasises beyond the CNS.183 Gliomas 
comprise 30% of all brain tumours and 70–80% of all malignant brain tumours.184 
Although brain tumours are less prevalent than other cancer types, with an incidence 
rate of 5–6 per 100,000 people worldwide, they are the leading cause of cancer-related 
deaths in Australians under 40.185,186 According to the World Health Organization 
(WHO), glioma tumours are classified as one of three types based on histological 
characteristics: astrocytoma (astrocytes), oligodendroglioma (oligodendrocytes), 
oliogoastrocytoma (mixed population of both), ependymoma (ependymal cells)182,185,187 
(Figure1-8).  
 
Figure 1-8 Classification of glioma tumours based on WHO 
Gliomas comprise all primary CNS tumours of glial-cell origin. Glial cells include astrocytes, 
oligodendrocytes, and ependymal cells which develop astrocytoma, oligodendroglioma, ependymoma. 
Each of these tumours is further graded according to their biological behavior to 
tumours with low (grades I and II; low-grade gliomas (LGGs)) and high malignancy 
(grades III and IV; high-grade gliomas (HGGs)).188  
Gliomas also can be categorised based on their invasiveness into normal brain tissue to 
‘diffuse gliomas’ and ‘circumscribed’. Diffuse gliomas not only have the ability to 
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infiltrate, but also over time recur and tend to progress to high-grade. Based on the 
WHO classification scheme astrocytoma can be graded into diffuse astrocytoma (Grade 
II), anaplastic astrocytoma (Grade III) and eventually glioblastoma (Grade IV) with a 
rapid clinical deterioration.189 Grade I astrocytomas are potentially curable through 
surgery alone whilst grade II astrocytomas, even after surgery and radiotherapy, 
frequently return as higher grade gliomas.190  
The leading risk factors for the development of glioma are largely unknown. Sequential 
and cumulative genetic alteration, exposure of the head and neck to ionizing radiation, 
aging and family history are the only risk factors indicated to date.191,192 Although a 
family history of glioblastoma is rare, where it is present it, increases the risk of 
developing glioma up to two-fold.191 Exposure to radiofrequency electromagnetic fields 
(EMFs) via cell phone is controversial, and despite a lot of attention as a potential risk 
factor for brain tumour development, it is not well supported as a risk factor.192,193 
Previous studies have indicated that dietary changes and supplementation provide a 
protective effect against glioma, although to date none has been proven effective and 
there has been no significant improvement in glioma survival rates for almost 30 
years.194 
The standard treatment for patients with glioma is usually surgery, followed by 
radiation therapy or combined radio- and chemotherapy depending on location, grade 
and type. While most benign tumours can be successfully treated by surgical excision, 
high-grade gliomas have poor prognoses.191 
Molecular characterisation of gliomas 
The previous WHO glioma classification was based on clinical, radiological and mainly 
histopathological characteristics of the tumour.195 Histologic criteria for GBM diagnosis 
include hypercellularity, nuclear atypia, mitotic activity and either microvascular 
proliferation and/or tumour necrosis. However, the histologic features may not 
distinguish between different subtypes nor capture the molecular and cellular 
heterogeneity of brain tumour. Therefore, molecular signatures became candidates in 
classification criteria, diagnosis and treatment of malignancies.189 For instance tumour 
protein 53 (TP53) mutation appears in the early stage of the development of an 
astrocytoma, whereas the loss or mutation of phosphatase and tensin homolog (PTEN) 
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and amplification of epidermal growth factor receptor (EGFR) occur in tumours that 
have progressed to a high grade.196 
In 2016, for the first time, genotypic identification of tumour pathology has become a 
feature of the WHO classification of CNS tumours.197 Thus, GBM is further classified 
based on somatic mutations of the metabolic enzyme isocitrate dehydrogenase isoforms 
(IDH1/2) into IDHWT and IDHMUT.196,198 All reported mutation for IDH1 and IDH2 is 
located at codon 132 and 172 respectively.198 IDHWT type tumours account for 10% of 
GBM known as primary glioblastomas without previous lesions. However, the mutation 
in IDH was detected in 90% of secondary glioblastomas as a definitive diagnostic 
molecular marker with higher reliability than clinical or pathological criteria.198 It has 
been suggested that IDH gene might be mutated after formation of the low-grade glioma 
to drive the progression of the disease to secondary glioblastoma.196  
IDH-mutant glioblastoma is associated with an earlier diagnosis and better prognosis, 
with a median survival time of 27.1 months.199 IDH genes encode a metabolic 
(isocitrate dehydrogenase) enzyme that plays a vital role in the citric acid cycle. Wild-
type IDH1 catalyses the oxidative decarboxylation of isocitrate to α-ketoglutarate to 
produce nicotinamide adenine dinucleotide phosphate.200 Mutation in either IDH1/2 
reduces enzymatic activity196 which results in decreasing nicotinamide adenine 
dinucleotide phosphate levels and produces an altered metabolite instead of 
nicotinamide adenine dinucleotide phosphate, 2-hydroxyglutarate201. Tumours 
harbouring IDH1/2 mutations in GBM have better prognosis in comparison to wildtype 
malignancies.201,202 Therefore, IDHMUT GBMs are sensitive to therapy and prolonged 
survival.  
EGFR gene is also over–expressed in up to 57% of GBM tumours.203 The majority of 
GBMs with EGFR amplification also carry the most common EGFR mutant gene, 
EGFRvIII.204 EGFR dysregulation, especially EGFR amplification, promotes cell 
growth and division and is associated with an unfavourable prognosis.205 The 
tumourigenic role for EGFR has made it a valuable target for therapeutic 
intervention.206 
TP53 gene at chromosome 17p13.1 plays the guardian role in the genome that activates 
DNA repair or induces cell death in response to cellular stress.207 TP53 network is also 
implicated in the tumourigenesis. TP53 is activated in 60% of early stage gliomas 
  ERROR! REFERENCE SOURCE NOT FOUND.  
 50 
(grade II & III astrocytoma) and found more frequently in secondary GBMs (>60%) 
than primary GBMs (~10%).208  
Chromosomal arm deletions are also associated with gliomas. For instance, codeletion 
of chromosome 1p and 19q (1p/19q codel) is of interest as it raises the survival rate in 
oligodendroglioma.209 Other low grade, IDH mutant tumours in the absence of 1p/19q 
codel contain TP53 mutation and ATRX inactivation  
(Figure1-9).198 
 
Figure 1-9 Genetic pathways to primary and secondary glioblastoma 
Primary and secondary glioblastomas are histologically largely indistinguishable, however, mutations in 
IDH1/2 occur in early tumourigenesis and persist during progression to secondary glioblastoma. Cells 
with IDH1/2 mutations that subsequently acquire TP53 and ATRX mutations develop astrocytomas, 
whereas oligodendrogliomas shows acquisition of 1p/19q loss in cells with IDH1/2 mutations. 
In low-grade gliomas, IDH1/2 mutations occur before TP53 mutation or 1p/19q loss as 
an early event in tumourigenesis. 
Glioblastoma multiforme 
Glioblastoma multiforme (GBM) is a grade IV astrocytoma. GBM is the most frequent 
and aggressive form of primary malignant brain tumour in adults, with a rising 
incidence over the last 20 years; notably in Australia.182,189,191,210 An older population 
and improvements in imaging and diagnostic techniques are responsible in part, for the 
increase in GBM diagnosis; however, the influence of other factors remains to be 
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determined.211 Unfortunately, GBM carries exceedingly poor prognosis with a median 
survival of 15 months, and most of the tumours recur locally.191,212  
The high mortality rate of GBM and its poor response to conventional chemotherapy 
and radiation attest to its invasive nature. Therefore, new diagnostic approaches are 
required for better understanding GBM invasion and its molecular processes.182  
GBM subtypes 
The Cancer Genome Atlas (TCGA) research network utilised a comprehensive study on 
GBM to examine the molecular characteristics and classification of these heterogeneous 
tumours.203 The TCGA study demonstrated that GBM might acquire or lose 
chromosomes and carry amplifications, mutations or deletions. These characteristics 
have provided details on the tumourigenesis of glioblastoma and potential targets for 
new therapeutic approaches. The TCGA has now further defined four subtypes for 
GBM: classical, mesenchymal, proneural and neural.182,203 Based on the new 
classification each subtype demonstrates particular mutations. The characteristic of each 
subtype is listed in Table 1-1.   
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Table 1-1 Characteristic of glioblastoma subtypes 
 
Abbreviations: EGFR, epidermal growth factor receptor, PTEN, phosphatase and tensin homolog, 
CDKN2A, cyclin-dependent kinase inhibitor 2A, TP53, tumour protein p53, cMET, hepatocyte growth 
factor receptor, NF1, neurofibromin, CHI3LI, chitinase-3-like protein, PDGFR, platelet derived growth 
factor receptor, IDH1, isocitrate dehydrogenase 1, SOX, Sry-related high mobility box, NEFL, 
neurofilament like polypeptide, GABARA1, gamma-aminobutyric acid type A receptor alpha 1 subunit, 
SYT1, synaptotagmin 1, SLCI2A5, solute carrier family 12 member 5. 
GBM pathophysiology 
GBM has a unique pathophysiology compared to other gliomas with high degree of 
aggression and malignancy, which allows the tumour to spread out quickly to the point 
where even total hemispherectomy has failed to be curative.210 The infiltrative growth 
of GBMs is a major challenge to managing their development and recurrence.182 GBMs 
are invasive due to an extensive vascular system, disruption in the integrity of the BBB, 
high migration rate of tumour cells along vasculature, and GBM cells’ potential to 
release proteases and degrade the extra-cellular matrix.187  
Furthermore, GBMs are extremely heterogeneous, composed of many different cell 
types. Cancer stem cells have emerged as a possible sub-class of cells within tumours. 
Subtype Mutations Clinical features 
Classical 
EGFR amplification, PTEN null, 
CDKN2A null, TP53 wild-type 
Aggressive treatment 
significantly improved 
survival rates 
Mesenchymal 
cMET amplification, PTEN null, 
CDKN2A null, NF1 mutated, 
mesenchymal markers (CHI3LI) 
Aggressive treatment 
significantly improved 
survival rates 
Proneural 
PDGFR amplification, PTEN null, 
CDKN2A null, IDH1 mutated, 
TP53 mutated, proneural 
development genes (SOX) 
Some benefits to 
aggressive treatment 
Neural 
Neural markers (NEFL, 
GABARA1, SYT1 and SLC12A5) 
Younger patients gain no 
survival benefit from 
aggressive treatment 
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In general, a tumour microenvironment consists of a variety of cells including the 
cancer cells, cancer stem cells and endothelial cells.213 GBM stem-like cells play a 
putative role in GBM aggressiveness and invasion194 and are a recent focus in GBMs 
pathogenesis and potential treatment214. They have stem-like properties such as self-
renewal and multi-lineage differentiation and as such are capable of repopulating the 
tumour after therapy, resulting in high rates of tumour recurrence and treatment 
failure.214 
On a cellular level GBM cells produce actin-rich protrusions of the plasma membrane 
with small punctuate finger like projections in contact with the extra-cellular matrix, 
named invadopodia. Invadopodia display proteolytic activity and actin 
polymerisation.215 Their function includes degradation of the extra-cellular matrix and 
facilitation of invasion and metastases in malignant tumours.  
Treatment 
The current standard of care for GBM, known as the Stupp protocol, consists of 
maximal surgical resection followed by radiotherapy and the chemotherapeutic drug 
temozolomide. The aim of surgery is maximal safe resection of the infiltrative tumour; 
however, resection is often incomplete, tumour recurrence inevitable, and the median 
overall survival following surgery, radiotherapy and chemotherapy is just over one 
year.216 After surgery, radiotherapy causes DNA damage to the remaining GBM cells 
and a marginal increase in the survival rate of GBM patients. The addition of 
temozolomide, with a capacity to cross the BBB, to surgery and radiotherapy is 
associated with a significant improvement in overall survival of 15 months.216  
Temozolomide is an oral DNA-alkylating agent currently used as first-line therapy for 
GBM treatment that adds methyl groups to DNA.217 Temozolomide efficacy can be 
predicted by O6-methylguanine-DNA-methyltransferase (MGMT) methylation.217 
Methylated MGMT is inactive and allows the temozolomide to damage the DNA and 
kill the tumour cells, however unmethylated MGMT actively repairs the DNA damage 
after temozolomide treatment.218 As such patients with unmethylated MGMT promoters 
have a lower median survival time, 12.7 months, compared to 21.7 months for patients 
with methylated MGMT (inactive).218  
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The diffuse infiltrative nature of GBM makes it challenging to treat. There is hope that 
more molecular characterisations of GBM will open up new avenues for treatment and 
monitoring. 
The role of exosomes and miRNAs in gliomas 
Biomarkers are measurable indicators with high diagnostic and prognostic value that 
can also monitor physiological response to a therapeutic intervention. Selective 
biomarkers can detect tumours at an early stage, leading to better chances of recovery 
and survival for these patients over those with more advanced neoplasma at the time of 
diagnosis.219 As described in the previous sections, biomarker status such as IDH1/2 
mutations and chromosomal co-deletion of 1p/19q has changed the traditional 
classification of some gliomas’ subtypes.  
miRNAs from a family of small non-coding RNA have emerged as powerful platforms 
for tumour-forming processes220 by playing a role in cell cycle regulation, cell 
proliferation, apoptosis, invasion, and angiogenesis221. Therefore miRNAs can be 
considered as cancer biomarkers. There is evidence that miRNAs are integrally involved 
in GBM oncogenic signaling and have the potential to serve a disease biomarker.219-221 
A previous study on miRNA expression in glioma tissue implicated some miRNAs as 
being involved in tumour formation and propagation.222 The researchers investigated the 
genome-wide miRNA expression pattern using miRNA microarray assay and deep 
sequencing. They reported 97 dysregulated miRNAs in glioblastoma compared to the 
healthy brain and 22 in adjacent brain samples in comparison to normal brain. The only 
outstanding miRNA was miR-625 which showed exclusive downregulation within the 
borders of tumours, but not in GBM samples.222 It has been reported that differential 
expression of miRNA-625 in gastric acid targets integrin-like kinase gene product and 
increases invasion and migration.223 
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Hypothesis and aims 
As detailed above there are a variety of molecules that can indicate the presence and 
progression of a disease or its therapeutic response. Exosomes are released by almost all 
cell types, carry a selective package of cargo and are enriched in miRNAs with a 
regulatory post-transcriptional function. 
The overarching HYPOTHESIS of this study is that exosomal-associated microRNAs 
present in the peripheral blood are sensitive, specific and robust biomarkers of 
neurological disease.  
The specific AIMS are as follows: 
1. Establish and validate a robust protocol for isolating exosomes and exosomal 
miRNAs from serum samples. 
2. Use the methods above for a pilot study to examine MS patients and their 
healthy matched control to determine if serum exosomal miRNAs are able to 
distinguish MS patients from healthy individuals, and MS patients in different 
disease phases. 
3. Use the methods in (1) above to examine the utility of serum exosomal miRNAs 
in monitoring response to the common MS drug Fingolimod in known RRMS 
patients.  
4. Use the methods in (1) above to examine the utility of serum exosomal miRNAs 
in the diagnosis of another neurological disease – glioblastoma.
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Chapter 2: 
Exosomal microRNA signatures 
in MS reflect disease status 
This chapter contains the original research article ‘Exosomal microRNA signatures 
in multiple sclerosis reflect disease status’ which has been published in the Journal 
of Scientific Reports, volume 7, article number: 14293 (2017). 
Abstract 
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the CNS. 
There is currently no single definitive test for MS. Circulating exosomes represent 
promising candidate biomarkers for a host of human diseases. Exosomes contain 
RNA, DNA, and proteins, can cross the blood-brain barrier, and are secreted from 
almost all cell types including cells of the central nervous system (CNS). We 
hypothesized that serum exosomal microRNAs (miRNAs) could present a useful 
blood-based assay for MS disease detection and monitoring. Exosome-associated 
miRNAs in serum samples from MS patients (n=25) and matched HCs (HC) (n=11) 
were profiled using small RNA next generation sequencing. We identified 
differentially expressed exosomal miRNAs in both relapsing-remitting multiple 
sclerosis (RRMS) (miR-15b-5p, miR-451a, miR-30b-5p, miR-342-3p) and 
progressive MS patient sera (miR-127-3p, miR-370-3p, miR-409-3p, miR-432-5p) in 
relation to controls. Critically, we identified a group of nine miRNAs (miR-15b-5p, 
miR-23a-3p, miR-223-3p, miR-374a-5p, miR-30b-5p, miR-433-3p, miR-485-3p, 
miR-342-3p, miR-432-5p) that distinguished relapsing-remitting from progressive 
disease. Eight out of nine miRNAs were validated in an independent group (n=11) of 
progressive MS cases. This is the first demonstration that miRNAs associated with 
circulating exosomes are informative biomarkers not only for the diagnosis of MS, 
but in predicting disease subtype with a high degree of accuracy. 
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Introduction 
MS is the most common cause of neurologic disability in young adults.224 MS is 
characterised by inflammation, demyelination, and neuro-axonal injury in the CNS, 
leading to progressive, long-term disability.224 The clinical phenotypes of MS 
include RRMS, and progressive forms: secondary progressive multiple sclerosis 
(SPMS) and PPMS.142 RRMS is the most prevalent MS subtype, comprising over 
70% of cases. Within 10 to 15 years of disease onset, the majority of patients with 
RRMS will transition to SPMS, a phase of the disease defined by gradual clinical 
worsening that does not respond to any available treatment. PPMS is clinically 
indistinguishable from SPMS, except that it manifests de novo, without a preceding 
relapsing-remitting phase. 
Currently there is no one definitive test for MS assessment; diagnosis and disease 
monitoring relies on multiple clinical parameters including clinical examination, 
magnetic resonance imaging, cerebrospinal fluid assessment, and 
electrophysiology.136 Such investigations are not only costly over the protracted 
disease course; they also have limited utility in distinguishing active RRMS from 
progressive disease.142,225 
Here we have assessed the utility of miRNA within serum exosomes as biomarkers 
of MS disease. MiRNA are small (18–25 nt) noncoding RNA with post-
transcriptional gene regulatory function.226 Exosomes are membrane-bound vesicles 
shed by almost all cell types, and packed with small regulatory RNAs such as 
miRNA.62 In many inflammatory diseases there is a significant increase in 
circulating exosome concentration.227,228 Given that exosomes can cross the blood-
brain barrier,8,9 it is thus likely that at least some of the circulating exosomes in MS 
patients are derived from affected CNS cells or the associated inflammatory milieu.  
We hypothesized that physiological changes associated with MS and its progression 
are reflected in differences in serum exosomal miRNAs. Using next-generation 
sequencing and integrative bioinformatics we found that serum exosome miRNA 
profiles can not only distinguish MS from HCs, but also distinguish RRMS from 
progressive forms of the disease with high accuracy.  
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Materials and methods 
Participants 
All patients attended the Royal Prince Alfred Hospital MS Clinic at the Brain and 
Mind Centre, The University of Sydney. The study was ethically approved by the 
RPA Hospital Human Research Ethics Committee (#X13-0264), and all patients 
provided written informed consent. All methods were performed in accordance with 
the relevant guidelines and regulations. MS was diagnosed according to the revised 
McDonald criteria,149 and SPMS patients were differentiated from the other clinical 
phenotypes (RRMS and PPMS) using the definitions offered by Lublin et al.142 
Sample collection and preparation 
A 20 ml blood sample was obtained from each participant’s using venepuncture with 
a 23-gauge butterfly needle. Blood was collected in three BD Vacutainer SST II 
Advance Serum-gel 7.5-ml Tubes (BD Vacutainer®, USA). Serum-gel tubes were 
left at room temperature for 30 minutes for coagulation, and then centrifuged at 
1,800 g for 10 minutes. The resulting serum was transferred into 15 ml tubes and 
centrifuged at 3,000 g for 20 minutes to remove any cellular debris. The serum 
sample was aliquoted into 2 ml microcentrifuge tubes with O-rings (Interlab®, New 
Zealand), immediately snap-frozen in liquid nitrogen and stored at -80°C. All serum-
gel tubes were processed within two hours of collection. 
Exosome purification and characterisation 
Serum (1 ml from each individual) was treated with RNase A at 37°C for 10 minutes 
(100 ng/ml, Qiagen, Australia) before exosome purification. The treated serum then 
underwent size exclusion chromatography (qEV iZON Science) by being overlaid on 
qEV size exclusion columns followed by elution with 5 ml freshly filtered PBS. Ten 
fractions of 500 µl each were collected and analysed with nanoparticle tracking 
analysis (NanoSight, Amesbury, UK). Fractions 8, 9, and 10 were pooled and stored 
at -80 °C for downstream analysis. 
CHAPTER 2: EXOSOMAL MICRORNA SIGNATURES IN MS REFLECT DISEASE STATUS 
 59 
Western immunoblotting 
Purified exosomes were resuspended with 4X sodium dodecyl sulfate loading buffer 
and heated at 95 °C for 5 minutes to lyse. Samples were resolved on 12% (w/v) 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis and were transferred onto 
polyvinylidene difluoride membrane at 400 mA for one hour using Criterion™ 
Blotter (BioRad, Hercules, CA, USA). Membranes were blocked in TBS-T 
containing 5% skim milk (w/v) followed by overnight incubation at 4°C with a 
primary antibody (CD63, Abcam, ab193349, CD81, ProSci, 5195, Alix, Cell 
Signaling 21715). Membranes were washed with TBS-T (triplicate, 5 minutes) and 
incubated with a secondary antibody (conjugated to horse-radish peroxidase) for one 
hour at room temperature followed by three more TBS-T washing steps. 
Immunoreactive bands were visualized with enhanced chemiluminescence 
(Amersham Biosciences, Inc.) detection reagent and imaged manually using X-ray 
film. 
Transmission electron microscopy 
10 µl of purified exosomes were loaded onto carbon-coated, 200 mesh Cu formvar 
grids (#GSCU200C; ProSciTech Pty Ltd, QLD, Australia) and fixed with 2.5% 
glutaraldehyde in 0.1 M phosphate buffer (pH 7.4). Samples were negatively stained 
with 2% uranyl acetate for two minutes and dried overnight. Then samples were 
visualised at 40,000 X magnification on a Philips CM10 Biofilter TEM (FEI 
Company, OR, USA) equipped with an AMT camera system (Advanced Microscopy 
Techniques, Corp., MA, USA) at an acceleration voltage of 80 kV. 
RNA extraction 
Purified exosomes were processed for RNA extraction using the Plasma/Serum 
Circulating & Exosomal RNA Purification Mini Kit (Norgen Biotek, Cat. 51000) 
according to the manufacturers protocol. To check the yield, quality and size of 
extracted total RNA we analysed samples with an Agilent 2100 Bioanalyser (Agilent 
Technologies, United States) on a Eukaryote Total RNA chip.  
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Small RNA sequencing 
Sequencing libraries were constructed from exosome RNA using the NEBNext 
Multiplex Small RNA Library Prep Kit for Illumina (BioLabs, New England) 
according to the manufacturer’s instructions. Yield and size distribution of resultant 
libraries were validated using Agilent 2100 Bioanalyser on a high-sensitivity DNA 
assay (Agilent Technologies, United States). Libraries were then pooled with an 
equal proportion for multiplexed sequencing on Illumina HiSeq2000 System at the 
Ramaciotti Centre for Genomics. 
Data pre-processing and differential expression 
analysis 
Data pre-processing was performed using a pipeline comprising of adapter trimming 
(cutadapt), followed by genome alignment to human genome hg 19 using Bowtie 
(18bp seed, 1 error in seed, quality score sum of mismatches <70). Where multiple 
best strata alignments existed, tags were randomly assigned to one of those 
coordinates. Tags were annotated against mirBase 20, and filtered for at most one 
base error within the tag. Counts for each miRNA were tabulated and adjusted to 
counts per million miRNAs passing the mismatch filter. Samples with low miRNA 
read counts (<50,000) and miRNAs with low abundance (<100 read counts across 
more than 50% of samples) were removed (two RRMS and three S/PPMS samples). 
Differential expression analysis was performed using three different statistical 
hypothesis tests including a non-parametric two-sample Wilcoxon test and two 
parametric tests: Student’s t-test, and an exact test (implemented in Bioconductor 
EdgeR) which tests for differences between the means of two groups of negative-
binomially distributed counts. Data pre-processing and differential expression 
analysis were performed using Bioconductor and R statistical packages. 
Univariate analysis 
We performed logistic regression (LR) and receiver operator characteristic (ROC) 
analysis to assess the predictive power of individual miRNAs between the two 
groups of interest. LR was used to identify linear predictive models with each 
miRNA as the univariate predictor. The quality of each model was depicted by the 
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corresponding ROC curve, which plots the true positive rate (i.e., sensitivity) against 
the false-positive rate (i.e., 1-specificity). The area under the ROC curve (AUC) was 
then computed as a measure of how well each LR model can distinguish between 
two diagnostic groups. We then used leave-one-out cross-validation (LOO-CV) to 
estimate the prediction errors of the LR models. LOO-CV learns the model on all 
samples except one, and tests the learnt model on the left-out sample. The process is 
repeated for each sample and the error rate is the proportion of misclassified samples. 
Overall, cross validation is a powerful model validation technique for assessing how 
the results of a statistical analysis can be generalized to an independent dataset.229 
These analyses were performed using R stats (glm) and boot (cv.glm) packages. 
Multivariate analysis 
The predictive power of multiple miRNAs as disease multivariate signatures was 
assessed using random forest (RF) modelling. RF modelling is an ensemble learning 
method for classification/regression that operate by constructing a multitude of 
decision trees at training time in order to correct for the overfitting problem.230 We 
used the R ‘RandomForest’ package which reports out-of-bag (OOB) errors as an 
unbiased estimate of the test set prediction error. The model computes the 
‘importance’ of each predictor by permuting OOB data; that is, for each tree the 
misclassification error rate on the OOB portion of the data is recorded. The same 
procedure is done after permuting each predictor variable. The difference between 
the two are then averaged over all trees, and normalized by the standard deviation of 
the differences. 
Results 
Serum exosomes carry a unique miRNA signature 
Patient blood was collected at the time of clinical consultation and pre-processed as 
detailed in the Methods. Exosomes were isolated from 1 ml of serum by SEC. Prior 
to exosome isolation, serum samples were treated with RNaseA to remove any 
unprotected circulating RNA. SEC fractions containing vesicles were pooled 
(fractions 8, 9, and 10; see Materials and Methods) and analysed by nanoparticle 
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tracking analysis (Figure 2-1A) and transmission electron microscopy (Figure 2-1B). 
These analyses revealed a population of nanovesicles with a predominant size of 
95 nm and cup-shaped morphology typical of exosomes. Western blotting of protein 
extracts for CD61, CD83 and Alix, confirmed that the particles isolated expressed all 
three characteristic exosome markers (Figure 2-1C). RNA extraction from each 
sample yielded the typical RNA profile for exosomes, with the absence ribosomal 
RNA and enrichment of small (<200nt) RNA species (Figure 2-1D). Small RNA 
libraries were constructed from the exosomal RNA and sequenced to yield on 
average about 10 million reads per sample.  
To confirm that our protocols were selecting for small RNAs protected by 
association with exosomes, we compared miRNA profiles between four samples with 
and without RNAse pre-treatment. This identified 62 miRNAs whose relative 
expression differed significantly by at least 2-fold (Figure 2-1E). This demonstrates 
that serum exosomes carry a distinct pool of protected miRNA that can be 
interrogated in MS diagnosis and progression. 
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Figure 2-1 Identification and characterisation of serum exosomes 
A) Size distribution of serum exosomes purified by size exclusion chromatography as analysed by 
nanoparticle tracking analysis. B) Transmission electron micrograph of serum exosomes demonstrates 
small vesicles with sizes ranging from 60–110 nm in diameter. C) Western blotting for exosome-
associated proteins CD63, CD81 and Alix in three separate patient samples. D) Bioanalyser trace of 
RNA extracted from serum exosomes reveals a predominant population of small RNAs without 
ribosomal RNA. E) Hierarchical clustering of differentially expressed miRNAs shows that RNaseA 
treatment of serum results in unique miRNA population, (p-value ≤ 0.05 and fold change ≥ 2). 
Exosomal miRNAs are dysregulated in MS patients and differentially 
expressed between disease subtypes 
Twenty-five unrelated individuals with a diagnosis of MS (relapsing-remitting n=14, 
progressive MS n =11 (SPMS n=7, PPMS n=4)) and 11 healthy individuals were 
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studied. A second, independent set of progressive cases (n=11) was then analysed; 
participant demographic and clinical characteristics are outlined in Table 2-1.  
Table 2-1 Characterisation of participants in this study 
Clinical characteristics 
RRMS 
(n = 14) 
S/PPMS (Dis.) 
(n = 11) 
HC 
(n = 11) 
S/PPMS (Val.) 
(n = 12) 
Age (mean ± SD) 42.5 (9.04) 53.4 (7.2) 40.3 (13.3) 53.1 (8.7) 
Age of onset (± SD) 35.6 (7.28) 38.4 (8.5) NA 33.9 (9.4) 
Gender (F/M) 10/4 5/6 9/2 11/1 
Disease duration in year (± SD) 6.9 (7.1)  15 (9.4)  NA 19.2 (6.1) 
Treatment (Y/N) 6/8 4/7 0/11 8/4 
EDSS (± SD) 1.5 (1.0) 5.3 (1.6) NA 6 (1.1) 
 
Abbreviations: RRMS, relapsing-remitting multiple sclerosis; S/PPMS, secondary/primary 
progressive multiple sclerosis; HC, health control; Dis., discovery set; Val., validation set; EDSS, 
expanded disability status score; NA, not applicable. 
The healthy control (HC) cohort was selected to match for age and gender to the 
RRMS group. While progressive MS is associated with older age and different 
gender ratio compared to RRMS,231 Pearson correlation demonstrates that age, 
gender and treatment did not correlate with the expression profiles of the identified 
miRNAs (Table 2-2). Also, these clinical characteristics when incorporated to the 
multivariate modeling have minimal contributions to the model’s prediction accuracy 
(Figure 2-2).  
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Table 2-2 Correlation of individual miRNA with demographic variables 
miR- Age Gender Treatment 
23a-3p 0.099 0.347 0.017 
374a-5p 0.013 0.295 0.000 
433-3p 0.411 0.225 0.330 
223-3p 0.124 0.347 0.000 
15b-5p 0.095 0.347 0.052 
485-3p 0.559 0.295 0.277 
432-5p 0.348 0.277 0.382 
30b-5p 0.096 0.416 0.000 
342-3p 0.126 0.468 0.069 
Average 0.212 0.322 0.168 
 
Pearson correlation of age, gender and treatment with individual miRNAs show that 
these clinical variables are not correlated with the expression profiles of identified 
miRNAs across RRMS and S/PPMS samples (similar results attained using ranked-
based correlation techniques, namely, Spearman or Kendall). 
 
Figure 2-2 Relative contribution of each variable 
Age, gender and treatment were incorporated as predictors into the random forest nonlinear and 
multivariate model. The importance plot demonstrates the minimal contribution of these variables in 
predicting MS subtypes and illustrates the predictive power of signature miRNAs independent of 
these clinical characteristics.  
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We employed three statistical approaches (Student’s t-test, Fisher’s exact, Wilcoxon 
rank sum) to identify differential expression of miRNAs between HCs, RRMS and 
progressive MS. miRNAs were identified as differentially expressed if they met a 
fold-change ≥2, and p-value ≤0.05 in at least two of the three statistical tests. Using 
this strategy, we identified four significantly dysregulated miRNAs between HCs and 
RRMS patients, and a further four between HCs and MS patients with progressive 
disease (SPMS/PPMS; Table 2-3). These represent miRNAs that have the potential 
to be exploited as blood-based diagnostic markers. 
We also compared miRNA profiles between the two clinically distinct MS subtypes, 
RRMS and progressive MS. Here we found nine miRNAs that were significantly 
differentially expressed between the two subtypes (Table 2-3). Importantly, in silico 
validation by leave-one-out cross validation (LOO-CV) correctly identified the test 
sample on average 80% of the time (range 77–86%; Table 2-3).  
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Table 2-3 Significantly dysregulated miRNAs across all group comparisons 
 MiRs CPM (B) CPM (A) FC t-test 
Exact 
test 
Wil- 
coxon 
Error 
rate 
Control (A) 
vs. RRMS (B) 
15b-5p 314.2 145.9 2.15 0.045 0.002 0.05 0.23 
451a 39,592 19,114.8 2.07 0.009 0.0003 0.005 0.20 
30b-5p 673.48 246.55 2.73 0.06 0.0004 0.026 0.21 
342-3p 329.58 132.79 2.48 0.05 0.0002 0.008 0.21 
Control (A) 
vs. S/PPMS 
(B) 
127-3P 1,715.1 752.4 2.28 0.007 0.001 0.003 0.17 
370-3p 707.66 321.77 2.2 0.008 0.002 0.007 0.18 
409-3p 2,893.2 1,385.2 2.08 0.005 0.002 0.002 0.17 
432-5p 682.88 308.67 2.2 0.002 0.001 0.003 0.16 
S/PPMS (A) 
vs. RRMS (B) 
15b-5p 314.2 135.73 2.31 0.04 0.008 0.05 0.23 
23-3p 1,116.69 506.34 2.2 0.04 0.005 0.025 0.21 
223-3p 2,646.92 934.56 2.8 0.026 0.002 0.047 0.22 
74a-5p 328.22 159.26 2.06 0.02 0.009 0.038 0.22 
30b-5p 673.48 219.50 3.06 0.05 0.001 0.015 0.2 
433-3p 195.47 414 0.47 0.003 0.0027 0.0007 0.14 
485-3p 295.44 618.44 0.47 0.0056 0.002 0.004 0.17 
342-3p 329.58 130 2.53 0.05 0.0016 0.02 0.22 
432-5p 329.88 682.88 0.48 0.004 0.006 0.005 0.19 
 
Abbreviations: CPM, miRNA counts per million; FC, fold change; RRMS, relapsing-remitting 
multiple sclerosis; S/PPMS, secondary/primary progressive multiple sclerosis; HC, healthy control; 
EDSS, expanded disability status score; NA, not applicable; error rate, estimated by leave-one-out 
cross validation. 
An independent validation set of 11 new progressive MS samples was then 
sequenced and analysed using the same methods. Differential expression analysis 
between this new group and HCs confirmed that three of the four original miRNAs 
(miR-370-3p, miR-409-3p, miR-432-5p) were significantly dysregulated. The fourth 
miRNA (miR-127-3p), while exhibiting close to two-fold change in expression 
between the groups, failed to reach statistical significance (Table 2-4). Differential 
expression analysis between the validation group and RRMS samples identified eight 
out of nine significantly dysregulated miRNAs as identified previously (miR-15b-5p, 
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miR-23a-3p, miR-223-3p, miR-374a-5p, miR-30b-5p, miR-433-3p, miR-485-3p, 
miR-342-3p, miR-432-5p) (Table 2-4). 
Table 2-4 Significantly dysregulated miRNAs using progressive MS validation set 
 MiRs 
CPM 
(B) 
CPM 
(A) FC T-test Exact test 
Wil- 
coxon 
Error 
rate 
Control (A) vs 
S/PPMS (B) 
127-3p 402 752 0.53 0.08 0.03 0.07 0.25 
370-3p* 625 322 1.94 0.05 0.17 0.04 0.24 
409-3p* 2585 1385 1.87 0.002 0.0002 0.003 0.19 
432-5p* 589 309 1.91 0.03 0.6 0.03 0.23 
15b-5p* 314 110 2.8 0.017 7E-08 0.0004 0.17 
223-3p* 2647 675 3.9 0.011 0.0004 0.0005 0.15 
23a-3p* 1116 557 2 0.047 0.6 0.015 0.20 
S/PPMS (A) 
vs RRMS (B) 
30b-5p* 673 90 7.5 0.014 2E-09 0.000001 0.00 
342-3p* 329 103 3.2 0.029 0.034 0.0007 0.17 
374a-5p* 328 188 1.7 0.033 6E-07 0.133 0.23 
432-5p* 329 589 0.5 0.051 0.0005 0.059 0.24 
433-3p* 195 492 0.4 0.006 1E-09 0.002 0.18 
485-3p 295 220 1.3 0.181 0.06 0.211 0.27 
 
*MiRNAs whose p-value < 0.05 in at least two tests and FC ≥ 1.7 in either directions. 
Abbreviations: c.f. Table 2-3. 
Serum exosomal miRNAs reflect MS subtypes 
We next examined the predictive power of each miRNA in our discovery sets using 
LR models in which the predictor was the individual miRNA expression profile. 
ROC curves were determined for each candidate miRNA, where the true positive rate 
(sensitivity) is plotted against the false positive rate (1 – specificity). AUC measures 
were ≥ 0.74 for each individual miRNA, for both RRMS and S/PPMS groups 
compared to HCs (Figure 2-3); for RRMS compared to S/PPMS the AUC 
measurements were ≥ 0.76 (Figure 2-4). 
CHAPTER 2: EXOSOMAL MICRORNA SIGNATURES IN MS REFLECT DISEASE STATUS 
 69 
 
Figure 2-3 Differentially expressed miRNAs for control vs. RRMS or S/PPMS groups 
Differentially expressed miRNA species were identified by Student’s t-test, Fisher’s exact test 
(EdgeR), and the Wilcoxon rank sum test for control versus RRMS (A) and control versus S/PPMS 
(B). MiRNAs with fold-change ≥ 2 and p-value ≤ 0.05 in at least two tests were identified as being 
differentially expressed. Left panels: Box-and-whisker plot for each miRNA species between the two 
groups (black box represents control group, red and blue boxes represent RRMS and S/PPMS 
respectively). Right panels: Logistic regression and receiver operator characteristic analysis performed 
on individual miRNAs to assess predictive power. LR was used to determine the linear model with the 
best discriminatory power between control and MS patient samples. The quality of this model was 
measured by the AUC displayed on each plot. 
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Figure 2-4 Differentially expressed miRNAs for RRMS vs. S/PPMS groups 
Differentially expressed miRNA species were identified as per Figure 2-3 above. Left panels: Box-
and-whisker plot for each miRNA species between the two groups (red = RRMS group and blue 
represent S/PPMS group). Right panels: Logistic regression and receiver operator characteristic 
analysis of individual miRNAs to assess predictive power. Logistic regression was used to determine 
the linear model with the best discriminatory power between control and MS patient samples. The 
quality of this model was measured by the AUC displayed on each plot. 
The relative importance of each miRNA in our discovery sets, when considered 
individually, was calculated using the random forest method and these shown in 
Figure 2-5A. Multivariate analyses using random forest were used to determine 
whether the combined expression patterns of multiple miRNAs could improve this 
predictive power. All possible miRNA combinations in each comparator group were 
trialed; the corresponding random forest multivariate models were then generated 
and OOB error rates estimated. Using these methods, we were able to achieve 
predictive power of 66% for RRMS and progressive MS versus controls. Strikingly 
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however, a combination of three or more miRNAs provided a predictive power of 
95% for distinguishing RRMS from progressive MS (Table 2-5 and Figure 2-5B). 
 
Figure 2-5 Random forest multivariate analysis 
A) Significantly dysregulated miRNAs in each comparator group were ordered by the importance of 
contribution towards clinical classification as measured by random forest models. B) Random forest 
model was run using all possible combinations of dysregulated miRNAs to find combinations (i.e., 
signatures) with highest multivariate predictive power. Error rates of different combinations were 
stratified by the number of miRNAs (signature size) and their distributions were displayed as violin 
plots. This figure shows results achieved in RRMS vs SPMS/PPMS comparisons. Similar analyses 
were performed for other comparator groups and summarized in Table 2-5. 
Table 2-5 miRNA combinations improve discriminatory power between relapsing-remitting 
(RRMS) and progressive (SPMS/PPMS) disease 
# of miRNAs miRNA composition Error 
9 miR-15b-5p, miR-23a-3p, miR-223-3p, miR-374a-5p, miR-30b-5p, miR-433-3p, miR-485-3p, miR-342-3p, miR-432-5p 0.15 
6 miR-15b-5p, miR-23a-3p, miR-223-3p, miR-30b-5p, miR-485-3p, miR-432-5p 0.05 
5 miR-23a-3p, miR-374a-5p, miR-30b-5p, miR-485-3p, miR-432-5p 0.05 
5 miR-23a-3p, miR-223-3p, miR-374a-5p, miR-30b-5p, miR-485-3p 0.05 
3 miR-223-3p, miR-485-3p, miR-30b-5p 0.05 
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We then examined the accuracy of random forest analysis in predicting the status of 
the validation set of new progressive samples using the same miRNA signatures. In 
this new test set, the original nine miRNAs reported for RRMS vs S/PPMS could 
predict 11/11 progressive MS samples in the validation sets (i.e., class specific error 
rate = 0%). 
Pathway analysis of dysregulated miRNAs 
We performed functional analysis on targets of identified miRNAs. For each 
signature, we retrieved validated targets of miRNAs from three major miRNA-target 
datasets, miRecords,232 miRTarBase233 and TarBase234 using the multiMiR R 
analysis package235. We then performed pathway overrepresentation analysis using 
KEGG pathways retrieved from the Molecular Signatures Database (MSigDB)-V 
6.0.236 Among top 5% of significantly enriched pathways (adjusted-p-value < 10E-5), 
we observed relevant pathways such as neurotrophin signalling pathway, focal 
adhesion, and T cell receptor signalling.  
Discussion 
In this study we have used unbiased high-throughput sequencing on RNA derived 
from serum exosome preparations in order to capture the complete profile of these 
miRNAs in patient sera. We used size exclusion chromatography for exosome 
isolation; a method that is known for high purity of exosome extracts as well as high 
reproducibility.237 This method, coupled with RNAse treatment of extracts, allows 
interrogation of exosomal-associated miRNAs; a source of biomarkers distinct from 
free circulating miRNA. Machine-learning approaches on miRNAs were used to 
examine their individual and collective predictive powers to identify disease subtype 
in MS. The results from this study confirm that exosome-associated miRNAs 
represent unique and potentially powerful biomarkers for this common neurological 
disease.  
We have identified dysregulated miRNAs that discriminate healthy individuals from 
RRMS or SPMS/PPMS patients with good predictive power. We also identified nine 
miRNAs that distinguish RRMS from SPMS/PPMS patients with a very high degree 
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of accuracy. A combination of just three miRNAs (miR-223-3p, miR-485-3p, miR-
30b-5p) had a 95% accuracy rate of predicting disease progressive forms of MS from 
RRMS as identified by random forest analyses, suggesting that they may be useful 
clinical biomarkers. An independent validation set of progressive MS samples 
confirmed the reproducibility of our findings, and random forest analysis correctly 
categorised all samples in this new test set as progressive MS. To date, there are no 
clear clinical, imaging, or pathologic criteria to determine the point when RRMS 
converts to SPMS.142 Our findings indicate that serum exosomal miRNA profiles 
may be a useful tool in assisting determination of this transition.  
Some of the miRNAs we have identified have been previously implicated as 
circulating biomarkers in multiple sclerosis, namely miR-23a, miR-15b, miR-223, 
and miR-374a.92,96,123,167,170,225,238-240 MiR-23a is involved in oligodendrocyte 
differentiation241 and increases within active and chronic MS lesions.96 Also, both 
miR-23a and miR-15b target the fibroblast growth factor-2 gene.242 The fibroblast 
growth factor-2 is implicated in demyelination and remyelination, and there is some 
evidence that cerebrospinal fluid (CSF) the fibroblast growth factor-2 may be a 
useful marker of inflammation in MS.243 MiR-223 is one of the few miRNAs that 
have been identified across several independent blood-based miRNA studies in 
MS,225 and it targets the transcription factor STAT5 and other inflammatory 
regulators implicated in MS such as heat shock protein 90 and E2F.244-246  
While several candidate miRNAs have been previously reported as potential MS 
biomarkers, the majority we have identified are novel. This likely reflects the unique 
constituent profile of exosomes versus free circulating miRNAs, and demonstrates 
that serum exosomal preparations represent a novel source of biomarkers. miR-451a 
was upregulated in RRMS patients compared to HCs; a miRNA previously reported 
as a regulator of oxidative stress with potential importance in a variety of 
neurodegenerative process.247 We also identified miR-342-3p to be upregulated in 
RRMS patients; a miRNA especially enriched in microglia and dysregulated in 
Creutzfeldt-Jakob and Alzheimer’s disease.248-250 Both miR-342-3p and mir-30b-5p 
have been proposed as free circulating miRNA biomarkers in Alzheimer’s and 
Parkinson’s diseases,27,28 and their association with MS in this study suggests that 
they may be more general markers of neuro-axonal injury. Pathway analysis of 
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transcripts known or predicted to be regulated by our candidate miRNA profiles 
yielded functional pathways highly relevant to MS disease pathogenesis such as 
neurotrophin signaling,251 focal adhesion252 and T cell receptor signalling 
pathways253. 
Small RNA analysis from biological fluids, including exosomal miRNAs, are subject 
to a variety of pre-analytical variables such as sample collection and processing 
methods, as well as differences in coagulation processes of serum and plasma.169,254 
This likely contributes to the only partially overlapping ‘free circulating’ miRNA 
profiles reported in different studies of MS to date.92,225 We have used size exclusion 
chromatography for exosome isolation, and analyses of our extracts with 
nanoparticle tracking, western blotting and electron microscopy demonstrate that this 
isolation method yields highly enriched vesicle populations with characteristics of 
exosomes. In line with recommendations from The International Society for 
Extracellular Vesicles,26 we have provided detailed technical information on our 
collection and isolation methodologies to allow comparison with future studies of 
serum exosomes in MS and other disorders. Our results with and without RNaseA 
treatment are in line with previous studies indicating that exosomes provide a 
protective environment for RNA,6 and that some miRNAs appear to be selectively 
packaged in exosomes255.  
In summary, this study demonstrates that exosomal-associated miRNAs have utility 
as biomarkers in MS. Our findings indicate that these biomarker profiles are distinct 
to those previously reported from serum or plasma circulating miRNA studies, while 
having comparable or superior predictive powers. Of note is the potential power to 
distinguish RRMS from progressive forms of the disease. The next generation of MS 
therapies offers the potential to specifically treat neuro-axonal and brain volume loss, 
and hence the ability to detect disease progression early may have major therapeutic 
and economic implications. If these exosomal biomarkers are able to indicate 
transformation to progressive disease earlier than current clinical methods, they are 
likely to have significant clinical utility. Longitudinal studies are needed to assess 
this question, and based on these initial investigations; these longitudinal studies 
should be pursued.  
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Chapter 3: 
Characterising the effect of 
Fingolimod therapy on exosomal 
miRNAs in patients with 
relapsing-remitting MS 
This chapter contains the original research article ‘Characterizing the effect of 
Fingolimod therapy on exosomal miRNAs in patients with relapsing-remitting 
multiple sclerosis’ which is in final preparation for submission to Neurology)  
Abstract 
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous 
system (CNS) and is a leading cause of neurologic disability in young adults. 
Although there is no definitive cure for MS, disease-modifying therapies have been 
shown to reduce disease progression by suppressing harmful inflammatory disease 
processes. Fingolimod is an orally administered immunomodulator, which prevents 
lymphocyte egress from lymph nodes and crosses the blood-brain barrier (BBB) 
having direct effects within the CNS. To manage treatment strategies and to tailor 
treatment to individual patients, there is an acute need to develop molecular 
biomarkers reflecting drug efficacy, and to determine drug-induced molecular 
processes to further the understanding of mechanisms of drug action and metabolism. 
Circulating exosomes carry distinct molecular cargo and represent promising 
candidate biomarkers for MS as they can be secreted from cells of the CNS and cross 
the BBB. It was hypothesised that the deregulation of serum exosomal microRNAs 
(miRNAs) expression is associated with the efficacy of Fingolimod therapy and is 
predictive of MS activity phases as determined by MRI, MS lesion activity. We 
profiled the expression of exosome-associated miRNAs in sera of 30 relapsing MS 
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patients prior to therapy and six months after treatment initiation using small RNA 
next generation sequencing. We then identified 15 miRNAs (i.e., miR-122-5p, miR-
1246, miR-127-3p, miR-19b-3p, miR-134-5p, miR-323b-3p, miR-370-3p, miR-375, 
miR-379-5p, miR-382-5p, miR-411-5p, miR-432-5p, miR-485-5p, miR-493-3p, and 
miR-889-3p) differentially expressed in post-treatment active versus quiescent 
phases of MS, and determined the predictive power of individual and subsets of 
miRNAs using univariate and multivariate models. We also predicted biological 
processes potentially affected by dysregulated miRNA targets associated with MS 
disease activities using an external dataset of gene expression profiling of post-
mortem MS lesions in active and quiescent phases of disease. Further, we identified 
miRNAs differentially expressed in drug responders associated with Fingolimod 
efficacy. Accordingly, we determined 11 miRNAs (i.e., miR-203a, miR-193a-5p, 
miR-379-5p, miR-370-3p, miR-382-5p, miR-493-3p, miR-432-5p, miR-485-5p, 
miR-2110, miR-1307-3p, miR-1908-5p) significantly dysregulated in stable 
responders whose disease phase remained inactive after treatment. We also identified 
5 miRNAs (i.e., miR-150-5p and miR-548e-3p, miR-130b-3p, miR-654-5p, miR-
487b-3p) differentially expressed in positive responders whose active MS phase 
turned to quiescent after six months of Fingolimod therapy. Pathways associated 
with dysregulated miRNAs were also predicted as potential molecular mechanisms 
induced in response to fingolimod treatment. As well as furthering the understanding 
of the action and metabolism of Fingolimod, this work also suggests that exosomal 
miRNA profiles have the potential to be utilised in MS clinical practice as 
biomarkers of disease activity and treatment response in the future.   
Introduction 
MS is a chronic inflammatory disease of the CNS characterised by demyelination 
and neurodegeneration.256,257 MS affects approximately 2.5 million people 
worldwide.256 Relapsing-remitting multiple sclerosis (RRMS) is the most prevalent 
subtype of the disease, occurred in about 85- 90% of patients.127,258 Patients with 
RRMS experience an unexpected flare-up of symptoms (relapse) for days or weeks 
followed by substantial remission, often with some remaining disability.127,259 Over 
time, as a result of disability accumulation and incomplete recovery following 
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relapses, up to 80% of RRMS patients develop secondary progressive MS with less 
inflammation and more neurodegenerative pathogenesis.259,260 
There is no definitive cure for MS and no therapies are available to repair existing 
damage of CNS caused by MS.10 Current disease modifying treatment (DMT) can 
help control the disease by suppressing the inflammatory response, slowing the 
progression of the disease and delaying lesion formation.256,261,262 The list of Food 
and Drug Administration (FDA) approved drugs has been increasing from two in the 
1990s to 12 in 2016.127,262 Fingolimod (marketed as Gilenya®) is the first oral 
immunomodulatory medication approved for the treatment of RRMS in 2010.263 It is 
a structural analog of sphingosine 1-phosphate (S1P) that acts as a S1P receptor 
modulator and prevents lymphocyte egress from lymph nodes. Fewer lymphocytes in 
the peripheral circulation reduces their infiltration into the CNS and limits myelin 
destruction.238,263-265 Furthermore, Fingolimod is able to cross the BBB and have 
direct effects within the CNS by contributing to a reduction of the neurodegenerative 
processes and promoting repair mechanisms.256  
To manage treatment strategies in individual MS patients, it is essential to study the 
contribution of patients’ molecular profiles in determining drug efficacy and 
mechanisms of action.266 Such pharmacogenomic approaches are aimed at 
developing genotype- or transcriptome-based predictive and markers of drug efficacy 
for improving and personalising drug therapy. Pharmacogenomics of miRNAs is an 
emerging field of research that holds promise for individualised tailor-made 
treatments.267,268  
MiRNAs are small (18–25 nt), non-coding RNA, regulating gene expression post-
transcriptionally.3 A single miRNA can target multiple genes, while an individual 
mRNA may be regulated by distinct miRNAs.4 This complexity reflects the 
involvement of miRNAs in the regulation of many molecular signalling pathways, 
such as in the immune system, and affecting various cellular processes, such as the 
function of immune cells.5,6 Many drugs act by regulating specific genes. The 
expression level of these pharmacogenomic genes can be changed by regulatory 
functions of miRNAs. Thereby, miRNA expression can determine drug mechanisms 
and influence drug efficacy.269  
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Exosomes are membrane-bound vesicles released by almost all cell types; they carry 
a selective package of small regulatory RNA, such as miRNA, and can cross the 
BBB.8,9 In our previous study, we have successfully profiled serum exosomal 
miRNAs to; (i) distinguish MS patients from health control (HCs), and (ii) separate 
the RRMS subtype from the progressive MS disease forms.270 The effect of 
immunomodulatory therapy on the expression levels of miRNAs in MS patients has 
also been previously reported.238,271,272  
In this study, we have used unbiased next-generation sequencing to consider miRNA 
deregulation within serum exosomes as markers of MS activity and therapeutic 
efficacy. We then used integrative bioinformatics to predict the functional role of 
dysregulated miRNAs. We hypothesised that the difference in serum exosomal 
miRNA profiles is predictive of disease activity in relapsing MS patients before and 
after Fingolimod therapy.  
Gadolinium (Gd) enhancing MS lesions on MRI are indicative of early lesion 
development, active inflammation and breakdown of the BBB. MS patients without 
corresponding clinical changes can have Gd enhancing lesions on MRI. This clinical-
radiological dissociation highlights why MRI is an important component of 
monitoring disease activity, and is a suitable tool for assessing treatment 
effectiveness.273,274  
Overall, this is the first demonstration that miRNAs associated with circulating 
exosomes are informative, minimally invasive and cost-effective biomarkers of MS 
disease activity and treatment efficacy. The functional roles of dysregulated miRNAs 
were systematically and comprehensively investigated providing insights into the 
mechanisms of Fingolimod action in therapy responders.  
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Materials and methods 
Experimental procedures 
Study population 
Relapsing MS patients naïve to Gilenya who attended the Royal Prince Alfred 
Hospital MS Clinic at the Brain and Mind Centre, The University of Sydney, 
Australia were enrolled in this study. Patients eligible for inclusion were diagnosed 
with MS according to McDonald 2010 criteria (as assessed retrospectively by 
analysis of clinical records and baseline MRI), have a relapsing disease course, 
disease duration <20 years, with expanded disability status scores (EDSS) 0-6.5 and 
normal kidney function. Patients were excluded if they had ever used cladribine, 
fludarabine, total body irradiation or alemtuzumab/Campath, received 
immunosuppressant agents in less than six months, or participated in any drug 
investigation trial or experimental procedure within the past 30 days. All patients 
assessed at baseline (prior to treatment) and six months with the same clinical and 
Gadolinium-based contrast agents for MRI scans (Gd-MRI). Patients were monitored 
with Gd-MRI, for relapses and rated using the EDSS scores. Written informed 
consent was obtained from each patient. This study was performed in accordance 
with relevant guidelines and regulations with the approval of the individual ethics 
committees of the institutions where the patients were being treated.  
Patient data collection ⎯ clinical, MRI and blood 
Prior to recruitment into this prospective study, written informed consent was 
obtained from each patient. Ethical approval for the study was through the University 
of Sydney Human Research Ethics Committee. All patients were assessed at 
baseline, prior to treatment with Fingolimod, and then at the six month mark, 
following Fingolimod commencement. Demographic and MS disease related data 
was documented at baseline and follow up for each patient and specifically included 
the collection of clinical relapse information and the performance of a formal EDSS 
score. Brain MRI with Gd was performed at both time points as well as a 12 month 
follow up using the same MRI protocol on the same 3T General Electric MRI 
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scanner located at the Brain and Mind Centre. The T1-weighted post-Gd MRI 
sequence was used in this study to assess for the presence or absence of MRI disease 
activity. Blood was collected from the patients at both time points and was stored 
(see section below). Clinical assessment, brain MRI with Gd and blood collection all 
took place at both baseline and six monthly follow up.   
Exosome purification and characterisation 
Blood samples were withdrawn from patients at baseline and six months at the time 
of Gd-MRI and clinical consultation. The serum sample (1 ml) was treated with 
RNaseA (37 °C for 10 minutes; 100 ng/ml; Qiagen, Australia) and accessed for 
exosome isolation by size exclusion chromatography (qEV iZON Science) as 
previously described.270 Captured exosomes were characterised by nanoparticle 
tracking analysis, transmission electron microscopy and immunoblotting (outlined by 
the Society for Extracellular Vesicles26) to monitor particles concentration and size, 
morphology and the presence of exosomes membrane markers. 
RNA extraction and small RNA sequencing 
RNA isolation from serum exosomes was performed to construct small RNA 
sequencing libraries as previously described.270 Briefly, purified exosomes were 
processed for RNA isolation using the Plasma/Serum Circulating & Exosomal RNA 
Purification Mini Kit (Norgen Biotek, Cat. 51000). The yield, quality, and size of 
extracted RNA were examined before constructing sequencing libraries from 
exosome RNA using the NEBNext Multiplex Small RNA Library Prep Kit for 
Illumina (BioLabs, New England). Finally, libraries were pooled with an equal 
proportion and sequenced on Illumina HiSeq.2000 System. 
Statistical analyses 
Data pre-processing and differential expression analysis 
Data pre-processing was performed using a pipeline comprising of adapter trimming 
(cutadapt), followed by genome alignment to human genome hg 19 using Bowtie 
(18bp seed, 1 error in seed, quality score sum of mismatches <70). Where multiple 
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best strata alignments existed, tags were randomly assigned to one of those 
coordinates. Tags were annotated against mirBase 20 and filtered for at most one 
base error within the tag. Counts for each miRNA were tabulated and adjusted to 
counts per million miRNAs passing the mismatch filter. All samples achieved 
miRNA read counts >45,000 read counts and miRNAs with low abundance (<50 
read counts across more than 20% of samples) were removed. Normalisation and 
differential expression analysis were performed using RNA-seq analysis tools in 
Bioconductor ‘limma’ package. Accordingly, read counts were first converted to 
log2-counts-per-millions to stabilize variances at high counts. The mean-variance 
relationship was then estimated at the individual observation level275 to adjust for 
different count sizes across samples and combined with sample-specific quality 
weights to down-weight outlier samples276 using ‘voomWithQualityWeights’ 
function. The transformed read counts were then entered the standard limma 
empirical Bayes method pipeline for differential expression analysis estimating 
moderated t-statistics and the corresponding p-values.277 In any comparison, 
differentially expressed miRNAs were identified as those whose p-value < 0.05 with 
fold-change doubled in either direction (i.e., |log2 (fold-change)| ≥1). The advantage 
of the above-mentioned limma strategy has been comprehensively confirmed in 
providing more powerful analysis and fewer false discoveries when compared to 
conventional approaches.276 
Analysis of the predictive power of the identified miRNAs 
Univariate logistic regression modeling 
We performed logistic regression (LR) and receiver operator characteristic (ROC) 
analysis to assess the predictive power of individual miRNAs between the two 
groups of interest. LR was used to identify linear predictive models with each 
miRNA as the univariate predictor. The quality of each model was depicted by the 
corresponding ROC curve, which plots the true positive rate (i.e., sensitivity) against 
the false-positive rate (i.e., 1-specificity). ROC curves were smoothed using Tukey’s 
method278 to improve readability. The AUC was then computed as a measure of how 
well each LR model can distinguish between two comparative groups. The 90% 
confidence intervals (CI) of AUC measures were estimated using Delong method279 
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to assess the significance of a model’s predictive power as compared to a random 
trial (i.e., AUC = 0.5). We then used leave-one-out cross validation (LOO-CV) to 
estimate the prediction errors of the LR models. LOO-CV learns the model on all 
samples except one and tests the learnt model on the left-out sample. The process is 
repeated for each sample and the error rate is the proportion of misclassified samples. 
These analyses were performed by R ‘stats’, ‘boot’ and ‘pROC’ packages using glm, 
cv.glm, roc and ci.auc functions, respectively. 
Multivariate random forest modeling  
The predictive power of multiple miRNAs multivariate signatures of MS activity was 
assessed using RF modeling. RF modeling is an ensemble learning method for 
classification/regression that operate by constructing a multitude of decision trees at 
training time in order to correct for the overfitting problem.280 We used out-of-bag 
(OOB) error as an unbiased estimate of the test set prediction error as implemented 
by the R ‘RandomForest’ package. 
Prediction of the functional role of the identified miRNAs 
To predict the putative function of deregulated exosomal miRNAs in MS, we 
performed pathway and gene ontology enrichment analysis on targets of miRNAs of 
interest. We used MSigDB,281 version 6.1, to retrieve KEGG pathways 
(186 pathways on 12,875 genes), Reactome pathways (674 pathways on 37,601 
genes) and gene ontology (GO) biological processes (4436 GO terms on 506,182 
genes). Human miRNA targets were retrieved from publicly available datasets of 
experimentally-validated and predicted datasets using multiMiR282— database v2.2, 
updated on 8/8/2017. MultiMiR is a miRNA-target interaction R package and 
database which compiles nearly 50 million records in human and mouse from 11 
different databases: validated targets were collected from miRecords,283 
miRTarBase,284 and TarBase 285 and predictions from DIANA-microT-CDS,286 
ElMMo,287 MicroCosm,288 miRanda,289 miRDB,290 PicTar, PITA,291 and 
TargetScan292. Targets of miRNAs under study were included if experimentally-
validated or predicted by at least two databases, and underwent pathway enrichment 
analysis using a one-sided Fisher’s exact test, in which the p-value for the null 
hypothesis is computed based on the hypergeometric distribution: 
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Where N is the total number of annotated genes in MSigDB, n is the number of genes 
targeted by miRNA(s), K is the total number of genes annotated by a pathway or 
gene ontology (GO) term, and k is the number of target genes annotated with a 
pathway or GO term. The nominal p-values were adjusted for multiple hypothesis 
tests using Benjamini & Hochberg (FDR) correction. Enrichment analyses were 
implemented in R using ‘stats’ packages.  
Results 
Patient characteristics and data preprocessing 
Thirty relapsing MS patients were included in this study based on the selection 
criteria described in Materials and Methods. Patients were grouped based on their 
Gd-MRI scans to either active or quiescent before and after therapy. Samples from 
one patient were removed, as post-treatment MRI status was not available. 
Participant demographic and clinical characteristics are outlined in Table 3-1. The 
expression of serum exosomal miRNAs by deep sequencing were analysed at two 
distinct time points (i.e., baseline when the patients were treatment-naïve) and six 
months after patients started an immunomodulatory therapy with Fingolimod 
(Gilenya). The total of 1,924 miRNAs were screened for each sample; all samples 
achieved miRNA read counts >45,000. For each comparison, miRNAs with low 
abundance (<50 read counts across more than 20% of samples) were removed 
retaining around 11-12% of miRNAs in any comparison. Read counts were 
normalized to adjust for RNA and sample-level biases. There is no significant 
difference in age (using Mann–Whitney U non-parametric test) and gender (using 
Fisher’s exact test) between any two groups compared in this study (p-value close to 
1 in most of comparisons).  
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Table 3-1 Characterisation of patients 
Characteristic n = 29 Description 
Gender (F/M) 17/12 F: Female, M: Male 
Age  38.8 ±10.1  Average age at enrolment, mean ± std 
Age of onset  32.9 ±10  Age when MS was first diagnosed, mean ± std 
Disease duration  61.3 ± 80 month Duration of disease from the first diagnosis, mean 
± std 
Active (pre/post) 14/8 Number of patients in active or quiescent phases 
of MS (based on Gd-MRI) before & after therapy 
Quiescent (pre/post) 15/21 
Therapy  Fingolimod 
(Gilenya) 
Immunomodulatory medication 
Deregulation and function of serum exosomal miRNAs in MS activity 
Exosomal miRNAs are potential markers of MS activity phases 
At each timepoint, we compared miRNA profiles of patients in active vs quiescent 
phases as determined by Gd-MRI scans (cf. (Figure 3-3 –A and Table supplementary 
A-1 for the list of patients in each comparison and their clinical characteristics). In 
the baseline, miR-194-5p and miR-374a-5p were differentially expressed based on 
the adopted criteria (i.e., |log2 (fold change)|>1 and p-value <0.05 using limma linear 
model and empirical Bayes method for assessing differential expression), both up 
regulated in the active compared to the quiescent phase. Six months after the 
Fingolimod treatment, the number of significantly deregulated miRNAs increased to 
15 including miR-122-5p, miR-1246, miR-127-3p, miR-19b-3p, miR-134-5p, miR-
323b-3p, miR-370-3p, miR-375, miR-379-5p, miR-382-5p, miR-411-5p, miR-432-
5p, miR-485-5p, miR-493-3p, and miR-889-3p, where all, except miR-q9b-3p, were 
up-regulated in the active phase (Figure 3-1A). The increase in the number of post-
treatment differentially expressed miRNAs in MS patients is consistent with the 
previous report on the study of patients’ RNA deregulation in response to the 
interferon ß treatment,272 and potentially reflects an improved within-group 
homogeneity ensued from the administration of the medication. To estimate within-
group sample heterogeneity, we measured variance of each miRNA expression 
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values across samples within each active and quiescent group, before and after 
treatment. The mean of variances significantly reduced in quiescent as well as active 
groups after-treatment compared to pre-treatment (p-value = 1.571e-05 comparing 
quiescent groups and p-value = 0.0207 comparing active groups after vs before 
therapy, using Mann–Whitney U non-parametric test). This can imply that reduced 
after-therapy heteroscedasticity ensued improved statistical hypothesis testing 
(reducing type II error). Hence, subsequent analyses were focused on 15 miRNAs 
dysregulated in after treatment MS activity phases. 
Next, we examined the predictive power of each dysregulated miRNA using a 
univariate LR model whose predictor was the individual miRNA expression profile. 
ROC curves were determined for each candidate miRNA, where the true positive 
rate, sensitivity, is plotted against the false positive rate and i.e., 1 – specificity 
(Figure 3-1B). Area under the ROC curve (AUC) measures and the corresponding 
95% confidence interval estimates were then computed for each miRNA (Figure 3-
1B). Only miRNAs whose AUC confidence intervals do not contain the null 
hypothesis value (AUC = 0.5 for a random prediction) were considered as 
statistically accurate univariate predictors of MS activity phases (Figure 3-1B). 
Accordingly, 11 miRNAs dysregulated in post-treatment samples were selected (i.e., 
miR-1246, miR-127-3p, miR-19b-3p, miR-134-5p, miR-370-3p, miR-375, miR-379-
5p, miR-382-5p, miR-432-5p, miR-485-5p, and miR-493-3p) and used as predictors 
of a linear multivariate LR model as well as a random forest (RF) model that is a 
nonlinear classifier, to investigate whether the combined expression patterns of 
multiple miRNAs could improve the predictive power. RF model achieved a higher 
predictive power compared to LR (i.e., the prediction error rates were 0.39 and 0.35 
in LR and RF, respectively). We therefore, opted for the RF model for subsequent 
multivariate analyses. We were interested to identify an optimal miRNA signature 
that is to find a minimum set of miRNAs whose combined expression patterns 
predict MS phases with the highest accuracy. Accordingly, all possible combinations 
of 11 miRNAs were trialled (the total of 2,037 signatures comprising 2 to 11 
miRNAs); the corresponding RF multivariate models were then generated, and OOB 
error rates estimated. A combination of two or three miRNAs provided a predictive 
power of 92% for distinguishing active from quiescent RRMS phases (Figure 3-1C). 
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Figure 3-1 Exosomal miRNAs as markers of disease activity 
A) Differentially expressed miRNAs were identified by limma linear model and empirical Bayes 
method with |log2 (fold change)|>1 and p-value < 0.05. Box-and-whisker plot represents for each 
miRNA species between active and quiescent patients 6 months after Fingolimod treatment. B) To 
examine the predictive power of each dysregulated miRNAs ROC analysis performed on individual 
miRNAs. AUC measured and the corresponding 95% confidence interval estimates were then 
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computed for each miRNA. 11 miRNAs with AUC confidence more than 0.5 were considered as 
statistically accurate univariate predictors of MS activity phases. C) RF model was run using all 
possible combinations of 11 dysregulated miRNAs to improve the predictive power. The 
corresponding RF multivariate models were then generated, and OOB error rates estimated. A 
combination of two or three miRNAs provided a predictive power of 92% for disease activity. 
Prediction of the functional role of dysregulated miRNAs 
To predict the potential function of miRNAs dysregulated in active vs quiescent 
RRMS phases, we first retrieved gene targets of differentially expressed miRNAs 
from multiple miRNA-target interaction databases and selected those targets that are 
either experimentally validated or computationally predicted in at least two datasets. 
Accordingly, 4,650 targets were retrieved for 15 miRNAs dysregulated in post-
treatment active vs quiescent samples. 
To enhance the specificity of subsequent functional analysis, we sought to identify 
targets specific to disease activity in MS brain lesions. Hence, we used a previously 
generated gene expression profiling of post-mortem brain tissues of MS patients in 
active and inactive RRMS phases.293 We identified genes differentially expressed in 
chronic active vs inactive MS lesions (RIM)—i.e., p-value < 0.05 using limma 
microarray linear model fit and empirical Bayes method on normalized gene 
expression data retrieved from GSE108000.  
We identified 153 and 102 target genes to be upregulated and downregulated in 
active compared to the inactive lesions, respectively. These targets were then 
undergone enrichment analysis for gene ontology biological processes. 
Overrepresented biological processes (FDR <0.01) were summarised and stratified 
under four categories of immune system, nervous system, signal transduction and 
biological regulation by consulting gene ontology hierarchy. Figure 3-2A visualises 
the network of dysregulated miRNAs interacting with the target genes up/down 
regulated in MS lesions. Targets were annotated with biological processes categories 
if the gene has been annotated by at least one GO term within the associated category 
(Figure 3-2B). Similar enrichment analyses were performed on curated pathways 
(KEGG and Reactome). 
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Figure 3-2 Predicted functional role of miRNAs associated with MS disease activity 
A) Target genes of 15 miRNAs differentially expressed in active vs quiescent phases of MS were 
retrieved. Target specific to disease activity in MS brain lesions were then identified using 
GSE108000. Accordingly, 153 and 102 target genes were identified to be upregulated (red) and 
downregulated (blue) which annotated with biological processes categories; immune system, nervous 
system, signal transduction and biological regulation. B) A summary list of overrepresented GO 
terms. 
Deregulation and function of exosomal miRNAs in treatment responders 
Exosomal miRNA deregulation is associated with Fingolimod 
efficacy 
To investigate miRNAs pharmacogenomic roles in response to Fingolimod therapy, 
we monitored MS activity phases of patients based on Gd-MRI scan results prior to 
therapy (baseline) and six months after treatment commencement and profiled their 
RNA-seq expression of exosomal miRNAs at each time point. Fifteen patients were 
indicated the quiescent phase at the baseline out of which 12 were remained in 
quiescent phase after six months (Figure 3-3). Also, out of 14 patients indicating 
active MS phase initially, nine were turned to quiescent mode after six months of 
Fingolimod treatment (Figure 3-3). Accordingly, the two main groups of stable 
responders (i.e., patients who were quiescent at baseline and six months after 
treatment) and positive responders (i.e., patients who were active at baseline and 
become quiescent after six months of treatment) were considered for differential 
expression analysis of exosomal miRNAs. Responders were stratified into the two 
groups to improve within-group homogeneity and reduce false negative rate (type II 
error). In the stable responder group, 11 miRNAs were dysregulated based on the 
adopted criteria (i.e., |log2 (fold change)|>1 and p-value < 0.05) including miR-203a, 
miR-193a-5p, miR-379-5p, miR-370-3p, miR-382-5p, miR-493-3p, miR-432-5p, 
miR-485-5p, miR-2110, miR-1307-3p, miR-1908-5p, all upregulated at six months 
after treatment (Figure 3-3). In the positive responder group, the expression level of 
miR-150-5p and miR-548e-3p decreased, while the level of the expression of miR-
130b-3p, miR-654-5p, miR-487b-3p increased after treatment (Figure 3-3). 
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Figure 3-3 miRNAs deregulation associated with drug response 
MS disease activity phase, based on Gd-MRI scan results, monitored at baseline (15 
quiescent and 14 active), and six months after commencement of Fingolimod 
treatment. Twelve out of 15 quiescent patients were remained in (stable responders) 
and nine out of 14 active patients were turned (positive responder) to quiescent phase 
after six months treatment. Then differentially expressed miRNAs were identified 
based on the adopted criteria |log2 (fold change)|>1 and p-value < 0.05 which 
represents 11 and 5 dysregulated miRNA in stable and positive responder groups as 
shown in the box-and-whisker plots. 
All patients remained on therapy for a longer period of time and monitored by Gd-
MRI scan at 12 months after treatment initiation (Table supplementary A-1). Seventy 
two per cent of patients were therapy responders at six-month post-treatment. This 
proportion increased to 90% in 12 months of treatment. Overall, the effect of 
Fingolimod therapy was adequately evident six months after treatment and was 
persistent for responder patients (except for patient 13 who indicated active MS in 
12-month post-therapy). On the other hand, patients not responded to the treatment in 
the six-month follow-up, have generally shown improved responses by 12 months of 
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treatment (five out of eight non-responders at six-month have turned to quiescent 
phase of MS at 12-month follow-up as indicated by Gd-MRI results). Accordingly, 
while expanding the course of medication improves the outcome, six months of 
therapy sufficiently reflects the Fingolimod effect and miRNA regulatory changes 
associated with the treatment efficacy. This observation is further corroborated by a 
former study on the effect of Fingolimod treatment on circulating miRNAs indicating 
that miRNA expression profile significantly changes after six months of therapy.238 
Prediction of the functional role of dysregulated miRNAs 
We were interested to investigate pathways potentially perturbed by dysregulated 
miRNAs to further understand how the identified pharmacogenomic miRNAs are 
affecting mechanisms of Fingolimod action and metabolism. Accordingly, for each 
differentially expressed miRNA associated with drug efficacy, we retrieved target 
genes from 16 miRNA-target interaction databases and selected those targets that are 
either experimentally validated or computationally predicted in at least two datasets 
(Figure 3-4A). We then performed pathway enrichment analysis using KEGG294 and 
Reactome295 databases comprising 860 pathways in total, to identify pathways 
overrepresented by targets of each miRNA (Figure 3-4B). Pathways enriched by 
multiple miRNAs propose more robust association with drug-induced perturbation. 
We therefore sorted pathways by total number of associated miRNAs and chose the 
top 10% of pathways (i.e., pathways enriched by ≥ 5 miRNAs) as shown in Figure 3-
4C. Selected pathways were sorted under 6 general categories of immunity system, 
nervous system, signal transduction, lipid metabolism, diseases, and cell cycle by 
consulting Reactome and KEGG pathway hierarchies (Figure 3-4D). Multiple 
pathways relevant to the pathophysiology of MS and therapeutic targets are 
frequently enriched by miRNAs dysregulated in response to therapy offering 
alternate mechanisms of Fingolimod actions (c.f. discussion section for examples). 
Besides, miR-130b-3p, miR-150-5p, miR-2110, directly target S1P enriching known 
Fingolimod-induced pathways such as sphingolipid metabolism296 and 
sphingolipid de novo biosynthesis256. 
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Figure 3-4 Functional roles of dysregulated pharmacogenomic miRNAs 
A) The total number of target genes for each of 16 dysregulated miRNAs. B) Pathway enrichment 
analysis performed to identify overrepresented pathways by targets of each identified 
pharmacogenomic miRNA. The number of enriched pathways by targets of each dysregulated miRNA 
displayed. C) Pathways enriched by multiple miRNAs propose more robust association with drug-
induced perturbation. This bar chart shows the distribution of a total number of miRNAs enriching a 
pathway across all pathways. The top 10% of robust pathways enriched by at least five miRNAs 
chosen. D) Selected pathways (top decile cut off) classified into four categories by consulting 
Reactome (black) and KEGG (blue) hierarchies. 
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Discussion 
There is a growing body of evidence highlighting the regulatory role of miRNAs in 
the pathogenesis of MS and therapeutic impacts.170,174,238,270,271,297-303 In this study, 
we have used unbiased high-throughput sequencing on serum exosome miRNAs 
capturing the complete profile of miRNAs in patient sera. We used size exclusion 
chromatography for exosome isolation—a method that is known for high 
reproducibility and purity of exosome extracts69—coupled with RNAse treatment of 
extracts in order to interrogate exosomal-associated miRNAs as a source of 
biomarkers distinct from free circulating miRNAs270. 
We identified miRNAs differentially expressed in patients experiencing relapse 
compared to remitting MS phases, as determined by Gd-MRI scans results. Machine-
learning approaches on dysregulated miRNAs were used to examine their individual 
and collective predictive powers in discriminating disease phases. Eleven 
differentially expressed miRNAs (miR-1246, miR-127-3p, miR-19b-3p, miR-134-
5p, miR-370-3p, miR-375, miR-379-5p, miR-382-5p, miR-432-5p, miR-485-5p, and 
miR-493-3p) have shown significantly high predictive power using logistic 
regression univariate analyses which subsequently used as predictors of random 
forest multivariate models. A combination of just two (miR-432-5p, miR-485-5p) or 
three miRNAs (miR-134-5p, miR-432-5p, miR-485-5p as well as miR-432-5p, miR-
375, miR-485-5p) had a 92% accuracy rate of predicting active from quiescent 
RRMS phases as identified by random forest analyses.  
Among the identified miRNAs, some have been previously indicated as circulating 
markers in MS or other immune system or nervous system related diseases. Yet, the 
majority of candidate miRNAs we have identified are novel, which likely reflects the 
unique constituent profile of exosomes versus free circulating miRNAs. Circulating 
miR-375 was shown to be dysregulated in sera of PPMS patients compared to 
controls.304 The upregulation of miR-1246 has been previously reported in an active 
phase of systemic lupus erythematosus, a severe autoimmune disease, compared to 
the disease inactive phase.305 Also, deregulation of miR-1246 in both naïve and 
regulatory T cells has been previously reported and identified as a marker 
characterizing the regulatory T cells phenotype.306 They have demonstrated that miR-
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1246 upregulation leads to the development of systemic autoimmune-like conditions 
in mice.306 MiR-19b-3p, downregulated in active vs quiescent post-treatment RRMS 
patients in our study, has been previously reported to be under-expressed in serum of 
Alzheimer’s disease patients compared to HCs.307  
Further, we developed an integrative bioinformatics pipeline to investigate the 
functional role of dysregulated miRNAs by constructing a comprehensive yet 
reliable network of miRNA-target gene interactions and improving prediction 
specificity by considering target genes associated with MS activity in brain lesions. 
Multiple biological processes relevant to MS activity were enriched by target genes 
under four categories of immune system, nervous system, signal transduction and 
biological regulation. The importance of immune system genes in the pathogenesis 
of MS has been frequently reported.308 Within the overrepresented biological 
processes, we found canonical immune-associated pathways such as positive 
regulation of interleukin 1 Beta production, which plays a role in MS-associated 
neurodegenerative damage and clinical progression.309 Other two outstanding 
immune-associated pathways are leukocytes activation and regulation of type I 
interferon production. In a healthy CNS, leukocytes have limited access to the 
brain and spinal cord, whereas in several neurological diseases, including MS, 
leukocytes infiltrate from the periphery into the CNS resulting inflammation.310 
Conversely, type 1 interferon is an immunomodulatory cytokine with anti-
inflammatory effect by controlling interleukin I.160 Overall, our functional 
predictions strongly support the role of dysregulated miRNAs in MS activity, 
corroborating the validity of novel exosomal miRNA biomarkers and providing 
further insights into disease pathogenesis. 
Investigating the role of miRNAs in the pathogenesis of MS and identifying miRNA-
based pharmacogenomic markers of the treatment response is an active field of 
research.160,271,297-299 This study was primarily aimed to interrogate the efficacy of 
Fingolimod therapy on RRMS patients in a prospective study monitoring disease 
progression based on Gd-MRI scan results and to assess the effect of treatment on 
patients’ circulating exosomal miRNA profiles. We identified the total of 16 
differentially expressed miRNAs associated with Fingolimod treatment efficacy. 
These include exosomal miRNAs dysregulated in sera of patients whose disease 
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phase remained inactive (i.e., miR-203a, miR-193a-5p, miR-379-5p, miR-370-3p, 
miR-382-5p, miR-493-3p, miR-432-5p, miR-485-5p, miR-2110, miR-1307-3p, miR-
1908-5p) or turned to inactive phase (i.e., miR-150-5p, miR-548e-3p, miR-130b-3p, 
miR-654-5p, miR-487b-3p) after six months of treatment. Deregulation and function 
of some of predicted miRNAs have been previously reported in peripheral blood of 
MS patients. The altered expressions of miR-130b and miR-203 have been 
previously reported in B-cells from peripheral blood samples of RRMS patients.160 
These two miRNAs in our study target the highest number of genes over representing 
multiple pathways involved in immune system, nervous system, lipid metabolism as 
well as critical signal transduction. The same study also reported the deregulation of 
miR-150 in B-cell of blood samples after treatment of MS patients with 
Natalizumab.160 The altered expression of miR-150 is also reported in T-cell311 and 
peripheral blood mononuclear cells of MS patients compared to HCs312. The 
downregulation of miR-193a-5p has been previously reported in peripheral blood 
mononuclear cells of RRMS patients after six months Interferon-beta therapy.313  
We also identified pathways consistently overrepresented by targets of multiple 
miRNAs associated with treatment response. Several pathways pivotal in MS 
pathogenesis and relevant to Fingolimod mechanisms were enriched and stratified 
under categories immune system, nervous system, signal transduction and lipid 
metabolism. Notably, T cells development and function is a common sight of disease 
pathogenesis and treatment response.313 transforming growth factor beta signalling 
pathway regulates differentiation of naïve CD4 T-cell into regulatory T cell and 
reduction in this signalling pathway results in less number of regulatory T cells 
observing in MS patients.314,315 Our results indicate that upregulated miRNAs in 
response to Fingolimod perturb Transforming growth factor beta signalling pathway, 
which in turn may ensue reduced susceptibility to developing MS. Another predicted 
pathway JAK-STAT pathway, which has indirect effect on interleukin-7 expression, 
an important cytokine for the regulation of B-cell and T-cell development and 
overexpressed in brain lesions of MS patients.314 Additionally, the role of JAK-
STAT pathway in interleukin-12 regulation has been reported to induce the 
expression of interleukin-7 mRNA and protein in microglia, macrophages and 
astrocytes.314 Another interesting pathway is Wnt signalling pathway enriched by 
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targets of seven pharmacogenomic miRNAs in our study. Wnt pathway modulates 
the immune response and involves in the process of remyelination by controlling the 
balance between immune tolerance/inflammation and neuronal 
survival/neurodegeneration in MS.316  
In summary, our results demonstrate that exosomal miRNAs are involved in MS 
immuno-pathogenesis and molecular mechanism of Fingolimod. We identified 
miRNAs perturbed in serum exosomes of treatment responders and predicted their 
impact on a variety of pivotal regulatory pathways. Nevertheless, due to the efficacy 
of therapy, the number of non-responder patients was too small to perform statistical 
comparison developing predictive markers of treatment positive vs negative 
response. To assess this question, longitudinal studies on a large cohort of RRMS 
patients are needed and based on these initial investigations; these longitudinal 
studies should be pursued. 
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Chapter 4: 
Deep sequencing of circulating 
exosomal microRNA allows non-
invasive glioblastoma diagnosis  
This chapter contains the original research article ‘Deep sequencing of circulating 
exosomal microRNA allows non-invasive glioblastoma diagnosis’ which is under 
review in the npj Precision Oncology (2018). 
Abstract 
Exosomes are nano-sized extracellular vesicles released by many cells that contain 
molecules characteristic of their cell-of-origin, including microRNA (miRNA). 
Exosomes released by glioblastoma cross the blood-brain-barrier (BBB) into the 
peripheral circulation, and carry molecular cargo distinct to that of ‘free-circulating’ 
miRNA. Serum exosomal-microRNAs were isolated from glioblastoma (n=12) 
patients and analysed using unbiased deep sequencing. Results were compared to 
sera from age- and gender-matched healthy controls (HCs), and to grades II-III 
(n=10) glioma patients. Significant differentially expressed microRNAs were 
identified, and the predictive power of individual and subsets of microRNAs were 
tested using univariate and multivariate analyses. Additional sera from glioblastoma 
patients (n=4) and independent sets of healthy (n=9) and non-glioma (n=10) controls 
were used to further test the specificity and predictive power of this unique 
exosomal-microRNA signature. Twenty-six microRNAs were significantly 
differentially expressed in serum exosomes from glioblastoma patients’ relative to 
HCs. Random forest (RF) modelling and data partitioning selected seven miRNAs 
(miR-182-5p, miR-328-3p, miR-339-5p, miR-340-5p, miR-485-3p, miR-486-5p 
and miR-543) as the most stable for classifying glioblastoma. Strikingly, within this 
model, two iterations of these miRNA classifiers could distinguish glioblastoma 
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patients from controls with perfect accuracy. The seven-miRNA panel was able to 
correctly classify all specimens in validation cohorts (n=23). Also identified were 
23 dysregulated miRNAs in mutant isocitrate dehydrogenase isoforms (IDHMUT) 
gliomas, a partially overlapping yet distinct signature of lower grade glioma. 
Serum exosomal-miRNA signatures can accurately diagnose glioblastoma 
preoperatively. miRNA signatures identified are distinct from previously reported 
‘free-circulating’ miRNA studies in glioblastoma multiforme (GBM) patients, and 
appear to be superior. 
Introduction 
Malignant gliomas, particularly GBM, represent the most lethal primary brain 
tumours, owing in part to their highly infiltrative growth patterns. The World Health 
Organization’s guidelines sub-categorise glioma by histopathologic evaluation into 
tumour grades I-IV, where GBM (grade IV) is the most aggressive and also the most 
common. Despite surgery, radiation, and chemotherapy, essentially all GBM tumours 
recur, at which point patients have reduced treatment options and worsening 
prognoses. Compounding this aggressive cancer phenotype are challenges in 
monitoring responses to treatment and tumour progression. While recent revisions to 
the Response Assessment in Neuro-oncology criteria helps to standardise glioma 
tumour monitoring,317 radiographic measurements can be unreliable and insensitive 
to early signs of treatment failure and tumour relapse. Moreover, there are still 
difficulties deciphering pseudo-progression and pseudo-responses in some patients. 
Brain biopsy and histologic analysis can provide definitive diagnoses and evaluation 
of disease progression, however serial biopsies are impractical given the cumulative 
surgical risk, and biopsied tissue may not reflect the heterogeneity of GBM tumours. 
An important step towards the provision of personalised GBM patient care is the 
ability to assess tumours in-situ. As such, there is a real need for biomarkers that can 
measure disease burden and treatment responses in GBM patients in a safe, accurate 
and timely manner, and preferably before changes become clinically apparent. The 
recently popularised idea of ‘liquid biopsy’ presents an ideal approach to monitor 
GBM tumour load and evolution in response to treatment. If developed and 
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implemented alongside new treatments, such tests would provide useful surrogate 
endpoints and allow clinical trial protocols to be more dynamic and adaptive.  
Exosomes are nano-sized (30–100 nm) membrane-bound extracellular vesicles 
released by all cells in both health and disease, and there is growing interest in their 
use as non-invasive biomarkers for disease diagnosis and monitoring of disease 
recurrence.318 GBM-derived exosomes circulate in the peripheral blood of patients, 
and can contain diagnostic nucleic acid.41 We recently described a GBM exosome 
protein signature319 and also showed that GBM exosomes contain abundant, 
selectively packaged sncRNAs.255 Using unbiased sncRNA deep sequencing, we 
identified several unusual and/or completely novel sncRNAs within GBM exosomes 
in vitro as well as an enrichment of miRNA implicated in oncogenesis, including 
miR-23a, miR-30a, miR-221 and miR-451.255 Thus, while GBM exosomal miRNA 
contents broadly reflect their cell of origin, there is a unique profile of miRNAs 
within exosomes. 
Some studies of exosomal miRNA in GBM patients have already been reported; 
these studies utilised methods that focused on pre-defined and relatively small groups 
of miRNA species. One previous study found that miR-21 levels in CSF exosomes of 
GBM patients were up-regulated 10-fold compared to controls,320 while another 
reported that serum exosomal miR-320, mir-547-3p, and RNU6-1 were significantly 
associated with GBM diagnosis, as well as outcome (RNU6-1)221. However, to date 
no comprehensive analysis of the entire miRNA repertoire of serum exosomes in 
glioma patients has been performed. Here, we have used unbiased next generation 
sequencing and an integrative bioinformatics pipeline270 to assay the complete 
repertoire of exosomal-associated miRNAs in the serum of patients with 
glioblastoma, lower grade gliomas, and HCs. We describe a novel miRNA signature 
within serum exosomes that is highly predictive of pre-operative GBM diagnosis. 
Furthermore, we show that this approach has potential for describing unique miRNA 
signatures for distinct glioma entities. 
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Material and methods 
Participants 
Serum (1 ml) was accessed from the Neuropathology Tumour and Tissue Bank at 
Royal Prince Alfred Hospital (RPAH), New South Wales, Australia (Sydney Local 
Health District, Human Research Ethic Committees (HREC) approval, X014-0126 & 
HREC/09RPAH/627). Twenty-six serum specimens were collected pre-operatively 
from patients with histologically confirmed glioma tumours, including 16 with 
GBM, IDH-wildtype (IDHWT) WHO (2016) grade IV, and 10 patients with grade II-
III IDH-mutant (IDHMUT) gliomas (refer to Table 4-1 and Table 4-2). Age- and 
gender-matched healthy control sera (n=16) were used for discovery miRNA 
analyses. Sera from an additional nine HCs and ten non-glioma patients (active 
multiple sclerosis, n=9, and ganglioglioma, n=1) were used to test the GBM miRNA 
signature. This study was performed under RPAH, and The University of Sydney 
HREC approved protocols (#X13-0264 and 2012/1684), and all participants provided 
written informed consent. All methods were performed in accordance with the 
relevant guidelines and regulations. 
Exosome purification and characterisation 
Exosomes were isolated from serum as previously described.270 Briefly, serum (1 ml 
from each subject) was treated with RNase A (37 °C for 10 min; 100 ng/ml; Qiagen, 
Australia) before exosome purification by size exclusion chromatography (qEV 
iZON Science). Ten fractions (500 µl) were eluted in phosphate buffered saline 
(PBS), as per manufacturer’s instructions. Fractions 8, 9, and 10 were previously 
shown to contain purified exosome populations270 and were collected and stored at 
−80 °C. Captured exosomes were characterised in accordance with the criteria 
outlined by the International Society for Extracellular Vesicles.26 Specifically, we 
identified more than three exosome-enriched proteins by mass spectrometry 
proteome profiling and characterised vesicle heterogeneity using two technologies, 
transmission electron microscopy (TEM) and nanoparticle tracking analysis (NTA).  
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Transmission electron microscopy 
Combined qEV-captured fractions 8-10 was loaded onto carbon-coated, 200 mesh 
Cu formvar grids (#GSCU200C; ProSciTech Pty Ltd, QLD, Australia), fixed (2.5% 
glutaraldehyde, 0.1 M phosphate buffer, pH7.4), negatively stained with 2% uranyl 
acetate for two minutes and dried overnight. Exosomes were visualised at 40,000 
times magnification on a Philips CM10 Biofilter TEM (FEI Company, OR, USA) 
equipped with an AMT camera system (Advanced Microscopy Techniques, Corp., 
MA, USA) at an acceleration voltage of 80 kV. 
Nanoparticle tracking analysis 
Particle size distributions and concentrations were measured by NTA software 
(version 3.0) using the NanoSight LM10-HS (NanoSight Ltd, Amesbury, UK), 
configured with a 532-nm laser and a digital camera (SCMOS Trigger Camera). 
Video recordings (60 s) were captured in triplicate at 25 frames with default minimal 
expected particle size, minimum track length, and blur setting, a camera level of 10 
and detection threshold of 5.  
Proteome analysis of exosomal preparations 
Serum exosome fractions 8, 9 and 10 were prepared for mass spectrometry MS-based 
proteomic analysis. Proteomes were concentrated using chloroform-methanol 
precipitation, dissolved in 90% formic acid, their concentrations estimated at 280 nm 
using a Nanodrop (ND-1000, Thermo Scientific, USA) and aliquots dried using 
vacuum centrifugation. Proteomes were then processed and quantified as before.321 
Peptides from each fraction were desalted using C18 ZipTipsTM, concentrations 
estimated by Qubit quantitation (Invitrogen), dried by vacuum centrifugation and re-
suspended in 3% acetonitrile (ACN; v/v)/0.1% formic acid (v/v). Samples (0.5 µg) 
from exosome elution fractions 8-10 were separated by nanoLC using an Ultimate 
nanoRSLC UPLC and autosampler system (Dionex) before analysed on a QExactive 
Plus mass spectrometer (Thermo Electron, Bremen, Germany) as previously 
described.321 MS/MS data were analysed using Mascot (Matrix Science, London, 
UK; v2.4.0) with a fragment ion mass tolerance of 0.1 Da and a parent ion tolerance 
of 4.0 PPM. Peak lists were searched against a SwissProt database (2017_11), 
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selected for Homo sapiens, trypsin digestion, maximum two missed cleavages, and 
variable modifications methionine oxidation and cysteine carbamidomethylation. 
Exosome proteins were annotated using Vesiclepedia (http://microvesicles.org)322 
and Functional Enrichment Analysis Tool (FunRich; v2.1.2; http://funrich.org)323. 
RNA extraction and small RNA sequencing 
Serum exosomes were processed for RNA extraction using the Plasma/Serum 
Circulating & Exosomal RNA Purification Mini Kit (Norgen Biotek, Cat. 51000) 
according to the manufacturer’s protocol. Extracted total RNA samples were 
analysed with a Eukaryote Total RNA chip on an Agilent 2100 Bioanalyser (Agilent 
Technologies, United States) to confirm sufficient yield, quality and size of RNA. 
Exosome RNA sequencing libraries were then constructed using the NEBNext 
Multiplex Small RNA Library Prep Kit for Illumina (BioLabs, New England) 
according to the manufacturer’s instructions. Yield and size distribution of resultant 
libraries were validated using Agilent 2100 Bioanalyser on a high-sensitivity DNA 
assay (Agilent Technologies, United States). Libraries were then pooled with an 
equal proportion for multiplexed sequencing on Illumina HiSeq. 2000 System at the 
Ramaciotti Centre for Genomics. 
Data pre-processing, differential expression analysis and pathway 
analysis 
Data pre-processing was performed using a pipeline comprising of adapter trimming 
(cutadapt), followed by genome alignment to human genome hg 19 using Bowtie 
(18bp seed, 1 error in seed, quality score sum of mismatches <70). Where multiple 
best strata alignments existed, tags were randomly assigned to one of those 
coordinates. Tags were annotated against mirBase 20 and filtered for at most one 
base error within the tag. Counts for each miRNA were tabulated and adjusted to 
counts per million miRNAs passing the mismatch filter. All samples achieved 
miRNA read counts >45,000 read counts and miRNAs with low abundance (<50 
read counts across more than 20% of samples) were removed. Differential expression 
analysis was performed using three different statistical hypothesis tests including a 
non-parametric two-sample Wilcoxon test and two parametric tests: Student’s t-test, 
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and an exact test (implemented in Bioconductor EdgeR), which tests for differences 
between the means of two groups of negative-binomially distributed counts. 
Benjamini & Hochberg adjusted p-values were also calculated. Data pre-processing 
and differential expression analysis were performed using Bioconductor and R 
statistical packages. Pathway analysis was performed using Ingenuity® software 
(Ingenuity Systems, USA; http://analysis.ingenuity.com). MicroRNA target filters 
were applied to significant, differentially expressed miRNAs (unadjusted p-
value≤0.05 in all three statistical methods) and mRNA target lists were generated 
based on highly predicted or experimentally observed confidence levels. Core 
expression analyses were performed with default criteria to determine the most 
significant functional associations (biological and canonical pathways) of mRNAs 
targeted by dysregulated miRNAs. 
Univariate analysis 
We performed logistic regression (LR) and receiver operator characteristic (ROC) 
analysis to assess the predictive power of individual miRNAs between the two 
groups of interest. LR was used to identify linear predictive models with each 
miRNA as the univariate predictor. The quality of each model was depicted by the 
corresponding ROC curve, which plots the true positive rate (i.e., sensitivity) against 
the false-positive rate (i.e., 1-specificity). The area under the ROC curve (AUC) was 
then computed as a measure of how well each LR model can distinguish between 
two diagnostic groups. We then used leave-one-out cross validation (LOO-CV) to 
estimate the prediction errors of the LR models. LOO-CV learns the model on all 
samples except one and tests the learnt model on the left-out sample. The process is 
repeated for each sample and the error rate is the proportion of misclassified samples. 
Overall, cross validation is a powerful model validation technique for assessing how 
the results of a statistical analysis can be generalized to an independent dataset.229 
These analyses were performed using R stats (glm) and boot (cv.glm) packages. 
Multivariate analysis 
To assess the predictive power of multiple miRNAs as disease signatures, samples 
were first randomly partitioned into two disjoint sets of discovery (70% of samples) 
and validation (30% of samples). miRNAs differentially expressed in the discovery 
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set (i.e., changes increased or decreased by fold change≥2 and unadjusted p-
value≤0.05 in all three statistical hypothesis tests) were then selected as 
features/predictors of RF multivariate predictive model. RF is a multivariate 
nonlinear classifier that operates by constructing a multitude of decision trees at 
training time in order to correct for the overfitting problem.324 RF was trained on the 
discovery set and the resultant predictive model was then used to predict GBM or 
GII-III patients versus HCs based on the read count values of identified miRNAs in 
validation samples. For statistical rigour, to account for random partitioning of the 
samples into discovery and validation sets, the whole process was repeated 100 
times. We then chose stable miRNAs—i.e., those identified to be differentially 
expressed in more than 75% of iterations—as predictors of an RF model using all 
samples and the out-of-bag (OOB) error was reported as an unbiased estimate of the 
model predictive power. The ‘importance’ or relative contribution of each feature 
(differentially expressed miRNAs) in the RF performance was then estimated based 
on the ‘mean decrease accuracy’ measure as detailed by Breiman in 2001.280 All the 
analyses were performed using R ‘caret’ and ‘RandomForest’ packages. 
Data availability 
Exosomal miRNA raw data will be accessible at NCBI Gene Expression Omnibus 
(GEO; accession number to be provided). In the interim, the miRNA sequencing data 
is available at: https://github.com/VafaeeLab/glioblastoma_exosomal_miR_markers.  
Results 
Characterisation of serum exosomes isolated prior to 
miRNA sequencing 
Serum exosomes were isolated by size exclusion chromatography. The combined 
elution fractions 8-10 showed particle sizes with a mean diameter 89.1 ± 2.5 nm and 
modal diameter of 81.7±5.5 nm (Figure 4-1A). TEM confirmed the presence of 
similarly sized particles with vesicular morphologies, characteristic of exosomes 
(Figure 4-1B). MS analysis confidently identified 1167, 861 and 636 proteins in qEV 
elution fractions 8, 9 and 10 from healthy serum, respectively. Overall, 87 of the top 
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100 proteins commonly identified in exosomes were confidently sequenced across 
the three fractions, including all top 10 exosomal proteins (Figure 4-1C-1). Primary 
sub-cellular localisations included significant enrichments of ‘exosome’ and ‘blood 
microparticle’ related proteins across all fractions, with minimal contamination from 
other compartments, including the nucleolus (Figure 4-1C-2) where certain miRNAs 
show specific nuclear enrichment.325 Prior to RNA extraction, serums were treated 
with RNaseA to remove circulating RNAs that may confound measurements of 
exosomal RNAs.270 RNA extracted from each sample yielded profiles typical for 
exosomes, showing an absence of ribosomal RNA and enrichment of small (<200 nt) 
RNA species (Figure 4-1D). 
 
Figure 4-1 Characterisation of serum exosomes isolated in fractions 8-10 by size exclusion 
chromatography prior to miRNA sequencing 
A) Size distribution of particles as analysed by NTA. B) Transmission electron microscopy allowed 
visualization of vesicles with sizes ranging from 60-110 nm in diameter, scale bars = 500 nm (B-1, 
wide field) and 200 nm (B-2, close-up). C-1) Mass spectrometry-based proteome analysis of size 
chromatographic elution fractions 8-10 identified all top 10 exosome marker proteins and (C-2) 
showed significant enrichment of proteins characteristic of exosomes and blood microparticles. 
Proteins identified in fractions 8-10 showed limited, non-significant associations to compartments like 
the nucleolus, where certain miRNA species are concentrated. D) Bioanalyser trace of RNA extracted 
from serum exosomes shows the main population of small RNA and no ribosomal RNA. 
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Differentially expressed exosomal miRNAs in GBM 
patient sera 
Circulating exosomal miRNA profiles from patients with histopathologically 
confirmed IDHWT GBM (n=12) were compared to age- and gender-matched HCs 
(n=12; see Table 4-1 for discovery cohorts; Table 4-2 for validation cases). We 
employed three statistical approaches (Student’s t-test, Fisher’s exact, Wilcoxon rank 
sum) to identify a discovery set of differentially expressed miRNA biomarkers. 
miRNA biomarkers were identified if their differential expression met a fold 
change≥2 in either direction and unadjusted p-values≤0.05 in all statistical tests 
applied. Using this approach, we identified 26 miRNAs significantly dysregulated 
between HCs and GBM patients (Table 4-3; Figure 4-3A). 
Table 4-1 Overview of cohorts used for discovery miRNA analyses 
 GBM, IDHWT GBM-matched HC  GII-III, IDHMUT GII-III-matched HC 
Sample n 12 12 10 10 
Age (mean ±SD) 63.3 ± 11.5 56.2 ± 12.4 42.9 ± 12.7 42.7 ± 10.2 
Gender 7M, 5F 7M, 5F 6M, 4F 6M, 4F 
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Table 4-2 Additional patients and cohorts used for validation 
Patient/cohort Age Gender Diagnosis Notes 
GBM1_relapse 46 M GBM IV 
Pre-operative blood taken after 
recurrence of GBM1 (8-month 
relapse) 
GBM12_prior 45 F GBM IV 
Pre-operative blood taken before 
removal of earlier GBM lesion 
(GBM12; 4.6 months prior) 
GBM13 33 M GBM IV Glioblastoma, IDH
MUT, WHO (2016) 
grade IV 
GBM14 56 M High-grade glioma 
No surgery/tissue pathology 
performed, diagnosis based on repeat 
MRIs. Overall survival of 8.1 months. 
GI_C 24 F Ganglioglioma grade I 
GFAP+ in glial component/ NeuN+ in 
neuronal component, IDH1WT, 
ATRX+, BRAF(V600E)+++  
HC (n=9) 36.2± 10.3 5F, 4M Healthy controls – 
MS_C (n=9) 35.3±10.4 5M, 4F 
Relapse-remitting 
Multiple Sclerosis 
All patients had active lesions; were 
untreated (n=5) or receiving different 
immunomodulatory therapies (n=4) 
 
Abbreviations: F, female; GBM, glioblastoma; GII-III, glioma grade II-III; GI_C, ganglioglioma 
grade I control case; HC, healthy controls; M, male; MS_C, multiple sclerosis control cohort. (Mean 
age with standard deviation is provided for each cohort.) 
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Table 4-3 Significant dysregulated miRNAs in serum exosomes from glioblastoma (GBM) 
patients (n=12) relative to healthy controls (HC; n=12) 
miR- 
CPM 
(GBM) 
CPM 
(HC) FC Exact test t-test Wilcoxon 
Error 
rate AUC 
486-5p 25291.6 8522.6 3.0 1.6E-07* 4.0E-04* 1.0E-04* 0.149 0.924 
182-5p 2090.5 850.6 2.5 5.7E-07* 3.0E-04* 2.0E-04* 0.151 0.917 
486-3p 277.4 114 2.4 5.0E-06* 0.002* 3.0E-04* 0.149 0.910 
378a-3p 2083.2 875.2 2.4 1.4E-06* 0.003* 4.0E-04* 0.158 0.903 
183-5p 645.8 267.9 2.4 2.0E-05* 0.001* 0.001* 0.176 0.882 
501-3p 359.6 157.3 2.3 1.1E-05* 0.002* 0.001* 0.161 0.875 
20b-5p 594.6 266.3 2.2 2.9E-06* 0.002* 1.0E-04* 0.133 0.938 
106b-3p 2703.2 1215 2.2 3.9E-06* 0.001* 0.001* 0.160 0.889 
629-5p 896.8 415 2.2 0.001* 0.047 0.04 0.235 0.743 
185-5p 23250.5 11424.1 2.0 4.3E-05* 0.007* 0.005* 0.207 0.833 
25-3p 21838.8 10949.9 2.0 0.001* 0.002* 0.006* 0.199 0.826 
21-5p 73535.3 142796.9 -2.0 2.7E-04* 4.2E-05* 5.0E-05* 0.133 0.944 
7a-3p 82.1 176.3 -2.0 0.003* 0.005* 0.010* 0.187 0.806 
381-3p 190.5 397.9 -2.0 0.009* 0.012 0.012 0.220 0.799 
409-3p 1146.9 2242.5 -2.0 0.019 0.029 0.024 0.233 0.771 
7d-3p 1050.5 1912.9 -2.0 0.005* 0.013 0.017 0.209 0.785 
323b-3p 117.3 288.3 -2.4 0.004* 0.010* 0.004* 0.199 0.840 
328-3p 382.5 922.5 -2.5 4.6E-06* 2.0E-04* 2.2E-05* 0.117 0.958 
339-5p 90.1 234.8 -2.5 1.2E-06* 2.0E-04* 3.3E-05* 0.109 0.951 
340-5p 1536 3848.1 -2.5 4.8E-06* 1.0E-04* 5.0E-05* 0.134 0.944 
126-5p 1222.3 2947 -2.5 5.6E-06* 0.002* 0.001* 0.150 0.896 
130b-5p 111.9 248.9 -2.5 0.007* 0.009* 0.024 0.203 0.771 
493-5p 210 514.4 -2.5 0.010* 0.015 0.028 0.221 0.764 
543 223.1 753.2 -3.3 2.5E-06* 3.0E-04* 2.0E-04* 0.143 0.917 
654-3p 110.2 342.5 -3.3 2.2E-04* 0.009* 0.006* 0.193 0.826 
485-3p 93.2 352.3 -3.3 5.8E-07* 1.0E-04* 3.3E-05* 0.123 0.951 
 
Abbreviations: CPM, miRNA counts per million; FC, fold change; error rates estimated by leave-one-
out cross validation; AUC, area under the receiver operating characteristic; Significant Benjamini & 
Hochberg adjusted p-values are indicated by asterisks. 
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Functional analysis of dysregulated miRNAs in GBM 
We explored biological and canonical pathways associated with exosomal miRNAs 
changing in GBM patient sera relative to HCs. The identities of 44 miRNAs (p-
value≤0.05 in all three tests; no fold change restriction) were uploaded into the 
Ingenuity Pathway Analysis environment to analyse molecular pathways 
overrepresented in their targets. The dysregulated miRNAs target mRNAs that are 
significantly associated with ‘cancer’ (1.96E-06<p-value<1.52E-16) and ‘neurological 
disease’ (1.72E-06<p-value<8.76E-13) with around half of targeted mRNAs implicated 
in GBM (p-value=3.36E-12) and glioma signaling pathways (p-value=1.25E-09; 
Figure 4-2B, C).   
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Figure 4-2 Differentially expressed miRNAs and their pathway analyses 
A) Hierarchical clustering of 26 differentially expressed miRNAs shows clear separation of GBM 
patients and HC exosomal profiles (fold change≥2 or ≤0.5; unadjusted p-values≤0.05 in all three 
statistical tests). B) Functional pathway analysis of mRNAs targeted by 44 significantly changing 
miRNA (unadjusted p-values≤0.05 in all three statistical tests) in GBM circulating exosomes. Top 
canonical pathways, diseases and disorders and molecular and cellular functions are listed with the 
numbers of overlapping molecules and significance of associations (right-tailed Fisher exact test, p-
value). C) Ingenuity Pathway Analysis revealed significant overlaps with Glioblastoma signaling 
pathway (p-value=3.36E-12). Glioblastoma signaling pathway annotated with molecules targeted by 
significant, differentially expressed exosomal miRNAs (in magenta).  
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Selection of signature miRNA classifiers for 
preoperative GBM diagnosis 
The predictive power of each miRNA was estimated using LR models, in which 
individual miRNA expression profiles were used as predictors. ROC curves were 
determined and AUC measures were ≥0.74 across the 26-dysregulated miRNAs 
(Table 4-3; Figure 4-3). 
 
Figure 4-3 ROC curves of differentially expressed miRNAs in GBM versus HCs 
In silico validation by LOO-CV correctly identified the test sample on average 83% 
of the time (range 77–89%). We then used partitioning (70% training and 30% test) 
and RF multivariate modeling to determine whether expression patterns of a subset 
of differentially expressed miRNAs could improve the predictive power. Using these 
methods, seven miRNAs (miR-182-5p, miR-328-3p, miR-339-5p, miR-340-5p, miR-
485-3p, miR-486-5p and miR-543) distinguished GBM patients from healthy 
subjects in more than 75% of the random data partitions and were selected as the 
most ‘stable’ miRNA classifiers (Figure 4-4A and B). The RF model was repeated 
using all iterations of the seven most stable miRNAs and achieved an overall 
predictive power of 91.7% for classifying GBM patients from HCs (Figure 4-4-C 
and D). Strikingly, within this model, several miRNA combinations were able to 
distinguish GBM patients from HCs with perfect accuracy, including a panel of four 
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miRNAs (miR-182-5p, miR-328-3p, miR-485-3p, miR-486-5p) and five miRNAs 
(miR-182-5p, miR-339-5p, miR-340-5p, miR-485-3p, miR-486-5p; Figure 4-4E). 
 
Figure 4-4 Selection of signature miRNAs 
A) miRNAs appearing in >75 of 100 partitions (70% training set, 30% test set) were selected as the 
most stable miRNA classifiers by Random Forest modelling (frequencies are specified in brackets). B) 
Box-and-whisker plots and ROC curves with AUC calculations demonstrate the individual 
discriminatory power of the seven most stable miRNA classifiers. C) miRNAs were ordered by the 
importance of their contribution to discriminating GBM from HCs; overall OOB error rate of the 
seven features was 8.33%. D) RF model was performed again using all possible combinations of 
seven most stable miRNAs to find combinations (i.e., signatures) with the highest multivariate 
predictive power. Error rates of different combinations were stratified by the number of miRNAs 
(signature size) and their distributions were displayed as violin plots. E) miRNA combinations that 
discriminate between GBM and HCs with the highest accuracy. 
To assess the temporal stability of the GBM miRNA signature in the same patients, 
we tested preoperative sera collected at a GBM recurrence (GBM1 patient relapsed 
and required additional surgery after eight months) and from an earlier GBM lesion 
(excised 4.6 months before GBM12; Table 4-2). Using the panel of seven exosomal 
miRNAs, both GBM1-relapse and GBM12-prior were classified as GBM, in line 
with diagnostic histopathology. We also tested two independent samples, including a 
patient diagnosed with IDHMUT GBM (GBM13) and a patient diagnosed with ‘high-
grade glioma’ based on repeat MRIs and overall survival of 8.1 months (GBM14; see 
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Table 4-2). Both GBM13 and GBM14 were classified as GBM using the miRNA 
panel. 
To further test the specificity of the GBM miRNA signature, we assessed its ability 
to distinguish GBM patients from additional healthy subjects and non-glioma disease 
controls. The panel accurately classified all additional healthy subjects (n=9; 
Table 4-2) as well as a patient with ganglioglioma WHO (2016) grade I, a slow-
growing, benign brain tumour with glioneuronal components (GIC-1). Next, we 
assessed the impact of neuroinflammatory disease processes on the specificity of our 
exosomal miRNA panel ability. The bioinformatics analysis above showed that 
dysregulated miRNAs also target mRNAs significantly associated with autoimmune 
rheumatoid arthritis and broadly to ‘neurological disease’ (see Figure 4-2B). Our 
GBM miRNA panel was used to discriminate patients with the inflammatory 
autoimmune disease, MS. Sera were sampled from MS patients with active 
gadolinium enhancing demyelinating lesions, either untreated or receiving 
immunomodulatory therapies (n=9; Table 4-2). All MS patients were classified as 
controls, indicating the robustness of our exosomal miRNA signature for GBM 
identification. 
miRNAs dysregulated in IDH-mutant II-III gliomas 
provide additional markers for glioma severity and 
IDH mutational status 
We then compared serum exosome miRNA profiles between IDHMUT grade II-III 
glioma patients (n=10; mean age=42.7) and matched HCs (n=10; mean age=42.9; see 
Table 4-1) and identified 23 differentially expressed miRNAs (fold change≥2; 
unadjusted p<0.05 in all three tests. Of these, 12 miRNAs were shared with the GBM 
analysis and showed the same direction of change (Figure 4-5A).  
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Figure 4- 5 Representing stable classifiers for glioma tumour grades II-III (IDHMUT) and 
glioblastoma (IDHWT)  
a) A Venn diagram summarises the differentially expressed miRNAs between IDHMUT glioma tumour 
grades II-III (GII-III; n=10), IDHWT glioblastoma (GBM; n=12) and corresponding age- and gender-
matched healthy controls (HC; fold change≥2 or ≤0.5; unadjusted p-values≤0.05 in all three statistics 
tests, i.e., exact, t-test and Wilcoxon), with 12 overlapping differentially expressed miRNAs. 
Decreased expression is indicated in blue and increased expression in red. The most stable miRNAs 
for classifying (b-1) GII-III IDHMUT and (b-2) GBM IDHWT from HCs are listed and show distinct 
features. (c-1) Summary of differentially expressed miRNAs between the GBM IDHWT and GII-III 
IDHMUT cohorts and (c-2) plot of ‘importance’ of each individual miRNA for discriminating GBM 
from GII-III; OOB error rate is 22.73%. Three of the top four features that distinguish GBM 
IDHWT from GII-III IDHMUT were only identified in the GBM vs. HC comparative analysis, are 
members of the GBM miRNA signature that together accurately classify GBMs from HCs and 
may be specific markers for GBM (indicated by asterisks in a, b-1, c-1, and c-2). 
AUC curve measures were ≥0.78 (average 0.88) across the 23 dysregulated 
miRNAs, and LOO-CV correctly identified the test sample on average 83% of the 
time (range 77–88%; Figure 4-6). 
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Figure 4-6 ROC curve of differentially expressed miRNAs between grades II-III glioma versus 
controls 
RF modeling performed on partitioned data selected miR-7d-3p, miR-98-5p, miR-
106b-3p, 130b-5p and 185-5p as the most stable features for classifying grade II-III 
glioma patients from healthy participants, with a predictive power of 75.0% (Figure 
4-5C and Figure 4-7). The most stable miRNAs for classifying GII-III IDHMUT from 
HCs were distinct from GBM IDHWT signature miRNAs (Figure 5-5 –b1, b2). 
 
Figure 4-7 Partitioning and RF modelling to select stable miRNAs for grade II-III glioma versus 
matched HCs 
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The sncRNA data was further interrogated to ascertain whether a subset of miRNAs 
showed potential for distinguishing glioma disease severity or IDH mutational status. 
Direct comparisons between GBM IDHWT and GII-III IDHMUT patients revealed 13 
differentially expressed miRNAs (fold change≥2; unadjusted p<0.05 in all three 
tests; (Figure 4-5C-1). AUC curve measurements were ≥0.78 (average 0.84) across 
the 13 dysregulated miRNAs and LOO-CV correctly identified the test sample on 
average 80% of the time (range 76–86%). Numbers of significant miRNA were too 
few to perform partitioning, so a single RF model was constructed from all 13 
dysregulated miRNAs that showed an estimated predictive power of 77.4% 
(Figure 4-5C-2) Interestingly, three of the top four features that discriminate GBM 
IDHWT from GII-III IDHMUT are members of the GBM miRNA signature (i.e., 
miR-543, miR-485-3p and miR-486-3p), changing only in GBM patient sera 
relative to healthy participants (indicated by asterisks in Figure 4-5). 
Discussion 
Using unbiased high-throughput next generation sequencing and an integrative 
bioinformatics pipeline;270 we have identified differentially expressed serum 
exosomal miRNAs that discriminate GBM patients from HCs. Machine-learning 
approaches on miRNAs were used to examine their individual and shared predictive 
abilities for a pre-operative GBM diagnosis via a blood test. Of the 26 differentially 
expressed miRNAs in GBM patients’ relative to HCs, we selected a stable signature 
panel of seven miRNAs. Together, expression levels of miR-182-5p, miR-328-3p, 
miR-339-5p, miR-340-5p, miR-485-3p, miR-486-5p and miR-543 predicted a 
preoperative GBM diagnosis with 91.7% accuracy. Within this multivariate model a 
combination of just four miRNAs (miR-182-5p, miR-328-3p miR-485-3p miR-486-
5p) distinguished GBM patients from HCs with perfect accuracy (100.0%). 
There have been multiple studies examining ‘free-circulating’ miRNAs in glioma 
patients with varying success. A recent meta-analysis of these studies found the 
specificity and sensitivity of circulating miRNAs was 0.87 and 0.86, respectively, 
while noting the large heterogeneity of circulating miRNAs within the included 
studies.326 The heterogeneity is likely due to differences in data normalisation used in 
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quantitative reverse transcriptase PCR studies, with no universally accepted 
endogenous housekeeping control.326 Interestingly, the majority of miRNAs 
identified in our exosomal signature have not been previously identified in ‘free-
circulating’ studies. This is consistent with the notion that exosomes represent a 
distinct pathway of nucleic acid release from cells, and contain selectively packaged 
miRNA species.255 We have previously shown the effects of RNAse pre-treatment of 
serum prior to exosome isolation, as performed in this study, drastically alters the 
miRNA profiles identified, presumably due to eradication of co-precipitated ‘free-
circulating’ miRNAs.270 Moreover, normalisation of deep sequencing data is not 
dependant on comparison to a reference signal or housekeeping gene, potentially 
reducing variability in data analysis. 
Functional pathway analysis of mRNA species targeted by exosomal miRNAs 
dysregulated in GBM patient sera showed highly significant associations to specific 
GBM molecular pathways. This provides confidence that the miRNA biomarkers 
resolved by our methods are relevant to this particular disease setting. Previous 
studies have identified roles for all seven GBM miRNA classifiers in various aspects 
of glioma and GBM biology. miR-182, detected here in significantly higher levels in 
GBM sera, was proposed as a marker of glioma progression, critical for glioma 
tumourigenesis, tumour growth and survival in vitro,327,328 with high miR-182 tissue 
expression observed in GBM329 and associated with poor overall survival330. Also in 
line with observations here, the up-regulation of miR-486 was shown to promote 
glioma aggressiveness both in vitro and in vivo.331 Exosomal miRNAs identified with 
lower expression levels in GBM patient sera are also substantiated by the literature. 
Functional assays indicate tumour suppressive roles of miR-328332, miR-340,333,334 
miRNA-485-5p335 and miR-543336 with low levels observed in tumour tissues 
relative to normal brain332,334-336 and low tissue expression levels significantly 
associated to poor patient outcomes 332,334. While miR-339 (decreased levels in GBM 
patients here) was shown to contribute to immune evasion of GBM cells by 
modulating T-cell responses,337 inhibitory roles for miR-339 were reported in acute 
myeloid leukemia,338 hepatocellular carcinoma,339 gastric,340 colorectal,341 breast342 
and ovarian cancers343. 
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The GBM miRNA signature was able to accurately classify all additional specimens 
in the validation sets (healthy, n=9; non-glioma, n=10), including patients with 
gadolinium enhancing active demyelinating lesions. Tumefactive demyelination is a 
well-recognised mimic of GBM.344 The GBM signature also correctly classified four 
additional GBM specimens, including two serial collections from patients within the 
discovery cohort as well as two independent patients. Further testing is needed to 
determine whether the miRNA panel can reliably diagnose GBM in large, 
independent patient cohorts. Moreover, the correlation between a positive GBM 
classification and tumour burden needs to be addressed. To this end, longitudinal 
studies should be pursued to assess whether the GBM miRNA panel can detect time 
critical GBM tumour recurrences. 
There is more than one pathological route to a GBM; primary and secondary GBMs 
are distinct entities with IDH mutations considered a genetic signpost.345 The only 
patients where early detection of a GBM tumour is likely are arguably those with 
diffuse and anaplastic (grade II-III) gliomas who progress with a secondary GBM 
recurrence (IDHMUT). Accordingly, the identification of reliable and readily 
accessible circulating progression markers is an important step towards precision 
medicine for patients diagnosed with low-grade gliomas. While the GBM miRNA 
signature was described in serum exosomes from IDHWT GBM patients, it was also 
able to categorise a patient with IDHMUT GBM (GBM13) from healthy participants. 
It is worth noting that miRNA members of the GBM signature panel (specifically, 
increased miR-182-5p, decreased miR339-5p and miR-340-5p) were also identified 
in the IDHMUT GII-III comparative analysis. Whether these miRNA changes are 
related to IDH mutational status, glioma grade, or a combination of the two, cannot 
be delineated here. However, our multivariate modeling did identify distinct panels 
of miRNAs for classifying GBM and glioma patients from their corresponding 
matched healthy control cohorts. Moreover, three GBM signature panel miRNAs that 
were unique to the GBM vs control comparative analysis (increased miR-486-5p and 
decreased miR-485-3p and miR-543) were among the top four features that 
distinguish GBM IDHWT from GII-III IDHMUT and therefore, might be specific for 
GBM IDHWT (indicated by asterisks in Figure 4-4). These encouraging results 
demonstrate the potential for exosomal miRNA profiles to be used for glioma 
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subtyping and grading, including the determination of mutational states. Expansion 
of these discovery analyses to include well defined cohorts of glioma subtypes with 
sufficient n, will likely resolve biomarkers of more nuanced specificity. 
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Chapter 5: 
Concluding remarks and future 
directions 
Conclusions 
Circulating exosomes in body fluids display a variety of protein and RNA contents in 
healthy individuals and patients with a different disease, and these can be measured 
to assess their potential as biomarkers.346 It has been reported that patients with 
glioblastoma can be distinguished from healthy individuals based on the increased 
level of EGFRvIII mRNA in tumour-derived exosomes.347 Yet another study 
reported that the presence of EGFR localized to exosome membranes could be useful 
as a biomarker for lung cancer diagnosis.348 In pancreatic cancer patients, the 
presence of proteoglycan glypican-1 positive exosomes not only distinguishes them 
from healthy individuals and patients in the benign stage of cancer349 but also the 
level of these exosomes correlated with tumour burden and survival of pre- and post-
surgical patients. It has been reported that plasma microvesicles released by prostate 
acinar cells represents a novel markers for prostate cancer and proteomics profiling 
of EVs identified candidate markers of the disease.350 
Exosomes have also been evaluated as a potential biomarker for other non-cancer 
diseases of multiple organs including lung,351 arteries,352 kidney,353 liver,354 and the 
central nervous system (CNS). The serum exosomal miRNA profiles from broncho-
alveolar lavage fluids of asthmatic patients differed them from healthy individuals.351 
In cardiovascular disease, significantly differentially expressed miR-192 in serum 
exosomes predicted the subsequent development of heart failure in patients after 
acute myocardial infarction.355 Also in patients with hepatocellular carcinoma, 
recurrence of tumour after liver transplantation correlated to increased levels of 
miRNAs in serum exosomes.356 In the CNS, extracellular accumulation of 
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abnormally processed tau protein results in tau-induced neurodegeneration. It has 
been reported that in the M1C neuroblastoma tauopathy model, exosomes are 
enriched in AT270 phospho-tau, can be used as a valuable biomarker for early 
Alzheimer disease.357 Profiling proteomics of serum circulating exosomes identified 
a variety of differentially abundant proteins as a biomarker to discriminate patients 
with Parkinson or Alzheimer diseases from healthy individuals.358 For instance, the 
level of autolysosomal proteins in serum exosomes distinguished patients with pre-
clinical Alzheimer disease from healthy individuals and patients with frontotemporal 
dementia.359 Furthermore, Bellingham and his colleagues reported that a small RNA 
deep sequencing of neuronal exosomes contained a diverse range of RNA species, in 
particular, a distinct miRNA signature that could be utilised for diagnosing 
neurodegenerative disorders.360  
In this thesis, I tested the hypothesis that circulating exosomes and their RNA cargo 
can be exploited as accessible and informative biomarkers for two disparate CNS 
pathologies: multiple sclerosis (MS) and glioblastoma. The presence of the blood-
brain barrier (BBB) that protects the CNS makes brain chemistry difficult to monitor, 
and currently available techniques are invasive and costly. A blood-based biomarker 
test based on exosomes that can cross the BBB will facilitate monitoring CNS 
diseases longitudinally in a cost-effective and minimally invasive manner.142,224 
Exosomes are enriched with selectively packaged RNA from their producing cell, 
and thus by interrogating the exosomal RNA from the serum of patients and control 
subjects, I was able to determine that serum exosome miRNA signatures not only 
reflect the presence of a pathological CNS condition, but can also indicate the 
subtype of CNS pathology, and in some cases predict treatment response. 
In chapter 2, I examined a clinical cohort to ask whether serum exosomal miRNA 
profiles might be useful as disease biomarkers. By comparing serum exosomal 
miRNA profiles among healthy control and MS patients with varying disease activity 
I found a core signature of four miRNAs that was able to discriminate healthy 
individuals from MS patients. I also identified and validated nine miRNAs within 
MS patients that were capable of differentiating MS patients with different states of 
disease activity: relapsing-remitting MS (RRMS) or secondary progressive 
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MS/primary progressive MS (SPMS/PPMS). This is important because it implies 
that, in addition to disease diagnosis, serum exosomal miRNAs may act as tools for 
monitoring disease progression and allow for the early detection of disease resulting 
in better control of disease symptoms and ultimately improving quality of life.  
Interestingly, the majority of serum exosomal miRNA biomarkers were novel in that 
they have not been previously reported to be associated with MS. These findings 
suggest that serum exosomes are a unique source of biomarkers that have the 
potential to reveal signatures of disease that may not be visible by examination, for 
example, of total free circulating miRNA. Taken together, the results of this chapter 
revealed that serum exosomal miRNA can be employed to diagnose MS, and 
furthermore is able to classify MS patient disease activity. 
In chapter 3 I focused on determining whether serum exosome miRNA signatures 
might reveal something about the efficacy of Fingolimod, a disease modifying 
treatment (DMT). Although Fingolimod is an oral immunomodulator for MS 
therapy263 with an advantage over other injectable DMTs with no side-effect due to 
injection, its efficacy must be monitored on a case–by–case basis to manage an 
individual treatment strategy. My findings in chapter 2 suggest that serum exosomal 
miRNA signatures can reflect MS disease status, and differentiate between patients 
with RRMS and SPMS/PPMS. Therefore, I first sought to identify molecular 
biomarkers that indicate the active phase of RRMS and the efficacy of Fingolimod 
treatment in RRMS patients. I identified 15 dysregulated miRNAs that individually 
could discriminate between patients in relapse and those in the remitting phase six 
months after treatment. Current monitoring of RRMS patients requires regular MRI 
scanning (6 -12 monthly) which is costly and difficult to access for patients living in 
rural or remote communities. Thus having blood-based biomarkers will assist in 
confirming the diagnosis and allow for closer monitoring of disease activity. Using 
machine-learning approaches, the 15 miRNAs were refined to a set of 11 with a 92% 
accuracy rate of predicting active from quiescent RRMS phase. The predicted gene 
targets of these dysregulated miRNAs suggest that they target genes and biological 
processes previously associated with MS activity, and this, together with the 
correlation between presence of the markers and disease progression as determined 
by gadolinium-based contrast agents for MRI (Gd-MRI) scans, supports the validity 
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of these unique biomarkers. My findings suggest that circulating exosomes and their 
RNA cargo may serve as signatures of disease activity/progression that can be used 
to complement or even potentially replace Gd-MRI scans.  
Next, I investigated the pharmacogenomic roles of miRNAs in response to 
Fingolimod therapy. By comparing the serum miRNA exosome profiles of quiescent 
vs active RRMS patients (as determined by Gd-MRI scan results), I identified 11 
miRNAs upregulated in the stable responders group (i.e., patients who were 
quiescent at baseline and six months after treatment) and five miRNAs dysregulated 
in the positive responders (i.e., patients who were active at baseline and become 
quiescent after six months of treatment). Collectively, these miRNAs were 
functionally associated with six distinct pathways implicated in MS pathogenesis and 
relevant to Fingolimod mechanisms: the immune system, the nervous system, signal 
transduction, lipid metabolism, diseases, and cell cycle regulation. These results 
suggest that serum exosomal miRNAs are associated with MS immuno-pathogenesis 
and the molecular mechanism of Fingolimod and thus can be exploited as a 
biomarker to monitor the activity statuses of RRMS patients and efficacy of therapy.  
In chapter 4, I changed disease paradigms and sought evidence to support the idea 
that investigated exosomal miRNAs can act as biomarkers to diagnose and monitor 
glioblastomas. This was motivated not only by the urgent need for better monitoring 
of this devastating illness, but also to further explore the applicability of my serum 
exosomal miRNA biomarker discovery pipeline, established with MS in chapters 3 
and 4. By comparing serum exosomal miRNA profiles between wildtype isocitrate 
dehydrogenase isoforms (IDHWT) GBM patients and their matched healthy controls, 
I identified 26 miRNAs differentially expressed between the two. These miRNAs 
demonstrated a significant association with pathways in cancer, neurological disease 
and importantly glioma-signalling, indicating their potential to be employed as GBM 
biomarkers. I used in silico validation and partitioning to reduce the number of 
informative miRNAs to a stable signature set of seven. Testing this panel on another 
independent sample set of GBM patients with different disease status, MS patients, 
and healthy controls (HCs), supported the utility of this exosomal miRNA signature 
for GBM diagnosis. 
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Chapter 4 also explored whether the serum exosomal miRNA profiles could be used 
to discriminate low-grade mutant IDH (IDHMUT), grade II-III, glioma patients from 
matched HCs. Patients with diffuse and anaplastic (grade II-III) gliomas may 
progress with a secondary GBM recurrence (IDHMUT) as another pathological route 
to develop GBM. I identified 23 differentially dysregulated miRNAs, which after 
random forest (RF) modelling and partitioning, was reduced to a stable signature 
panel of five miRNAs that could distinguish between healthy and low-grade glioma 
patients. Interestingly these five miRNAs were distinct from the seven GBM IDHWT 
signature miRNAs, suggesting that miRNAs may be able to act as markers of glioma 
severity and IDH mutational status.  
To confirm this, I directly compared the miRNA profiles of GBM IDHWT and GII-III 
IDHMUT serum exosomes. While 13 dysregulated miRNAs were identified as 
potential biomarkers for the differentiation of GBM from glioma, this was not 
enough for partitioning analysis, and thus a larger independent patient cohort is 
required for confirmation. The results I achieved however show that serum exosomal 
miRNA signatures have utility as biomarkers for GBM diagnosis.  
Limitations of this work and future directions 
Significant effort has been devoted to improving the diagnosis of diseases by 
discovering miRNA-based biomarkers. However, fundamental challenges arise for 
the translation of circulating miRNAs in body fluids from bench to patient care.95 In 
many studies, a single miRNA has been introduced as a biomarker for the diagnosis 
of a specific disease. For instance, miR-21 has been reported as a biomarker in many 
diseases, while further research indicates that miR-21 is a potential biomarker in 
solid cancers361 and may even serve as a general disease marker. Hence, signatures 
that consist of multiple miRNAs seem to be more robust biomarkers to improve 
differentiation between pathologies, and reflect the complexity of disease 
phenotypes.95 Yet, non-concordant results have been obtained for miRNA signatures 
even within a particular disease. This may be due to variations in sample handling, 
patient recruitment criteria, profiling techniques, and statistical analysis.169 
Therefore, following the discovery phase, miRNA signatures should be validated in 
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independent cohorts.   
While I developed an efficient protocol to capture the complete profile of serum 
exosomal miRNAs for use in the diagnosis and monitoring of CNS diseases, due to 
time and financial limitations my technical choices were limited. There are different 
biophysical and biochemical properties such as size, density, shape, charge and 
antigen exposure that can be used to isolate extracellular vesicle (EVs)362 and each 
has advantages and disadvantages. Although size-exclusive chromatography (SEC) 
separates the majority of small EVs and removes almost all of the soluble serum and 
plasma proteins,68 it pools EVs originating from a variety of cell types. Perhaps it 
would be worthwhile to combine some immunoaffinity capture with SEC in order to 
improve the sensitivity and remove any potentially contaminating exosomes. In 
general, despite numerous studies on exosomal biomarkers in association with 
various diseases, due to methodological differences, there is a poor match in the 
results of individual studies.363 
The data presented in chapter 2 supported the ability of exosomal RNAs to act as 
blood-based biomarkers to diagnose MS patients and distinguish RRMS from 
progressive forms of the disease. Although, the discovery set of biomarkers was 
validated, this is an initial investigation. In order to assess the clinical utility of 
predictive biomarkers, more samples and well-controlled prospective clinical trails 
with appropriate justification should be pursued. 
The results of chapter 3 demonstrate that exosomal miRNAs can monitor disease 
activity and identify patients who respond to Fingolimod therapy. However the high 
efficacy of Fingolimod therapy and the limited sample size resulted in too few non-
responder patients to usefully quantify the predictive power. Longitudinal studies on 
a larger cohort of RRMS with longer follow up and more time points are needed to 
define standardised relationships between therapeutic intervention and response.  
In chapter 4, my data suggests that serum exosomal miRNA signature can predict a 
GBM diagnosis. Though again, it is required to have larger longitudinal cohort of 
GBM patients to assess signature’s utility in clinical practice.  
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In this thesis I focused on serum exosomal miRNAs, whereas there are many other 
sncRNA subsets present in exosomes that should be investigated in the development 
of future exosomal sncRNA-based biomarkers. Beyond the sncRNAs, exosomes also 
carry protein and lipids, which may also have value as biomarkers. Taken together, 
despite the need for further clinical studies in both MS and GBM, the results are 
promising enough to warrant investigation of other CNS diseases by the methods 
developed here. 
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Appendix 
Table supplementary A-1 MS disease activity phase based on Gd-MRI scans and clinical 
examinations 
De-identifier Gd(BL) Clinical (BL) Gd(6M) Clinical (6M) Gd(12M) 
1 A A (34until20days) A Q Q 
2 A Q A Q Q 
3 A Q A Q A 
4 A Q A Q Q 
5 A Q A Q A 
6 A Q Q Q Q 
7 A A (20days_Start) Q Q Q 
8 A Q Q Q Q 
9 A A (46until 16days) Q Q Q 
10 A Q Q Q Q 
11 A 
A (clinically active in 
MRI day) Q Q Q 
12 A 
A (the day of MRI last 
day of activity) Q Q Q 
13 A Q Q Q A 
14 A Q Q Q Q 
15 Q Q A Q Q 
16 Q Q A Q Q 
17 Q Q A Q A 
18 Q Q Q Q Q 
19 Q Q Q Q Q 
20 Q Q Q Q Q 
21 Q Q Q Q Q 
22 Q Q Q Q Q 
23 Q Q Q Q Q 
24 Q Q Q Q Q 
25 Q Q Q Q Q 
26 Q A (15until8days) Q Q Q 
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De-identifier Gd(BL) Clinical (BL) Gd(6M) Clinical (6M) Gd(12M) 
27 Q Q Q Q Q 
28 Q Q Q Q Q 
29 Q Q Q Q Q 
 
